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Metastasis is one of the main causes of cancer related death worldwide; hence elucidation of this 
mechanism, at least in part, will support development of effective therapies to improve the 
morbidity and mortality of people with cancer. Cells continually expel a large number and variety 
of extracellular vesicles. Of these secreted vesicles, exosomes have been studied extensively over 
the past decade. Exosomes are between 30–100 nm in diameter and contain protein and nucleic 
acids. They have only very recently become appreciated as communication mediators that 
transport signals between cells. 
It was hypothesised that exosomes secreted by more metastatic cells may have the ability to 
increase the motility of less metastatic cells, and vice versa. The motile capacity of nine ovarian 
cancer cell lines was established using the scratch wound healing assay. Following this, exosome 
swapping experiments were performed between more and less metastatic cells. It was shown 
that exosomes were unable to influence the motility of recipient cells, irrespective of the 
metastatic phenotype of their cells of origin.  
It was also hypothesised that exosomes derived from stressed cells increase the invasive capacity 
of recipient cells. Exosomes were extracted from heat shocked or cisplatin treated cells and were 
introduced to naïve cells. The invasive capacity of recipient cells was tested following 
administration of stressed cell-derived exosomes. It was discovered that cell invasiveness 
increased following uptake of either heat shock or cisplatin exosomes. Additionally, both heat 
shock and cisplatin exosomes were found to be statistically significantly smaller in diameter than 
those extracted from control cells, when measured using transmission electron microscopy.  
This has implications for patients with cancer because tumour cells that resist, but become 
stressed during administration of cisplatin therapy, could be expelling exosomes that increase the 
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PKH67   green fluorescent lipophilic cell membrane dye 
RNA   ribonucleic acid 
rpm   revolutions per minute 
R2    coefficient of determination 
siRNA   small interfering RNA 
SKOV-3   ovarian cancer cell line 
μg    micrograms  
μl    microlitres  
μM    micromoles  
w/v   weight per total volume 
yl    yottalitres 











Cancer is a growth or tumour that is caused by uncontrollable proliferation of abnormal cells in 
the body (Weinberg, 1996). Almost all mammalian cells have anti-cancer defence machinery that 
is responsible for regulating their proliferation, differentiation, and death (Hanahan and 
Weinberg, 2000). These protective mechanisms are generally very effective in preventing 
development of cancer (Hanahan and Weinberg, 2000). However, when these mechanisms are 
overcome, malignant cells are able to flourish. Transformation of normal human cells into 
malignant cancers is a multistep process facilitated by mutations that occur in essential genes 
responsible for normal cell proliferation and homeostasis (Foulds, 1954; Nowell, 1976). As a result 
the cell acquires a combination of: (1) oncogenes with dominant gain of function and (2) tumour 
suppressor genes with recessive loss of function. 
 
1.1.1. The six hallmarks of cancer 
Cancer research has revealed six common molecular, biochemical, and cellular characteristics (or 
acquired capabilities) shared by all types of human cancer. These essential alterations in cell 
physiology collectively dictate malignant growth and represent successful breach of cellular 
anti-cancer defence mechanisms. The six hallmark capabilities are: (1) initiation of replicative 
immortality; (2) induction of angiogenesis; (3) evasion of growth suppressors; (4) activation of 
invasion and metastasis; (5) sustained proliferative signalling; and (6) resistance to programmed 
cell death (apoptosis) (Figure 1.1) (Hanahan and Weinberg, 2000). A cell must acquire all six of 
these capabilities in order to develop malignancy. More recently, additional hallmarks have been 
proposed including: deregulating cellular energetics, and avoiding immune destruction. 
Additionally, the enabling characteristics: genome instability, and mutation and tumour 





Figure 1.1: The six hallmarks of cancer. (1) initiation of replicative immortality; (2) induction of 
angiogenesis; (3) evasion of growth suppressors; (4) activation of invasion and metastasis; (5) sustained 
proliferative signalling; and (6) resistance to programmed cell death (apoptosis). Adapted from Hanahan 
and Weinberg, 2000. 
 
Each of these protective mechanisms are controlled by several proteins, the functionality of at 
least one protein essential to each pathway must be inhibited, or significantly reduced, in order to 
overcome the cancer defence strategy. This occurs through mutations in the DNA sequence of the 
genes associated with the essential proteins (Hanahan and Weinberg, 2000). The mechanisms by 
which mutations occur, and the affected genes, do not need to be identical between different 
tumours in order for cancer to prevail. Additionally, the sequence in which the hallmark 
24 
capabilities are acquired varies across different cancer types and subtypes (Hanahan and 
Weinberg, 2000). Moreover, in some tumours, a single genetic mutation may result in the 
acquisition of several hallmark capabilities simultaneously, which reduces the number of 
mutational events needed for successful tumourigenesis. For example, loss of function of the p53 
tumour suppressor can enable both angiogenesis, resistance to apoptosis, and genomic instability 
(Fridman and Lowe, 2003). In other instances, a hallmark capability may only develop following 
occurrence of two or more distinct genetic mutations, which lengthens the tumourigenesis 
process (Hanahan and Weinberg, 2000). 
1.1.2. Ovarian cancer 
Ovarian cancer refers to growth of an invasive tumour that arose from cells of the ovary. Over 
90% of diagnosed ovarian cancers are of epithelial origin (Cancer Research UK, 2014b). In 2012, 
152,000 women were killed by ovarian cancer; approximately 4200 of these fatal cases occurred 
in the UK (Cancer Research UK, 2014b). Ovarian cancer, despite being only the fifth most 
prevalent malignancy in women, is accountable for more deaths than all other gynaecological 
cancers combined (National Institute for Health and Care Excellence, 2010). Symptoms manifest 
once the disease has become well-established, therefore the prognosis is poor (Schwartz et al., 
2002). Little is known on how progression occurs from a primary tumour to an invasive and 
metastatic disease (Brooks et al., 2010; Lancaster et al., 2006). Only 35% of patients survive for 
10 years following diagnosis (Cancer Research UK, 2014b).  
1.1.3. Breast cancer 
Breast cancer is the term used to describe growth of a malignant mass of cells inside the breast 
tissue. The vast majority of breast cancers are carcinomas meaning that the cancer began in the 
epithelial layer. Breast cancer is the most common malignancy of women in the Western world 
(Cancer Research UK, 2014a; Scully et al., 2012; Torre et al., 2015; Weigelt et al., 2005). In 2012, 
522,000 women worldwide died of breast cancer; 11,600 of these were British (Cancer Research 
UK, 2014a). Seventy-five percent of deaths caused by breast cancer that occurred in British 
women were in individuals who were over the age of 60 (Cancer Research UK, 2014a); it is now 
recommended by the NHS Breast Screening Programme that all women aged between 47 and 73 
should have a mammographic screen every three years. Because of increases in breast cancer 
awareness, and frequency in screening, unlike ovarian cancer breast cancer is usually diagnosed 




therapy is much more successful, and has decreased metastasis and mortality rates (Scully et al., 
2012; Weigelt et al., 2005). In contrast to ovarian cancer, 78% of patients survive for 10 years 
following diagnosis (Cancer Research UK, 2014a). 
 
1.2. Metastasis 
In terms of tumour survival and progression, an important factor is the ability of the tumour to 
invade and metastasize. This is usually the final hallmark acquired by a primary tumour (Hanahan 
and Weinberg, 2000). Typically, for both ovarian and breast cancers, current treatment involves 
removal surgery and chemotherapy. The majority of patients respond well initially, but eventually, 
in most cases, a chemoresistant and metastatic malignancy recurs, sometimes following multiple 
rounds of treatment (Appleton et al., 2007). This is usually the final stage of tumour progression, 
with few treatment options remaining. Metastasis is responsible for approximately 90% of cancer 
related deaths (Steeg, 2006), and is the main cause of death in both ovarian and breast cancer. 
Metastasis is the process whereby rare subpopulations of cells within the primary tumour attain 
advantageous genetic alterations, which enable these cells to leave the primary site and 
metastasize to form new solid tumours at distant locations where there are reduced nutrient and 
space constraints (Fidler and Kripke, 1977; Fidler, 2003; Weigelt et al., 2005).  
 
1.2.1. The metastatic cascade 
Neoplastic cells must successfully complete a cascade of events in order for a tumour to become 
established at a secondary site (Brooks et al., 2010). Millions of cells are shed from a tumour 
every day, but very few successfully complete all steps of the metastatic cascade (Bockhorn et al., 
2007; Butler and Gullino, 1975; Liotta et al., 1976). It is thought that shear stress experienced in 
the circulation and destruction by immune cells, are the two major factors that prevent all but the 
most capable cells from establishing secondary colonies (Bockhorn et al., 2007). There are an 
extensive number of molecular mechanisms that contribute to the metastatic cascade and it is 
very complex, however the events involved can be summarised into seven key physiological steps 
(Figure 1.2) (Brooks et al., 2010; Polyak and Weinberg, 2009): 
 (1) Angiogenesis – the development of new blood vessels inside the tumour for supply of 
nutrients. 
(2) Detachment of tumour cells from their neighbours and subsequent escape from the primary 
tumour mass. 
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(3) Invasion of, and migration through, the tumour basement membrane and surrounding
extracellular matrix (ECM). Subsequently, malignant cells burrow through the basement 
membrane of blood vessels (or lymphatics). 
(4) Intravasation of the tumour cells into the blood vessel (or lymphatic). Malignant cells travel to
distant anatomical sites assisted by the circulation. 
(5) Adhesion of a single circulating tumour cell to the endothelial vessel lining at the capillary bed
of the target organ at a remote location. 
(6) Extravasation of the metastatic cells where they invade through vascular endothelial cells and
surrounding basement membrane, and colonise in the target organ tissue. 
(7) Establishment of a secondary colony of tumour cells at the target organ site (Brooks et al.,
2010). 
The process described above is typical of haematogenous or lymphatic metastasis whereby 
tumour cells are assisted by either the circulation or lymphatics, respectively. Breast cancer 
metastasis follows the haematogenous route described (Weigelt et al., 2005). Ovarian cancer, 






























































































































































































































































































































































































1.2.2. Phenotypic plasticity 
Epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are 
important processes in the mechanisms of metastasis. Without these processes cells would not be 
able to detach from tissues at the primary site and reattach to tissues at secondary locations 
(Figure 1.2) (Franzen et al., 2015; Tsai and Yang, 2013). 
 
1.2.2.1. Epithelial-mesenchymal transition 
EMT is the transition from a stationary epithelial-like cell to one that has the ability to detach 
from the tissue mass and migrate, characteristics that are usually associated with cells of 
mesenchymal lineage (Charpentier and Martin, 2013). Cellular migration is not only essential for 
normal development but is a vital trait developed by aggressive and advanced tumours that 
metastasize to new sites (Liu et al., 2012). E-cadherin (an epithelial marker) expression becomes 
reduced with synergistic increase in N-cadherin expression during EMT. Vimentin is a marker of 
cells with a mesenchymal phenotype expressed in cells that have successfully undergone EMT 
(Kalluri and Weinberg, 2009). 
 
1.2.2.2. Mesenchymal-epithelial transition 
On arrival at the secondary site there is a recapitulation of the events that were required for 
primary tumour growth. Cells undergo MET where they become able to re-attach to the tissue 
matrix and proliferation increases, consequently a tumour is created at a new site (Chaffer et al., 
2007). During the MET process cancer cells lose their invasive capacity and acquire self-renewal 
competence (Liao et al., 2014).  
 
1.2.3. Ovarian cancer metastasis 
Ovarian cancer metastasis demonstrates the ‘seed and soil hypothesis’ proposed by Paget in 1889 
(Ramakrishna and Rostomily, 2013). The ‘soil’ for ovarian carcinoma ‘seeds’ is either the 
omentum, a highly vascular protective fat pad; or the peritoneum, a serous membrane that 
consists of a single layer of mesothelial cells supported by a thin layer of ECM; both of which 
cover all organs of the abdomen and act as a protective layer (Lengyel, 2010). The ovarian cancer 
‘seed and soil’ concept was supported by a study performed in patients living with severe ascites 
caused by inoperable cancer. To relieve abdominal pain and distension, peritoneovenous shunts 
were used to drain excess fluid from the peritoneum and transfer it, via the jugular vein, to the 
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systemic circulation for disposal. Despite continuous shunting for up to two years, and hence 
infusion of billions of cancer cells into the venous system, patients did not develop aggressive 
metastases outside the abdominal region (Tarin et al., 1984).  
Despite ovarian carcinomatosis to the omentum/peritoneum being well documented, the specific 
cascade responsible is not well understood. Of paramount importance is the ability of ovarian 
cancer cells to invade the innermost layer of the peritoneum known as the mesothelium, a 
monolayer of mesothelial cells that protect abdominal organs (Figure 1.3) (Heath et al., 2004). 
Once this barrier has been breached, tumour cells can adhere, infiltrate, and proliferate within 
the submesothelial ECM (Kenny et al., 2009). Patients with extensive intra-abdominal cancer 
metastasis have a particularly poor prognosis (Kenny et al., 2007; Kenny et al., 2009; Kenny et al., 
2011). 
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Figure 1.3: Ovarian cancer transcoleomic metastasis. Ovarian cancer cells are notorious for thriving in the 
peritoneal cavity however they rarely metastasize beyond this region. This is because of the mechanism of 
ovarian cancer metastasis that is distinctive from typical haematogenous pathways. Instead, exfoliated 
single ovarian carcinoma cells, or chains, or spheroids are transported to the secondary site (omentum or 
peritoneum) in the peritoneal fluid, assisted by natural physiological movement. For this reason, ovarian 
cancer typically metastasizes transperitoneally, most commonly to the omentum or the peritoneum but 
also to organs found in the peritoneal cavity for example the liver. Adapted from Singh and colleagues, 
2008. 
1.2.3.1. Extracellular matrix 
The ECM is a dynamic matrix of molecules secreted by cells, which form a scaffold that provides 
structural and biochemical support to neighbouring cells (Badylak et al., 2015; Bonnans et al., 
2014; Michel et al., 2010). The ECM includes the interstitial matrix and the basement membrane 
(Badylak et al., 2015; Brownlee, 2002). Interstitial matrix is the gel of polysaccharides and fibrous 
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proteins that fill the space between cells. Basement membranes are composed of sheet-like 
layers of ECM on which epithelial cells are grounded and supported (Brownlee, 2002). 
The ECM has many functions, such as providing cellular support, assisting cell adhesion, 
separating tissues from one another, and modulating intercellular communication (Abedin and 
King, 2010). ECM formation is essential in many mechanisms including: growth, wound healing, 
and fibrosis (Maquart and Monboisse, 2014). ECM degradation is a key step in the metastatic 
cascade (Figure 1.2 and Figure 4.1). The elasticity of the ECM modulates cell migration (Lo et al., 
2000), gene expression (Wang et al., 2007), and cell differentiation (Engler et al., 2006). Cells 
constantly assess their ECM elasticty/rigidity, and regulate this depending on desired cell activity. 
For example, cell migration is guided by rigidity gradients of ECM, where cells preferentially 
migrate towards more rigid surfaces (this process is called durotaxis) (Choquet et al., 1997; Lo et 
al., 2000). Additionally, ECM elasticity regulates gene expression that can impact cell 
differentiation and cancer progression (Adams and Watt, 1993; Provenzano et al., 2009).  
ECM constituents are synthesised intracellularly and secreted into the local intercellular 
environment by exocytosis. Once secreted, the new ECM components combine with the existing 
matrix (Badylak et al., 2015). The ECM is composed of an interlocking mesh of fibrous proteins 
and proteoglycans. Proteoglycan components include: heparan sulphate, chondroitin sulphate, 
and keratan sulphate (Iozzo, 1998). ECM-associated heparin sulphate binds to a number of 
protein ligands and regulates several biological activities including tumour metastasis (Kim et al., 
2011). Hyaluronic acid is a non-proteoglycan polysaccharide component of ECM responsible for 
the regulation of numerous processes including tumour development (Peach et al., 1993). 
Collagen, elastin fibres, fibronectin, and laminin are other common components of ECM (Bonnans 
et al., 2014; Brownlee, 2002; Di Lullo et al., 2002). 
1.2.4. The role of the tumour microenvironment in metastatic disease 
The best strategy to reduce morbidity and mortality caused by cancer is to prevent development 
of disseminated disease (Eccles and Welch, 2007). Despite significant developments and successes 
in cancer research, current treatments do not target metastatic disease (Eustace et al., 2004; 
McCready et al., 2010). Tumours are not just a mass of abnormal cells but complex pathogenic 
organs, which attract and corrupt many other types of cell. The interactions between transformed 
cancer cells and healthy cells of the surrounding stroma create the tumour microenvironment 
(Balkwill et al., 2012). Recent data suggests that the tumour microenvironment plays a vital role in 
both initiation and progression of cancer (Marcucci et al., 2013). Before cancer cells can establish 
a tumour at a distant site, the secondary organ must be prepared so it can provide an ideal 
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environment to accommodate metastasising cancer cells (Ramakrishna and Rostomily, 2013). 
Organs that are suitable for remote tumour implantation may be primed ahead of the arrival of 
metastasizing cells to promote grafting and prosper (Bidard et al., 2008). The mechanism 
responsible for tumour cell-tumour microenvironment communication is not fully understood. 
The healthy cells of the tumour microenvironment have a dynamic relationship with the tumour 
(Balkwill et al., 2012). They support carcinogenesis by coordinating a complex network of 
cytokines, chemokines, growth factors, inflammatory proteins, matrix remodelling enzymes, and 
RNA molecules that disrupt the physical and chemical properties of the surrounding tissue 
enabling tumour growth and spread (Hanahan and Coussens, 2012). Most recently, the impact of 
extracellular vesicles (EVs) in tumour cell-tumour microenvironment communication has become 
appreciated (section 1.6.3) (Hosseini-Beheshti et al., 2012; Paltridge et al., 2013; Svensson et al., 
2013). 
1.2.5. Cancer cell interactions with healthy stroma 
In addition to cytokine stimulation (Esquivel-Velázquez et al., 2015), an alternative way that 
cancer cells interact with the normal stroma is through secretion of hyaluronan. Hyaluronan 
concentration increases in cancer cells and causes disruption to normal cell-cell and cell-ECM 
interactions by interfering with cell-cell adhesions (Kamińska et al., 2015). This leads to aberrant 
epithelial morphogenesis that is associated with pre-malignant changes, including intraluminal 
invasion and deregulated epithelialisation (Bose and Masellis, 2005; Twarock et al., 2009). It is not 
clear whether cancer cells directly or indirectly secrete hyaluronan, however conditioned media 
collected from cancer cells was shown to increase the proliferation of non-cancerous cells. This 
effect was caused by soluble factors in the conditioned media secreted by the tumour cells. It is 
possible that EVs may mediate this activity by transporting hyaluronan from cancer cells to cells of 
the surrounding healthy stroma (Pistone Creydt et al., 2013). 
1.3. Extracellular vesicles 
Cells continually expel a large number and variety of EVs. Analysis of the contents, size and 
membrane composition of EVs suggests that they are a highly heterogeneous and dynamic 
population of vesicles. Data suggest that their composition is dependent upon the cell of origin, 
cellular state, and environmental conditions (Yáñez-Mó et al., 2015). At present, three main 
subgroups of EVs have been defined (Gould and Raposo, 2013): (1) apoptotic bodies/plasma 
membrane blebs, (2) microvesicles (microparticles/ectosomes), and (3) exosomes (Figure 1.5) 
(Yáñez-Mó et al., 2015). The main distinguishing factor between these different classes of EV is 
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their biogenesis mechanisms. Apoptotic bodies are released as a result of plasma membrane 
blebbing during apoptosis, they are 1–5 µm (1000–5000 nm) in diameter (Hristov et al., 2004). 
Microvesicles range in size between 100–1000 nm (Raposo and Stoorvogel, 2013) and pinch off 
directly from the plasma membrane (Gould and Raposo, 2013). Exosomes are intraluminal 
vesicles (ILVs) that originate from membrane enclosed sub-compartments of cells (multivesicular 
bodies [MVBs]). Exosomes are secreted into the extracellular environment upon fusion of MVBs 
with the plasma membrane (Théry et al., 2002; Yáñez-Mó et al., 2015). 
It is difficult to distinguish between these subgroups of EVs as many of the protein markers are 
expressed across all types of EVs. Some specific characteristics have been identified for these 
sub-classifications of EVs, however there is currently a lack of widely accepted markers that 
distinguish these populations (Kalra et al., 2013; Tauro et al., 2012). This may be due, in part, to 
the lack of standardisation of both EV extraction and characterisation procedures. In particular, 
EV isolation procedures, at present, are generally unable to separate specific types of EV, instead 
a mixture of different EV types are yielded (Gould and Raposo, 2013; Yáñez-Mó et al., 2015). 
Therefore, the best practice following EV extraction is to characterise EVs using multiple 
techniques (Yáñez-Mó et al., 2015) (section 3.3.1). 
1.4. Exosomes 
Over the past decade, exosomes have been extensively studied (Vader et al., 2014), and an 
appreciation of their role in cell-cell communication has been gained (Denzer et al., 2000; Raposo 
et al., 1996; Vlassov et al., 2012). The term ‘exosome’ was first used by Trams et al. in 1981 to 
describe vesicles 40–1000 nm in diameter that exfoliated from ectoenzyme-active cells (Trams et 
al., 1981). Later that decade, this nomenclature was adopted for vesicles that were 40–100 nm in 
diameter and originated in the endosome (Pan et al., 1985). In the same study electron 
microscopic analysis was performed where the secretion of vesicles approximately 50 nm in 
diameter by sheep erythrocytes was observed. These vesicles contained the transferrin receptor, 
no longer needed by the maturing erythrocytes; hence it was thought that the role of exosomes 
was limited to the removal of proteins. This study also identified the initial stages of biogenesis in 
endosomes where, what are now referred to as MVBs, are created (Pan et al., 1985). Exosomes 
were first isolated by Johnstone and colleagues in 1987 who also identified that they contained 
numerous active enzymes (Johnstone et al., 1987). 
In 2007, Valadi and colleagues discovered that exosomes were able to deliver murine mRNA and 
miRNA to human mast cells, determined by the expression of mouse proteins in human recipient 
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cells (Valadi et al., 2007). Realisation that exosomes may elicit epigenetic effects through transfer 
of selected molecules between cells has revolutionised the outlook within the exosome research 
field regarding potential mechanisms of exosome signalling (Stoorvogel, 2012). This study alone 
triggered great interest, and therefore increased exploration into exosome molecular biology 
(Lässer et al., 2011). As a result, the exosome has become the most well-defined member of the 
EV family and exosome research continues to increase exponentially (Marcus and Leonard, 2013). 
Exosomes are small vesicles released by a variety of cell types into the extracellular environment 
(Février and Raposo, 2004; Théry et al., 2002; Vlassov et al., 2012). Exosomes can be distinguished 
from apoptotic bodies and microvesicles by size. Exosomes are approximately 30–160 nm (Ludwig 
and Giebel, 2012; Théry et al., 2002; Théry, 2011), with the exosomal lumen predicted to be 20–
150 nm across, making the volume of an exosome approximately 4.2–380 yL (yottalitres [10-24 L]). 
Using this value it is estimated that an exosome can hold ≤100 proteins and ≤10,000 nucleotides 
(Vlassov et al., 2012). Exosomes are spherical but have a cup-shaped morphology when visualised 
by electron microscopy; this is caused by the effects of dehydration (Pan et al., 1985). They are 
pelleted at 100,000–120,000 × g (Eldh et al., 2012; Johnstone et al., 1987) and float at a density 
between 1.13 and 1.19 g/mL on a sucrose gradient (Mathivanan et al., 2012; Raposo et al., 1996). 
This distinguishes them from larger EVs, Golgi bodies, and vesicles of the endoplasmic reticulum 
(Raposo et al., 1996; van Niel et al., 2006). 
Exosomes are biologically active vesicles that have paracrine, endocrine, and autocrine effects 
(Skog et al., 2008; Valadi et al., 2007). Their protein (Johnstone et al., 1987), mRNA, and miRNA 
(Palma et al., 2012; Valadi et al., 2007) cargo are enclosed by a lipid-rich bilayer, of similar, yet 
distinctive consistency to the cellular plasma membrane (Figure 1.4). mRNAs are RNA molecules 
representative of cellular DNA that hold the specific genetic code involved in gene expression. 
miRNAs are non-coding RNA molecules that have silencing and post-transcriptional regulation of 
gene expression capabilities. The biological content of exosomes is influenced by both the cell of 
origin and the intended recipient cell. The RNAs isolated with exosomes have been shown to be 
enriched relative to the RNA profiles of the cells of origin suggesting that RNA molecules are 
specifically selected for packaging into exosomes (Nolte-'t Hoen et al., 2012a; Ratajczak et al., 
2006; Skog et al., 2008; Valadi et al., 2007). Exosomes have been shown to transfer the protein 
and RNA they contain to recipient cells; examples of transported material include surface 
receptors, bioactive lipids, and signalling molecules (Ratajczak et al., 2006; Silva et al., 2012).  
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Figure 1.4: Illustration of an exosome. The size of the membrane and cargo are approximately proportional 
(green shapes represent proteins, blue ribbons represent RNAs). 
The horizontal transfer of RNA is now appreciated as a form of intercellular communication, 
whereby donor cells can regulate gene expression of recipient cells (Chen et al., 2012). Exosomes 
can reprogram surrounding cells by altering their translational profile, for example, mRNA 
transferred by exosomes can be translated into protein inside the recipient cell (Valadi et al., 
2007), inducing potent epigenetic changes (Baj-Krzyworzeka et al., 2006; Deregibus et al., 2007; 
Ratajczak et al., 2006; Valadi et al., 2007). Additionally, exosome-delivered miRNAs have been 
shown to interfere with translation by pairing to the un-translated regions (UTRs) of target mRNAs 
in the recipient cell (Bartel, 2004; Bartel, 2009). Exosome-delivered miRNAs were functional in 
recipient cells as gene expression was inhibited (Antonyak et al., 2011; Baj-Krzyworzeka et al., 
2006; Hong et al., 2009; Sheldon et al., 2010; Skog et al., 2008; Valadi et al., 2007; Zhuang et al., 
2012). It is important to consider, however, that an alternative exosome-independent RNAi 
pathway exists involving miRNAs in blood plasma that are associated with argonaute proteins. 
The association with argonaute proteins appears to protect miRNA in the extracellular 
environment and enable them to execute RNAi in recipient cells (Turchinovich et al., 2011). More 
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recently, a diverse range of small RNA sequences that can mediate transmission of functional 
gene silencing have been identified inside exosomes suggesting that exosomal RNA content is not 
limited only to mRNA and miRNAs (Bellingham et al., 2012; Pan et al., 2012). 
Exosomes are released by all types of cells in culture and are also present in body fluids. The 
durability of exosomes in culture enables collection of a high number of exosomes through 
differential/sequential centrifugation of culture medium (Sahoo et al., 2011). It is difficult to know 
whether the concentration of membrane vesicles observed in vitro correspond to those secreted 
in vivo and whether they function in the same way in vitro as in vivo (Théry, 2011).  
The exosomal microenvironment remains tightly controlled and provides a platform that 
accommodates complex interactions between numerous molecules. These molecules remain safe 
from, but still able to interact with, the extracellular environment (Anderson et al., 2010; Chaput 
and Théry, 2011; Valadi et al., 2007). Hence, exosomes are excellent signal transporters (Taylor 
and Gercel-Taylor, 2008) capable of carrying small soluble molecules such as cytokines, growth 
factors, transcription factors, and RNAs, which would otherwise be hydrolytically or enzymatically 
degraded if they subsisted as free molecules in the extracellular milieu (Chaput and Théry, 2011). 
Exosomes have the ability to transfer messages to both neighbouring and distant cells, a process 
facilitated by the circulation, and other biological fluids (Al-Nedawi et al., 2008; Raposo et al., 
1996; Skog et al., 2008; Valadi et al., 2007). Consequently they have become recognised as 
potential mediators of disease, amongst many other applications (Alvarez-Erviti et al., 2011; Ohno 
et al., 2013; O'Loughlin et al., 2012; Raposo et al., 1996; Zitvogel et al., 1998). In addition, 
exosomes have excellent potential as gene therapy nanovehicles since they are 
non-immunogenic, have exceptional potency, biodistribution and biocompatibility, and can cross 
the blood brain barrier (Zhuang et al., 2011). siRNAs have been successfully introduced to 
exosomes and delivered to recipient cells causing selective gene silencing (Wahlgren et al., 2012). 
There is a promising possibility that exosomes could be packed with cancer therapeutics and 
targeted to specific recipient cancer cells (Fan et al., 2013; Lakhal and Wood, 2011). 
Exosome­based gene therapy awaits accurate understanding of the mechanism of exosomes’ 
target selection (Seow and Wood, 2009). 
1.4.1. Exosome biogenesis and secretion 
Exosome biogenesis and secretion is a highly controlled process (Stoorvogel et al., 2002; Théry et 
al., 1999). The release process involves four stages: initiation, endocytosis, formation of MVBs, 




the initiation stage is unknown, however following initiation, membrane proteins are sorted into 
endosomes depending on whether they need to be degraded (e.g. epidermal growth factor 
receptor [EGFR]) or recycled (e.g. transferrin receptor, low-density lipoprotein receptor) (Fader 
and Colombo, 2009; Razi and Futter, 2006). The mechanisms involved in protein sorting into ILVs 
are not yet fully understood. However, there is evidence to suggest that ubiquitin and endosomal 
sorting complexes required for transport (ESCRT) machinery are involved in this process 
(Lakkaraju and Rodriguez-Boulan, 2008; Stoeck et al., 2006), along with lipids (including ceramide) 
and tetraspanin proteins (Kowal et al., 2014). It is well established that tumour susceptibility gene 
101 (TSG101) facilitates trafficking of ubiquitinated receptors from early endosomes to late 
endosomes through interactions with the early endosome associated protein hepatocyte growth 
factor-associated tyrosine kinase (Hrs) (Bache et al., 2003; Lu et al., 2003; Pornillos et al., 2003) 
and the late endosomal protein Alix (von Schwedler et al., 2003). Its detection in exosomes 
suggests that TSG101 is involved in exosome biogenesis. Additional ESCRT proteins, for example, 
vacuolar protein sorting 4 (VPS4), also direct the formation of and cargo selection for MVBs 
(Henne et al., 2011; Hurley and Stenmark, 2011). MVBs are then formed by internalisation of the 
delimiting endosomal membrane through clathrin-coated pit assembly (Sorkin and von Zastrow, 
2009). Selected endosomal membrane proteins and soluble factors are sequestered in the 
membrane and cytosol of ILVs (Sorkin and von Zastrow, 2009). The ~100 nm internal vesicles are 
referred to as ILVs whilst contained inside the MVBs and are only referred to as exosomes 
following secretion (Février and Raposo, 2004). Vesicle accumulation is mediated by Hrs (Razi and 
Futter, 2006). After sufficient vesicle accumulation, MVBs endure one of three fates: (1) they are 
directed to fuse with the lysosome for degradation (Futter et al., 1996); (2) are trafficked to the 
trans-Golgi network or plasma membrane for recycling (Johnstone et al., 1991); (3) the MVB 
limiting membrane fuses with the plasma membrane, releasing ILVs (exosomes) into the 
extracellular milieu (Babst, 2005; Bedoui et al., 2009; Johnstone et al., 1991). The RAB proteins 
RAB11, RAB27, and RAB35 have been shown to participate in transfer of MVBs to the plasma 
membrane and subsequent exosome secretion (Kowal et al., 2014). It is predicted that soluble 
N-ethylmaleimide sensitive fusion protein attachment receptor protein (SNAREs) also participate 
in fusion of MVBs with the plasma membrane. Different types of EVs bud directly from the plasma 
membrane, these are typically referred to as microvesicles or microparticles (Kowal et al., 2014). 
Exosomes are the only identified vesicles to be derived from intracellular membranes (Raposo and 
Stoorvogel, 2013). Since multiple stimuli and different cellular microenvironments have been 
shown to induce exosome release (including hypoxia [Park et al., 2010], cytokine interaction 
[Skokos et al., 2001], and viral infection [Barreto et al., 2010]), it is presumed that MVBs (derived 
from the same cell type) synthesised in different conditions hold vesicles with distinct 
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compositions that reflect their environment during production. Neural progenitor cell-derived 
exosomes have been shown to carry a specific selection of viral miRNAs relative to intracellular 




















































































































































































































































































































































































































































































































































































































































































































































































































































































1.4.2. Exosome uptake 
Because of the multiple functions of exosomes in humans, particularly their role in metastasis 
during cancer development (section 1.6), it is essential that the process responsible for exosome 
signal transmission is elucidated. Many mechanisms have been proposed including: endocytosis 
of exosomes (Escrevente et al., 2011; Montecalvo et al., 2012; Morelli et al., 2004); exosome-cell 
fusion, where exosome contents are released into the cytoplasm of the recipient cell, and the 
exosomal membrane merges with the plasma membrane (Parolini et al., 2009); and direct 
activation of cellular surface-expressed ligands (Christianson et al., 2013; Morelli et al., 2004; 
Raposo et al., 1996; Svensson et al., 2013; Tumne et al., 2009), see Figure 1.6. For a more in depth 
assessment of exosome uptake mechanisms refer to the author’s recent review article (Mulcahy 
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1.4.3. Exosome markers 
Exosomes contain specific protein markers including tetraspanins, chaperone proteins, ESCRT 
machinery components, and plasma membrane components (Kharaziha et al., 2012; Théry et al., 
1999). 
1.4.3.1. Tetraspanins 
Tetraspanins are membrane bound proteins with four transmembrane domains known to 
function principally as scaffolding proteins responsible for anchoring multiple proteins to a region 
of the plasma membrane (Hemler, 2005; Maecker et al., 1997). Humans have 33 tetraspanins 
(Rubinstein, 2011). They are present on the cellular plasma membrane and some, most commonly 
CD9, CD63, and CD81, are present on the exosomal membrane. CD63 and CD81 have ESCRT 
machinery binding capabilities (Gan and Gould, 2011), and CD9 and CD81 play key roles in cell 
penetration, invasion, and fusion events (Hemler, 2003). These proteins are also MVB/late 
endosome markers that are efficiently sorted into ILVs; hence they are also regarded as exosome 
markers (Booth et al., 2006; Escola et al., 1998; Heijnen et al., 1999; Koumangoye et al., 2011; 
Mathivanan and Simpson, 2009; Rana and Zöller, 2011; Théry et al., 1999). In addition, 
tetraspanins are more concentrated in exosomal membranes compared with both endosomal and 
cellular membranes; CD63 is found at approximately 7-fold greater concentration in the ILV 
membrane in comparison with the endosomal limiting membrane (Escola et al., 1998). 
1.4.3.2. Chaperone proteins 
Heat shock protein 70 kDa (HSP70), HSP90 and HSP60 are heat shock cognate proteins that are 
ubiquitously expressed in human cells (Tavaria et al., 1995). HSP70 has numerous cellular 
functions one of which involves specific selection and escort of proteins to the lysosome or late 
endosomal surface for subsequent microautophagy during chaperone-mediated autophagy (Sahu 
et al., 2011; Salvador et al., 2000). It is therefore reasonable to suggest that exosome synthesis 
and protein content determination occurs via a similar mechanism to chaperone-mediated 
autophagy, which could explain the high HSP70 concentration (and high concentrations of other 
heat shock proteins) detected in exosomes. It is now well-established that HSP70 plays a key role 
in exosome formation and/or release inside cells (Théry, 2011). 
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1.4.3.3. ESCRT machinery components 
Because of their endosomal origin the majority of exosomes hold proteins that play a role in 
membrane transport and fusion (Escrevente et al., 2011). The ESCRT is essential in ILV formation 
and content selection (Williams and Urbé, 2007) for this reason, exosomes are enriched in ESCRT 
constituents, namely TSG101 and Alix (Figure 1.5). 
1.4.3.4. Plasma membrane components 
The exosomal membrane is comparable, yet distinct from, the plasma membrane of the cells in 
which they were synthesised (Mathivanan et al., 2010). The exosomal membrane is far more rigid 
compared with the fluid cellular membrane because of a decreased phosphatidylcholine content 
and enrichment in lipid-raft components including sphingomyelin, cholesterol, and ceramide (Eldh 
et al., 2012; Laulagnier et al., 2004; Mitchell et al., 2009; Trajkovic et al., 2008). Ceramide is 
speculated to mediate membrane invagination of ILVs, hence it is enriched in the exosomal 
membrane. Exosomes also carry the distinctive lipid-raft markers: caveolins, flotillins (Logozzi et 
al., 2009; Staubach et al., 2009), and clathrin, because of the process through which they are 
synthesised in endosomes (Figure 1.5) (Février and Raposo, 2004). Cholesterol concentration is 
elevated in the exosomal membrane compared with the typical cholesterol concentration of the 
plasma membrane (Zakharova et al., 2007). The presence of resident lipid-raft components in the 
exosomal membrane suggests that multiple pathways contribute to MVB formation and 
consequential exosome secretion, possibly because of specific cellular stimulation or dependent 
on the cargo to be loaded into the exosome (Meckes and Raab-Traub, 2011).  
1.5. Role of exosomes in tumour development 
Exosomes are released into the organ microenvironment or directly spilled into the blood stream 
by both normal cells and tumour cells (Koga et al., 2005; Llorente et al., 2004; Théry et al., 2002; 
Wolfers et al., 2001). There are many differences between exosomes derived from tumour cells 
and normal cells, at both the molecular and functional levels (McDonald and Baluk, 2002; 
Morikawa et al., 2002; St Croix et al., 2000). Cancer cell-derived exosomes have been proposed to 
act as regulators of cancer progression (Merkerova et al., 2008; Rabinowits et al., 2009). They can 
support progression of cancer by mediating interactions between the tumour and its surrounding 
stroma (Antonyak et al., 2011; Kahlert et al., 2014; Muralidharan-Chari et al., 2010; Webber et al., 
2010), activating proliferative, migratory, and angiogenic pathways (Epple et al., 2012; Hood et 
al., 2011; Tadokoro et al., 2013); initiating development of pre-metastatic sites (Hoffman, 2013; 
44 
Rolfo et al., 2014; Zhang and Grizzle, 2014); and by suppressing the immune-surveillance 
machinery (Whiteside, 2013). Tumour cells may be able to escape apoptosis by liberation of 
selected apoptosis-inducing proteins via exosomes (Jang et al., 2013).  
It has been hypothesised that cancer cells send specific signals via exosomes by dictating their 
content. Additionally they only accept signals from exosomes holding beneficial information in 
order to aid tumour growth (Liu et al., 2006; Qu et al., 2009; Zhang et al., 2013). Furthermore, 
they are predicted to assist tumour progression through their elevated RNA content, enabling 
increased intracellular communication through transfer of oncoproteins, oncogenes, and 
onco-miRNA (Al-Nedawi et al., 2008; Andre et al., 2002; Chairoungdua et al., 2010; Higginbotham 
et al., 2011; Keller et al., 2009; Miyanishi et al., 2007; Taylor and Gercel-Taylor, 2008; Valadi et al., 
2007; Verweij et al., 2011), it is also possible that exosomes released from the surrounding tissues 
may alter cancer cell gene expression, which repress tumour progression (Renzulli et al., 2010). 
1.5.1. Elevated levels of exosomes in patients living with cancer 
In comparison with the normal population, exosomes are found in greater abundance in the 
biological fluids of patients living with cancer (Silva et al., 2012; Taylor and Gercel-Taylor, 2008). 
Additionally, exosome concentration in serum increases with tumour stage in ovarian cancer 
(Taylor and Gercel-Taylor, 2008), and other cancers (Logozzi et al., 2009; Rabinowits et al., 2009; 
Tavoosidana et al., 2011). Therefore exosome blood plasma concentrations correlate with shorter 
patient survival; consequently exosomes are potential diagnostic and prognostic biomarkers 
(Al-Nedawi et al., 2008; Silva et al., 2012; Taylor and Gercel-Taylor, 2008; Zhou et al., 2006). It has 
been hypothesised that oncogene activation and tumour suppressor gene deactivation may 
contribute to this increased exosome secretion (Kharaziha et al., 2012). It has been shown that 
hypoxic environments cause an increase in exosome secretion (King et al., 2012). Tumour-derived 
exosomes carry both pro- and anti-tumour microRNAs (Fernández-Medarde and Santos, 2011; 
Kogure et al., 2011; Ohshima et al., 2010; Roccaro et al., 2013). The net outcome of these 
contradictory factors in vivo has not yet been established. The general opinion within the field 
supports the hypothesis that tumours actively release exosomes to promote their growth. 
However this has not been proven, and it is possible that increased levels of tumour-derived 
exosomes in the biological fluids of people living with cancer could be the result of tumour 
expansion, instead of an indicator of active participation of these vesicles in tumour progression 
(Théry, 2011). 
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1.6. The effect of exosomes on metastasis 
EVs have been shown to facilitate cancer progression; more specifically, in many studies 
exosomes have been linked with increased metastatic activity (Bobrie et al., 2012; Minciacchi et 
al., 2015; Zomer et al., 2015). Several different mechanisms through which exosomes mediate 
metastasis have been identified.  
1.6.1. Increased cell motility 
Increased motility is an important step in the progression of a cancer cell towards metastasis. Cell 
surface proteoglycans have been shown to be integral in exosome-mediated stimulation of cancer 
cell migration (Christianson et al., 2013). Additionally, it has been shown that there is a synergistic 
association between exosome secretion and invadopodia synthesis (section 4.1.1) in head and 
neck squamous cell carcinoma cells signifying an essential role for exosomes in supporting cancer 
cell motility (Hoshino et al., 2013). 
1.6.2. Involvement of protein in exosome-mediated metastatic mechanisms 
Exosomes isolated from metastatic human isogenic colorectal cancer (Ji et al., 2013) and 
melanoma (Xiao et al., 2012) cell lines have been found to be enriched in metastatic factors 
compared with those derived from non-metastatic cell equivalents. Specific proteins have been 
identified in exosome-mediated pro-metastatic activity, more specifically in ECM degradation and 
EMT regulation that support metastasis (Banyard and Bielenberg, 2015; Mu et al., 2013). For 
example, amphiregulin-carrying exosomes, derived from human breast and colorectal cancer 
cells, had the capacity to increase invasiveness of recipient breast and colon cancer cells 
(Higginbotham et al., 2011). There is also evidence to suggest that exosome-associated Wnt-5a 
increases invasion of breast cancer cells (Menck et al., 2013). In addition, exosome-associated 
Synuclein­γ (Liu et al., 2014a) and prominin-1/CD133 (Rappa et al., 2013) have been linked with 
increased cell migration and invasiveness. 
1.6.2.1. ECM degradation 
HSP90α­containing exosomes derived from a breast cancer cell line were shown to activate 
plasmin, a protease that participates in metastasis. Plasmin contributes to metastasis through 
interactions with many proteins including ECM proteins, integrins, endocytosis receptors, and 
growth factors. These interactions promote degradation of ECM during invasion (Andreasen et al., 
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2000). Matrix metalloproteinases (MMPs) degrade the ECM, and hence advocate cell invasion. 
Exosome uptake has been associated with increased MMP1 (Atay et al., 2014) and MMP9 (Deng 
et al., 2012) production in recipient cells. 
1.6.2.2. Exosome-associated EMT regulation 
Exosomes have been associated with increased metastasis by promoting EMT. Mesenchymal stem 
cell-derived exosomes increased the migratory potential of the non-metastatic breast cancer cell 
line, MCF-7 (Lin et al., 2013). Additionally, the proteome of exosomes released by cells that have 
undergone induction of an EMT-like state through blockade of E-cadherin and EGFR stimulation 
was shown to be distinct from control cells. Differences in protein enrichment were identified, 
many associated with cell movement (Garnier et al., 2013). Also, exosomes derived from 
metastatic human bladder cancer cells have been shown to be enriched with EMT associated 
proteins, including vimentin and hepatoma-derived growth factor that were located in the 
exosomal membrane; and casein kinase IIα and annexin A2 that were located in the exosomal 
lumen (Jeppesen et al., 2014). Furthermore, hypoxia-inducible factor 1-alpha (HIF1α) was shown 
to participate in exosome-mediated pro-metastatic effects in recipient human embryonic kidney 
cells through decreased E-cadherin and increased N-cadherin expression (Aga et al., 2014). 
1.6.3. Interactions between metastasis promoting exosomes and surrounding normal stroma 
Several studies have reported the pro-tumour effects of exosomes on the surrounding normal 
stroma. For example, gastrointestinal stromal tumour development has been shown to be 
promoted by tumour-derived exosome uptake in stromal cells (Atay et al., 2014). The surrounding 
stroma of breast cancer became more accommodating to the tumour following 
exosome-mediated delivery of tumour-promoting factors (Dutta et al., 2014). In a different 
report, exosome-associated changes in breast cancer morphology and phenotype were observed, 
which resulted in increased cell motility (McCready et al., 2010). Furthermore, fibroblast-secreted 
exosomes have been shown to interact with neighbouring breast epithelium and promote breast 
cancer cell protrusive activity and motility. This was supported by co-injection of breast cancer 
cells with fibroblasts, which significantly increased metastasis in a mouse model (Luga et al., 
2012). 
In addition to this, invasive capacity of recipient cells has been shown to increase following 
administration of exosomes derived from a brain metastatic cancer cell line compared with a 
non-brain metastatic melanoma cell line (Camacho et al., 2013). This was also observed in a renal 
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cancer cell line (Chen et al., 2014). Evidence suggests that integrin alpha 3 (ITGA3) and integrin 
beta 1 (ITGB1)/CD29 components of prostate cancer cell-derived exosomes have the capacity to 
manipulate non-cancerous surrounding prostate epithelium (Bijnsdorp et al., 2013). Additionally, 
pancreatic and colon carcinoma-derived exosomes presenting HSP70 on their surface have been 
shown to stimulate a migratory phenotype in natural killer cells (Gastpar et al., 2005). Hao and 
colleagues (2006) also showed that the tumour antigen Met 72 was transferred from highly 
metastatic melanoma cells to non-metastatic cells by exosomes (Hao et al., 2006).  
1.6.3.1. Preparation of the metastatic niche 
It is now well-recognised that distant sites are pre-conditioned in preparation for the arrival of 
metastatic cells. These distant microenvironments are known as the ‘metastatic niche’ (Brooks et 
al., 2010). Haematopoietic stem cells migrate to these sites, and induce remodelling of the ECM, 
and alter secreted growth factor combinations resulting in creation of a microenvironment that 
both attracts circulating metastatic cells and supports secondary tumour establishment (Kaplan et 
al., 2005; Kaplan et al., 2006). It has been suggested that exosomes may be sent to prepare the 
metastatic niche in foreign microenvironments (Hendrix and Hume, 2011; Minciacchi et al., 2015; 
Rana et al., 2013) and promote metastasis through communication with neighbouring normal 
stromal cells (McCready et al., 2010). In a comprehensive study, melanoma-derived exosomes 
were shown to effectively prepare the metastatic niche in bone marrow through stimulation of 
vascular leakiness (Peinado et al., 2012). Additionally, CD105-bearing microvesicles were reported 
to stimulate lung metastasis through preparation of the pre-metastatic niche in renal cancer 
(Grange et al., 2011). Also there is evidence to show that melanoma-derived exosomes condition 
lymph nodes in preparation for metastasis through molecular signals that induce vascular 
proliferation, ECM deposition, and promote melanoma cell establishment (Hood et al., 2011). 
1.6.3.2. The role of exosomes in Paget’s ‘soil and seed’ hypothesis 
There is some evidence to suggest that exosomes participate in Paget’s proposed metastatic 
organotropism (Paget, 1989). Exosomes have been shown to prepare cells of specific organs to 
facilitate cancer cell metastasis at specialised sites. Exosomes derived from metastatic mouse and 
human lung, liver, and brain tumour cells were taken up by cells at their preferred destination 
organ: fibroblasts and epithelial cells in the lung, Kupffer cells in the liver and brain endothelial 
cells (Hoshino et al., 2015). These tumour-derived exosomes were shown to prepare the 
pre-metastatic niche; specifically, exosomes from lung tumour cells redirected the metastasis of 
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bone tumour cells. The exosomal integrins α6β4 and α6β1 were identified as facilitators of 
lung metastasis, and αvβ5 was associated with liver metastasis. Exosome uptake was reduced by 
interfering with the binding ability of the exosomal integrins α6β4 and αvβ5 that resulted in 
decreased lung and liver metastasis, respectively (Hoshino et al., 2015). 
Understanding the molecular basis of metastasis is therefore imperative if the effective treatment 
of cancer is to be prolonged, and if novel treatment strategies are to be identified (Lengyel, 2010; 
Weigelt et al., 2005). Our current knowledge of the effects of exosomes upon metastasis are 

















































































































































































































































1.6.4. Investigating exosome uptake by human cells 
Prior to exploring the project outlined below (section 1.7) exosome uptake in human cells was 
investigated. Twelve months was spent optimising labelling of exosomes using: (1) fluorescent 
lipid dyes, (2) transfecting exosome-producing cells with a plasmid that induced expression of 
ubiquitous green fluorescent protein, and (3) [35S]-radiolabelling of proteins of exosome donor 
cells with the expectation that radiolabelled proteins would incorporated into exosomes. The 
future objectives were to quantify exosomes in terms of either fluorescence intensity or 
radioactivity. Quantified exosomes would have been administered to human cells, and their 
uptake would have been measured using a fluorescence plate reader and/or confocal microscope, 
or a scintillation counter. Following this a number of compounds and antagonistic antibodies 
could have been tested to see which ones were able to prevent exosome uptake. This could have 
elucidated, at least in part, the mechanism of exosome uptake by human cells. The direction of 
this project changed once it became clear that specifically labelling exosomes is very difficult. It 
became apparent that two large groups (one at Harvard) are working on this mechanism so the 







1.7. Project aims 
This project had two aims, (1) to investigate whether exosomes derived from highly motile 
ovarian cancer cell lines could induce a more motile phenotype in less aggressive ovarian cancer 
cell lines; (2) to determine the effect of stressed cell-derived exosomes upon metastatic capacity 
cancer cell lines in vitro. The findings of this investigation may indicate the suitability of exosomal 
communication modulation as a possible future cancer therapeutic. The key objectives of this 
project were to: 
 Characterise exosomes using western blotting (WB), confocal microscopy, transmission 
electron microscopy (TEM), and nanoparticle tracking analysis (NTA) to identify specific 
exosome protein components 
 Establish the motility of nine ovarian cancer cell lines using the scratch wound healing 
assay 
 Cell proliferation, invasion and exosome secretion rates were also confirmed 
 Confirm the effect of exosomes derived from more motile ovarian cancer cell lines on the 
motility of less motile cell lines 
 Confirm the effect of exosomes derived from stressed cells (stressed by heat shocking or 
cisplatin treatment) upon invasive capacity of recipient ovarian cancer cell lines 
 
1.8. Novel contribution 
Novel work in this project was the demonstration of an increased metastatic phenotype 
expressed by cells in response to uptake of exosomes derived from cells that had been stressed by 
either heat shocking or cisplatin treatment. In addition, this project involved the first comparative 
investigation of motility, proliferation, invasion, and exosome secretion rates of nine ovarian 




















2.1. Cell culture 
For conventional cell culture, the MCF-7 breast cancer cell line, and IGROV-1 and OVCAR-5 
ovarian cancer cell lines were seeded in T75 culture flasks (Thermo Fisher Scientific), these are cell 
culture flasks that have a surface area of 75 cm2 on their base (the area in which cells area able to 
attach and grow), with Dulbecco's modified eagle's medium (DMEM) (Life Technologies) 
supplemented with 10% foetal bovine serum (FBS) (Life Technologies) and 2.0 mM L-glutamine 
(Thermo Fisher Scientific). A-2780, MCP-1, CP-70, OVCAR-3, OVCAR-8, and SKOV-3 cell lines were 
cultured in Roswell Park Memorial Institute (RPMI) media (Life Technologies) supplemented with 
10% FBS and 2.0 mM L-glutamine. OVCAR-3 cell culture medium also contained 0.01 mg/mL 
bovine insulin (SigmaAldrich), and 1.0 mM sodium pyruvate (SigmaAldrich). Cultures were 
maintained at 37°C in a humidified incubator in an atmosphere of 20% O2, 5% CO2, and 75% N2. 
The cell lines were maintained within cell concentrations between 2.0 × 105 and 
1.0 × 106 cells/mL. MCF-7 cells were a generous gift from Dr Miriam Dwek (University of 
Westminster). A-2780, CP-70, and MCP-1 cells were kindly donated by Professor Robert Brown 
(University College London). IGROV-1, SKOV-3, OVCAR-3, OVCAR-4, OVCAR-5, and OVCAR-8 were 
purchased from National Cancer Institute, Frederick Cancer Division of Cancer Treatment and 
Diagnosis Tumor/Cell Line Repository (Bethesda, USA). Details of the cell lines used in this project 






Table 2.1: Origins of ovarian cancer cell lines and their chemotherapeutic resistance status. 
Cancer cell line Tissue Origin Resistance Reference 





(Godwin et al., 
1992) 




10-fold more resistant 
to cisplatin than 
parent A-2780 cells 
(Louie et al., 
1985) 





(Bénard et al., 
1985) 





(Soule et al., 
1973) 
 




More resistant to 
cisplatin than parent 
A-2780 cells but less 
resistant than CP-70 
cells 
(Anthoney et al., 
1996) 
OVCAR-3 Ascites Malignant ascites Cyclophosphamide 
Adriamycin 
Cisplatin 
(Hamilton et al., 
1983) 
OVCAR-4 Ascites Malignant ascites Cyclophosphamide 
Adriamycin 
Cisplatin 
(Godwin et al., 
1992) 
OVCAR-5 Ascites Malignant ascites Advanced untreated 
tumour 
(Godwin et al., 
1992) 
OVCAR-8 Associated with 
ovarian cancer 
Unknown Carboplatin (Godwin et al., 
1992) 
SKOV-3 Ascites Malignant ascites Diphtheria toxin 
Adriamycin 
Cisplatin 
(Fogh et al., 1977) 
 
2.1.1. Sub-culturing 
Assessment of the degree of confluency of the cells was performed every two to three days using 
a Nixon TMS inverted microscope, using x100 magnification. When cultures were approximately 
70–80% confluent, spent medium was removed and replaced with fresh pre-warmed complete 
media. When cultures were >70–80% confluent they were sub-cultured in order to maintain cell 
growth. Spent medium was removed and the cell layer was washed with phosphate buffered 
saline (PBS) (Thermo Fisher Scientific). 0.05% (w/v) trypsin and 0.53 mM 
ethylenediaminetetraacetic acid (EDTA) (Thermo Fisher Scientific) in PBS was used to wash the 
cell layer of A-2780, CP-70, MCP-1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SKOV-3 cells. 
0.25% (w/v) trypsin and 2.65 mM EDTA in PBS was used to wash the cell layer of IGROV-1 and 
MCF-7 cells. 1.0 mL per 25 cm2 of the flask surface area was used, excess trypsin/EDTA was 
immediately decanted and the flask was returned to the 37°C incubator for 2–10 minutes. Once 
detached, the cells were resuspended in fresh pre-warmed complete media; the minimum 
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volume of media used to resuspend cells was at least equivalent to the volume of trypsin/EDTA 
used initially. This ensured there was enough serum (FBS) available in the media to effectively 
inactivate the trypsin/EDTA. At this point the cell concentration could be determined if necessary 
(section 2.1.2). The required number of cells were transferred to a new flask containing 
pre-warmed complete media. The cells were returned to the 37°C incubator. 
2.1.2. Cell concentration determination 
Adherent cells were brought into suspension using trypsin/EDTA as described in section 2.1.1. The 
cell resuspension was concentrated by centrifuging at 300 × g (1500 rpm) in the MSE Centaur 
centrifuge for five minutes and the cell pellet was resuspended in a smaller volume. 15 µL of the 
cell resuspension was removed and loaded onto a haemocytometer. Cells within the 5 x 5 square 
were counted under a Nixon TMS inverted microscope, using x100 magnification. A minimum of 
100 cells were counted to increase the accuracy of the cell count. At least three counts were 
recorded. The cell concentration was calculated by taking the average of the three cell counts and 
multiplying by 104 to give the number of cells present in 1.0 mL of the cell suspension. 
2.1.3. Clearing foetal bovine serum for exosome-free medium 
Exosomes were collected from supernatants of cell culture medium, therefore, for all exosome 
investigative experimentation, cells were cultured in exosome-free medium (EFM). This required 
clearing FBS of bovine exosomes. This was achieved by ultracentrifuging FBS at 120,000 × g using 
Beckman Coulter Optima LE-80K ultracentrifuge overnight at 4°C (Eldh et al., 2012). Following 
clearing, the media was sterilised by passing through a syringe filter with pore size of 0.22 µm 
(Thermo Fisher Scientific). The cleared FBS replaced the non-cleared FBS in EFM.  
2.2. Exosome extraction 
2.2.1. Standard exosome extraction 
Cells were grown in T175 flasks (Thermo Fisher Scientific), cell culture flasks that have a surface 
area of 175 cm2 on their base (the area in which cells area able to attach and grow), to 70–80% 
confluence (~2.0 × 107). Exosome-containing medium was removed and centrifuged at 300 × g for 
five minutes in the MSE Centaur centrifuge to remove suspended dead cells. The harvested 




Avanti J-25I centrifuge for 20 minutes at 4°C to remove cell debris and suspended cellular 
organelles. Syringe filters with a pore size of 0.22 µm were blocked with 0.1% bovine serum 
albumin (BSA) (SigmaAldrich) to prevent exosomes sticking to the hydrophilic polyethersulfone 
membranes inside the filters. Cell conditioned (exosome-containing) medium was then passed 
through these filters to remove the remaining cell debris and bacteria. The supernatant was 
ultracentrifuged at 120,000 × g (40,400 rpm in 70Ti fixed angle rota) using a Beckman Coulter 
Optima LE-80K ultracentrifuge for 90 minutes at 4°C to pellet exosomes. The extracted exosomes 
were resuspended in PBS, and finally pelleted once more at 120,000 × g (Eldh et al., 2012). The 
exosome pellet was then resuspended in 50 µL PBS and used in subsequent experiments. When 
not used immediately after extraction, the exosomes were stored at -80°C.  
 
2.2.2. Stress exosome collection 
2.2.2.1. Heat shocked cell-derived exosomes 
T175 flasks of cells were seeded. Once 70% cell confluence was reached, complete 
(serum-containing) medium was removed from the flasks. The cell layers were washed with PBS 
and were then replenished with EFM (section 2.1.3). Half of the flasks were heat shocked at 45°C 
in an atmosphere of 5% CO2 for 1 hour. The remaining flasks were maintained at 37°C to be used 
as controls. 
 
2.2.2.2. Cisplatin treated cell-derived exosomes 
T175 flasks of cells were seeded. Once 70% cell confluence was reached, half of the flasks were 
treated with 40 µM cisplatin (SigmaAldrich). Each flask contained 25 mL of complete media 
therefore 60 µL 16.7 mM cisplatin in PBS was spiked into the media of each flask ([0.040 mM x 
25,000 µL] ÷ 16.7 mM). The flasks were swirled to mix the media and then returned to the 37°C, 
5% CO2 incubator. After 2 hours, cisplatin-containing media was removed from treated flasks and 
spent media was removed from control cells. The cells in all of the flasks were washed with PBS 
and replenished with EFM (section 2.1.3). Two hours later, media was removed from all of the 
flasks to alleviate cisplatin secreted by the treated cells. The cells were replenished with EFM. 
 
2.2.2.3. Stress exosome extraction 




2.3. Exosome characterisation 
2.3.1. Western blotting of whole cell and exosome protein extracts 
2.3.1.1. Whole cell protein extraction 
Cells were scraped from the surface of a culture flask into ice cold PBS and pelleted at 300 × g. 
Cells were scraped rather than trypsinised to prevent degradation of surface proteins that were 
later probed for. The cells were pelleted at 300 × g in the MSE Centaur centrifuge, the pellet was 
resuspended in ice cold PBS, and further pelleted at 300 × g. Cell preparations were then lysed in 
1X radioimmunoprecipitation assay (RIPA) buffer (0.1 M Tris-hydrogen chloride, 0.3 M sodium 
chloride, 0.1% sodium dodecyl sulphate [SDS], 0.5% sodium deoxycholate, 1% Triton X 100) under 
constant agitation using a Revolver 360° sample mixer (Thermo Fisher Scientific) for 30 minutes at 
4°C. Nuclei and cell debris were removed by centrifugation at 14,000 × g in a Heraeus biofuge 
fresco centrifuge.  
 
2.3.1.2. Exosome protein extraction 
Exosomes were extracted from 8 x T175 cells that were 70–80% confluent and had been 
conditioned for 24 hours in EFM, as described in section 2.2. Exosome pellets from 8 x T175 flasks 
were resuspended in PBS, pooled into one tube, pelleted at 120,000 × g and resuspended in 50 µL 
1X RIPA buffer (section 2.2). The samples were mixed by pipetting and vortex mixing using Van 
Waters and Nat Rogers (VWR) lab dancer (VWR International Ltd, Lutterworth) for 15 seconds. 
The sample was then sonicated three times for five minutes in a Decon FS100 frequency sweep 
sonicating water bath (Decon) filled with ice cold water (in order not to denature the sample 
proteins). Between sonications the sample was vortex mixed for 15 seconds. Following sonication 
steps, the exosome samples were spun at 14,000 × g for 20 minutes at 4°C in a Heraeus biofuge 
fresco centrifuge to pellet non-protein debris. 
 
2.3.1.3. Sample protein concentration determination using bicinchoninic acid assay 
Following whole cell (section 2.3.1.1) or exosome protein extraction (section 2.3.1.2), lysates 
were quantified using a bicinchoninic acid (BCA) assay kit (Life Technologies), whereby 0–
2000 µg/mL BSA (ampule provided in kit) were made using 1X RIPA buffer. Working reagent was 
made using 50 parts BCA reagent A and one part BCA reagent B. Working reagent was incubated 
at room temperature for five minutes. 25 µL of whole cell protein or 5.0 µL exosome protein 




Technologies). Working reagent, 200 µL or 40 µL for whole cell and exosome samples, 
respectively, was loaded and the content of each well was mixed by pipetting. The plate was 
incubated at 37°C for 30 minutes and allowed to cool for five minutes before the absorbance at 
570 nm was determined for each well using a Labtech LT-4000MS Microplate Reader. 
 
2.3.1.4. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
The protein samples were solubilised at 100°C for 10 minutes in 5X sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) loading dye under reducing conditions 
(1.0 M Tris-hydrogen chloride, 50% glycerol [SigmaAldrich], 5% SDS, 0.05% bromophenol blue 
[SigmaAldrich], 1.0 M dithiothreitol [DTT] [SigmaAldrich]). Protein samples were cooled on ice for 
five minutes prior to loading into the gel. After protein concentration determination 
(section 2.3.1.3), 10.0 µg protein from whole cells or solubilised exosomes were loaded into wells 
of 12% pre-cast acrylamide gels (Bio-Rad) (used because the proteins of interest ranged in sizes 
from 9–130 kDa). Gels were enclosed in the gel cassette and running buffer (25 mM Trisbase 
[Thermo Fisher Scientific], 192 mM glycine [SigmaAldrich], 0.1% SDS, pH 8.3) was poured to the 
correct level in the gel tank. An electric field was applied across the gel at 80 V for the first 
10 minutes, then 120 V for 60 minutes, causing the negatively charged proteins to migrate down 
the gel towards the anode. 
 
2.3.1.5. Protein transfer 
Separated proteins were transferred onto polyvinylidene difluoride (PVDF) membrane (Bio-Rad) 
by semi-dry blotting for 10 minutes using high molecular weight protocol on a Trans-Blot® Turbo™ 
Transfer Starter System (Bio-Rad).  
 
2.3.1.6. Protein detection 
The membrane was blocked for 1 hour with 5% dried skimmed milk powder (Marvel) in tris 
buffered saline with 0.05% Tween 20 (TBST) and cut into sections so that different parts of the 
membrane could be incubated with different antibodies. The membrane was incubated overnight 
at 4°C with anti-human primary antibodies (Abcam) diluted in 5% dried skimmed milk powder in 
TBST. 1:2500 monoclonal mouse anti-human HSP70 (ab5439), 1:1700 monoclonal rabbit 
anti-human cytochrome C oxidase (ab150422), 1:15,000 monoclonal rabbit anti-human GAPDH 




rabbit anti-human GM130 (ab31561). The membrane was then incubated for 60 minutes at room 
temperature with 1:2000 polyclonal goat anti-mouse-DyLight 550 conjugate (84540, Thermo 
Fisher Scientific) for sections of the membrane that had been incubated with mouse anti-human 
antibodies, or 1:2000 polyclonal goat anti-rabbit-horseradish peroxidase (HRP) conjugate 
(170-6515, Bio-Rad) secondary antibody for all sections of the membrane that were incubated 
with rabbit anti-human primary antibodies. The secondary antibodies were also diluted in 
5% dried skimmed milk powder in TBST. After each antibody incubation period the membrane 
was washed three times for five minutes in TBST to remove background signal. Fluorescence or 
chemiluminescence was visualised using ChemiDoc MP (Bio-Rad) using the blot: Chemi or blot: 
Cy3 protocols. 
 
2.3.1.7. Verification of heat shock induced cell stress by western blotting 
Cells were heat stressed as described in section 2.2.2.1. Twenty-four hours later the media was 
removed for exosome extraction and the cells were harvested for protein, as described in 
section 2.3.1.1. Cell lysate protein concentration was quantified, as described in section 2.3.1.3 
and western blotting (WB) was performed (section 2.3). 
 
2.3.2. Transmission electron microscopy of exosome samples 
2.3.2.1. Grid preparation 
A fraction of each exosome sample was combined with an equal volume of 4% paraformaldehyde 
(SigmaAldrich) and was preserved on ice for 15 minutes. A droplet of each sample was distributed 
using a pipette onto Parafilm (Thermo Fisher Scientific). Carbon-formvar coated copper 300 mesh 
grids (Agar Scientific, Stanstead) were placed dull-side downwards onto each sample droplet and 
left to incubate at room temperature for 30 minutes. Grids were then washed three times by 
placing dull-side downwards onto a droplet of 0.22 µm filtered ultrapure water. Between each 
wash, excess water was removed using filter paper. Finally, each grid was placed onto a 30 µL 
droplet of 2% uranyl acetate (aqueous) (SigmaAldrich) for two minutes. Excess solution was 





2.3.2.2. Transmission electron microscopy 
Grids were visualised using a Hitachi H7650 Transmission Electron Microscope at 100 kV with 
x40,000 magnification. Exosome diameter was measured using the measurement function in AMT 
software (Advanced Microscopy Techniques, Massachusetts, USA). 
 
2.3.3. Visualisation of exosome and cellular interactions by confocal microscopy 
2.3.3.1. Fluorescent staining exosomes with PKH26 
The membrane stain PKH26 was used for confocal visualisation of exosome-cell interactions. Of 
the lipid stains tested, PKH26 was the most stable and did not photo-bleach easily. Its 
lipid-dissociation rate was low; therefore PKH26 was ideal for staining exosomes. Following the 
first 120,000 × g ultracentrifugation step in the exosome extraction protocol (section 2.2) the 
resuspended exosome pellet or 2000 ng BSA (used as a positive control) was introduced to 1.0 mL 
Diluent C (SigmaAldrich). Diluent C is a solution of unknown composition provided by 
SigmaAldrich as part of the PKH26 staining kit. 1.0 mM PKH26 lipophilic membrane dye 
(SigmaAldrich) was then diluted to 4.0 µM in 1.0 mL Diluent C and subsequently combined with 
the exosome-Diluent C mixture (or the BSA positive control) to give a total volume of 2.0 mL (final 
concentration of PKH26 = 2.0 µM). The mixture was incubated for five minutes at room 
temperature with periodic mixing with P1000 pipetman. To quench the staining reaction, 2.0 mL 
of 10.0 mg/mL BSA in PBS was added to the mixture to bind excess dye. Then the final 
ultracentrifugation step of the exosome extraction protocol was performed. The PKH26-labelled 
exosomes were transferred to a 300 kDa molecular weight cut-off Vivaspin 6 ultracentrifugal filter 
(GE Healthcare, Little Chalfont) and centrifuged at 4000 × g in a Beckman Coulter Allegra 25R 
centrifuge. The sample was washed three times with 5.0 mL of PBS before being transferred to a 
new 300 kDa ultracentrifugal filter, and washed twice with 5.0 mL complete medium. The 50 µL 
stained exosome sample was transferred from the concentrate pocket to an Eppendorf tube 
(Eppendorf, Stevenage) and stored at -80 °C in the dark until use (Lässer et al., 2011). 
 
2.3.3.2. Confocal microscopic analysis of exosome-cell interactions 
A-2780 cells were seeded at 250,000 cells/cover slip in 6-well plates (Thermo Fisher Scientific) and 
grown for 24 hours to reach 70–80% confluency. At this point, 5.0 µL of PKH26-labelled exosomes 
(equivalent to 2 million cells worth of exosomes secreted over 24 hours) were introduced to the 
cells and incubated at 37°C for 60 minutes. Cells were fixed in 4% paraformaldehyde 




(SigmaAldrich). The fixed cells and exosomes were mounted and simultaneously the nuclei were 
stained using 15 µL of DAPI supplemented ProLong Fade Gold mounting media (Thermo Fisher 
Scientific). After overnight incubation at 4°C in the dark, the exosome-cell interaction was 
visualised using a Zeiss LSM 880 inverted confocal microscope (Zeiss, Cambridge), using x630 
magnification. Viable cells were identified by their DAPI stained nuclei using 405 nm laser. 
PKH26-exosome interaction and trafficking inside A-2780 cells was observed using the 543 nm 
laser. Brightness and contrast were adjusted to improve visibility of particles. Images and z-stacks 
were collected using LSM 510 software (Zeiss, Cambridge). 
 
2.3.4. Exosome size determination and quantification by nanoparticle tracking analysis 
One T175 flask of cells was cultured in EFM for 24 hours. Cell conditioned media was removed 
and exosomes were extracted (section 2.2). The cells from which exosomes were extracted were 
counted (section 2.1.2) to establish the size and number of exosomes released per cell for each 
cell type. Exosome pellets were resuspended in 50 µL PBS and diluted 1 in 100, leading to particle 
concentrations of approximately 5.0 × 108/mL (Sokolova et al., 2011). Exosome size and 
concentration were determined by NTA with a NanoSight LM10 instrument equipped with the 
NTA 2.0 analytical software (Malvern Instruments Ltd, Malvern). Three biological replicates for 
each cell line were collected (Figure 2.1). Five, 30 second videos of each sample were recorded, 
and from these the software calculated the mean diameter (nm) and exosome concentrations 
(x × 108). Each sample was measured in duplicate. The standard error of the mean was calculated 
for all data. Differences in exosome size and concentration between the different cell lines were 
determined using the two tailed T-test. All values are reported to three significant figures. 
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Figure 2.1: The procedure performed to collect a single biological replicate of exosomes from eight 
ovarian cancer cell lines in order to determine exosome size and the concentration differences by NTA. To 
determine the size difference by NTA and to quantify exosomes released by eight different ovarian cancer 
cell lines by NTA, eight T175 flasks of cells (one for each ovarian cancer cell line) were conditioned in media 
containing 10% exosome-free FBS for 24 hours. Following the conditioning period, media was removed and 
the exosomes were extracted. Cells were counted using a haemocytometer to allow the concentration of 
exosomes to be associated with the number of cells from which they were extracted. Exosome pellets were 
resuspended in PBS and stored at -80°C. A total of 24 samples were collected by repeating this procedure in 
triplicate on three different days over a seven day period to provide three biological replicates for each of 
the eight ovarian cancer cell lines. When analysed by NTA, two technical replicates were used to represent 
each biological replicate. 
2.4. Exosome uptake inhibition 
The procedure described in section 2.3.3 was used to verify exosome uptake and inhibition of 
exosome uptake. Uptake was inhibited using heparin or proteinase K, as described below. 
Following isolation of stress exosomes (section 2.2.2) they were pooled, then stained with PKH26 
(section 2.3.3.1) and, finally, treated with an exosome uptake inhibitor prior to administration 
onto cells.  
2.4.1.1. Exosome uptake inhibition with heparin 
Prior to addition of exosomes to cells, cells and half of the pooled exosome sample were both 
pre-treated with 10.0 mg/mL heparin sodium salt from porcine intestinal mucosa (SigmaAldrich) 
for 30 minutes at 37°C. The other half of the pooled exosome sample (control sample) was 




2.4.1.2. Exosome uptake inhibition with proteinase K 
The exosome sample was split in half. One half of the sample was treated with 1.0 mg/mL 
proteinase K (Thermo Fisher Scientific), and the other half (control sample) was treated with an 
equal volume of PBS, both for 30 minutes at 37°C. Proteinase K activity was inhibited immediately 
following the treatment incubation period by boiling the sample for 10 minutes. 
 
2.4.1.3. Quantification of exosome uptake 
Confocal microscopic analysis was used to visualise exosome-cell interactions and to confirm 
inhibition of exosome uptake (section 2.3.3.2). Three slides, seeded at 250,000 A-2780 cells, were 
prepared for each treatment type. Each slide received PKH26-stained exosomes extracted from 
1 x T175 flask of A-2780 cells (equivalent to approximately 10 million cells worth of exosomes). 
Three z-stacks for a single layer of cells for each slide were acquired at 1.0 µm slice intervals. 
Volocity 3D Image Analysis software version 6.3 (PerkinElmer, Coventry) was used to quantify 
exosome uptake by measuring the volume (µm3) of exosomes (PKH26 signal) inside each cell. The 
average volume of exosomes per cell was then calculated for each treatment type using 140 cells 
from each slide using Microsoft Excel 2010.  
 
2.5. Cell motility assay 
2.5.1. Scratch wound healing/cell motility assay 
Cells were seeded at an optimal concentration (this varied depending upon cell type, Table 2.2) in 
24-well tissue culture plates (Corning, Deeside) (Figure 2.2B). The plates were marked with three 
horizontal lines on the bottom to enable alignment of the plate on the microscope to ensure the 
same area of the well was imaged at each data collection point (Figure 2.2A). The cells were 
maintained at 37°C, 5% CO2 for 48 hours. During this time the cells proliferated and reached 100% 
confluence, i.e. a monolayer of cells had formed over the bottom surface of each well. A scratch 
was made in a straight line down the centre of three wells of each cell type using a P200 pipette 
tip (Figure 2.2C). The media containing floating cells was removed carefully, and the cell 
monolayer was washed with 1.0 mL pre-warmed media to smooth the edges of the scratch. Each 
well was replenished with 2.0 mL pre-warmed media. Each point along the scratch (A, B and C) 
was located using the marks on the bottom of the plate (Figure 2.2C), and photographed under a 
Motic AE31 inverted microscope (Motic, Wetzlar, Germany), using x100 magnification. The cells 
were incubated at 37°C, 5% CO2. Photographs were taken every 12 hours, unless stated 





Table 2.2: Optimum cell seeding concentrations in 24-well plates for scratch assay. 
Cell Line 

















Figure 2.2: Scratch motility assay. A) The base of 24-well plates were marked to enable alignment of the 
plate on the microscope to ensure the same area of the well was imaged at each data collection point. B) 
Cells were seeded in plates and grown to 100% confluency over a 48 hour period. C) A scratch was made 







2.5.2. Scratch wound healing assay with exosome treatment 
Two T175 flasks (Thermo Fisher Scientific) containing cells of each cell line (OVCAR-5 and SKOV-3), 
at 70–80% confluency, were cultured in 10% cleared FBS (section 2.1.3) containing media for 
24 hours (approximately 6 million cells per flask). Exosomes were then extracted from the culture 
media following the procedure described in section 2.2. The exosomes were filtered using 
0.22 µm filters previously blocked with 0.1% BSA, mixed with fresh media, and then distributed 
across three wells of a 24-well plate. This was performed twice, once 24 hours prior to creating 
the scratch, and once immediately after the scratch was made, then the cells were washed with 







































































































































































































































































































































































































































2.5.3. Scratch assay image analysis using ImageJ 
ImageJ (National Institutes of Health, Bethesda, USA) was used to determine the scratch size in 
terms of percentage of the image size. The ‘autoAdjust’ tool was used to correct the brightness 
and contrast of the scratch image (Figure 2.4A). In order to convert the image into a binary 
drawing that could be analysed by the ImageJ software, the ‘Analysed Image Generating Macro’ 
script file was installed. This macro performed the following steps: inverted the image, created 
north facing shadows, found edges, sharpened and smoothed the image, and made the final 
image binary. This process resulted in an image where the cells and the empty scratch area were 
distinguishable (Figure 2.4B). ImageJ automatically fills the largest area white, but in order to 
analyse the scratch, the scratch area must be black. For scratches that covered >50% of the image 
area, the image was inverted (Figure 2.4C). The freehand selection tool was used to select the 
scratch area, the particles in this section of the image were analysed using the following settings: 
size: 12,000; circularity: 0.00–1.00; show: outlines; flag: summarise. This produced a drawing of 
the scratch outline and a percentage value for the scratch area (Figure 2.4D). The percentage 
value for the scratch area did not represent the area of the scratch in the entire image, only the 
percentage within the area that was selected. In order to determine the scratch size, the scratch 
areas were filled black on the drawing of the scratch outline. This image was then converted to 
binary format. For images where the scratch area was >50%, the image inversion step was 
repeated. The particles within the entire image were analysed once more (Figure 2.4E). The final 
percentage value given in the summary table represented the percentage area of the scratch 
within the image area (Figure 2.4F). This analysis was performed on each scratch image to 
determine the speed of scratch closure in terms of percentage area reduction per hour, an 
example is shown in Figure 2.5. Scratch width percentage values were normalised to scratch area 






Figure 2.4: Scratch assay analysis using ImageJ. A macro was designed to enable analysis of the captured 
scratch images using ImageJ. IGROV-1 cells were used as an example. A) Image brightness and contrast was 
adjusted automatically. B) The image was converted into binary format. C) The image was inverted if 
necessary. D) Scratch area was selected and isolated using the ‘Analyse Particles’ tool. E) Scratch size was 





Figure 2.5: Scratch images of OVCAR-5 cells over a 24 hour period were used as an example to show the 
different images generated by ImageJ during scratch image analysis. The original image (A) was initially 
converted into a binary format (B). The area of interest was selected (C) enabling outlines of the scratch 
area (D) and calculation of percentage scratch area to be made. 
 
2.5.4. Scratch assay with stress exosomes 
To determine whether cells released signals into the media that had the capacity to increase 
motility of MCF-7 cells following heat stress, the scratch assay (section 2.5.1) was used. In this 
experiment, heat shock media transfer was performed instead of exosome extraction (because of 
insufficient resources). MCF-7 cells were seeded in four 24-well plates at 560,000 cells/well and 
were grown to 100% confluence over a period of 48 hours. After 24 hours, complete media on 
plate A was replaced with EFM and the cells were heat shocked for 1 hour at 45°C. 24 hours later, 
heat shocked cell conditioned media was aspirated from plate A. The media on cells in plate B was 
removed and the cells were washed with PBS. Then the heat shocked cell conditioned media from 
plate A was administered to the naïve MCF-7 cells in plate B. At the same time, plate C was heat 




scratches were made down the centre of six wells of each cell type in plate B and six wells of 
directly heat shocked cells in plate D using a P200 pipette tip (Figure 2.2C). The media containing 
floating cells was removed carefully and the cell monolayer was washed to smooth the edges of 
the scratch with 1.0 mL pre-warmed EFM. Each well was replenished with 2.0 mL heat shocked 
cell conditioned media that had been aspirated from plate C. The scratch was visualised and 
photographed under a Motic AE31 inverted microscope, using x100 magnification. The cells were 
incubated at 37°C, 5% CO2. Photographs were taken every 12 hours with the last photograph 
taken 48 hours after the scratch was made. Scratch images were analysed as described in 
section 2.5.3. 
 
2.6. Cell proliferation assay 
2.6.1. Measurement of cell proliferation 
Ovarian cancer cell lines were seeded at 500,000 cells per flask in 15 T25 flasks (Thermo Fisher 
Scientific) per cell line. T25 flasks are cell culture flasks that have a surface area of 25 cm2 on their 
base (the area in which cells area able to attach and grow). Over the following five days, every 24 
hours the total number of cells in three flasks was determined by counting the cells as described 
in section 2.1.2. The cell concentration per millilitre was multiplied by the total volume of the cell 
resuspension to establish the total number of cells in each flask at each data collection point. 
These values were used to determine the proliferation rates of each cell line. 
















time = 0 hours (t0) 
cell number at time = 0 hours (q0) 
time = 96 hours (t96) 






2.7. Assessment of cellular migratory capacity and invasiveness 
2.7.1. Matrigel trans-well cell invasion and migration assays 
Cell cultures were starved of serum over a 24 hour period (Guo et al., 2014). Only cultures that 
were <80% confluent and would not reach 80% confluency over the next 24 hours were used to 
ensure cells were starved of FBS effectively. Complete medium was removed and the cell layer 
was washed with PBS. Complete culture medium was replaced with serum-free medium (SFM). 
The cells were returned to the incubator at 37°C, 5% CO2 for 24 hours. Cells were harvested using 
a cell scraper (Thermo Fisher Scientific) instead of trypsin because the trypsin method (section 
2.1.1) requires the use of FBS which would reverse the effects of serum starvation. The cells were 
centrifuged at 300 × g (1500 rpm) in the MSE Centaur centrifuge to pellet them. The cell pellet 
was resuspended in PBS. The cells were further pelleted at 300 × g. Cell concentration was 
determined as described in section 2.1.2. The cells were distributed into either uncoated (no 
Matrigel, 8.0 µm pore membrane only) (BD Biosciences) or Matrigel (artificial ECM secreted by 
Engelbreth-Holm-Swarm mouse sarcoma cells) coated 8.0 µm pore membrane trans-well inserts 
(BD Biosciences) at 100,000 cells/well. There were three biological replicates for each cell line (in 
three separate wells). To act as a chemoattractant, complete medium (10% FBS) was loaded into 
receiver wells (24-well plate). The cells in the trans-wells were incubated for 24 hours. Following 
the incubation period, medium from assay/receiver plate and trans-well inserts was aspirated 
carefully. The upper surface of the control/Matrigel inserts were swabbed with a cotton bud to 
remove cells that had not invaded the Matrigel/membrane. The inserts and receiver wells were 
washed with PBS and the cells that had invaded were stained with 1% crystal violet (SigmaAldrich) 
(1.0 g crystal violet in 25 mL 100% methanol and 75 mL de-ionised water) for 10 minutes. After 
staining, the inserts were rinsed under running water until the water ran clear. Inserts were dried 
completely before they were removed from the insert housing using a scalpel (Swann Morton, 
Sheffield). The membranes were then mounted onto glass slides using 
di-N-butyle phthalate in xylene (DPX) and glass coverslips. The membranes were visualised under 
the Zeiss Axioplan inverted microscope using x125 magnification in differential interference 
contrast. Where possible, all cells that invaded the membrane were counted, where this was not 
possible (because there were too many cells to count accurately), cells were counted in five 
representative fields of view. The field of view was 0.005 cm2 and the membranes had a total area 
of 0.33 cm2, therefore the average number of cells in each field of view was used to calculate the 
total number of invading cells using this calculation: = ([average number of invasive cells in five 






Figure 2.6: Trans-well Matrigel invasion and trans-well migration assays. A) Cells were seeded at 100,000 
cells/trans-well in SFM. Inserts had membranes with 8.0 µm pores coated in Matrigel (trans-well invasion 
assay) or uncoated inserts with no membrane coating (trans-well migration assay). Complete media 
containing 10% FBS was added to receiver wells. B) Cells were left (at 37°C) to invade the membrane. C) 
After 24 hours, non-invasive cells were removed from the insert using a cotton bud. D) Remaining cells on 
the bottom side of the membrane were stained with 1% crystal violet. E) Membranes were washed with 
water until all the excess crystal violet stain was removed. Subsequently membranes were cut out of the 






2.7.1.1. Matrigel invasion assay with exosome treatment of cells 
Control or stressed cell-derived exosomes were extracted from approximately 60 million cells 
(sections 2.2 and 2.2.2), resuspended in SFM and administered to cells at the same time as SFM 
(24 hours prior to harvesting for the Matrigel assay). Exosomes extracted from 6 million cells were 
administered to approximately 1 million cells. The control and stress exosome extraction 
procedures were repeated the following day and a second dose of exosomes was added to the 
cells immediately after they were seeded in the Matrigel trans-well inserts. For all stress exosome 
invasion experiments, all invasive cells on each membrane were counted. This method is 
illustrated in Figure 2.7. 
 
2.7.1.2. Matrigel invasion assay with cisplatin exosome treatment and additional DNA-PK 
inhibition in recipient cells 
In addition to cisplatin exosomes, 10.0 µM NU7441, an inhibitor of DNA-PK, was administered to 
cells (at the same time as cisplatin exosomes were added), both 24 hours prior to and 










Figure 2.7: Trans-well Matrigel invasion assay with stress exosome treatment of cells. Friday, cells that 
were to be stressed and from which exosomes were to be extracted were seeded in T175 flasks. Monday, 1) 
Media was changed to EFM and cells were stressed by either heat shocking or cisplatin treatment. 2) Fresh 
cells were seeded in T25 flasks at 500,000 cells/flask. Tuesday, 3) A second batch of cells were stressed 
(step 1 was repeated). 4) Stress and control exosomes were extracted and resuspended in SFM. Drug 
treatment of exosomes/cells was performed at this point in the procedure, where necessary. 5) 
FBS-containing medium was removed from cells in T25 flasks and media was replaced with SFM containing 
stress or control exosomes, or SFM only for control flasks. Exosomes extracted from 6 million cells were 
administered to approximately 1 million cells. Wednesday, 6) Step 4 was repeated. 7) Serum-starved, stress 
exosome-treated cells were harvested and cell concentration was determined. 8) Cells were seeded into 
trans-well inserts in a 24-well plate, exosomes were administered to the appropriate trans-well inserts, 
exosomes extracted from 6 million cells were administered to 100,000 cells. Complete media was added to 
the receiver wells to act as a chemoattractant. 
 
2.8. Proteome profiler human phospho-MAPK array 
2.8.1. Sample collection 
The proteome profiler human phospho-MAPK array (R&D Systems, Abingdon) procedure was 
performed as outlined in the manufacturer’s protocol. Cells were seeded at 
1.0 × 107 cells/T175 flask. Cells were stressed using the appropriate method, heat shocking for 
MCF-7 cells (section 2.2.2.1) and cisplatin treatment for A-2780 cells (section 2.2.2.2). 
Twenty-four hours later, stressed cell-derived exosomes were collected (section 2.2.2) and 
administered to cells (1 x T175 flask worth of exosomes/1.0 × 106 cells). Twenty-four hours later, 
spent media was removed and the cell layer was washed with PBS; the PBS was discarded. Fresh 
PBS was added and the cells were scraped into suspension. After cell concentration determination 
(section 2.1.2) the cells were pelleted at 300 × g for five minutes at room temperature. The 
supernatant was removed and the appropriate volume of Lysis Buffer 6 was added to each cell 
sample to give a final concentration of 1.0 × 107 cells/mL. Cells were solubilised initially by pipette 
mixing, and then by gentle rocking at 4°C for 30 minutes. Protein samples were then centrifuged 
at 14,000 × g at 4°C for five minutes in a Heraeus biofuge fresco centrifuge. The supernatant was 
transferred to a fresh tube. Cell lysates were stored at -70°C until use. 
 
2.8.2. Assay procedure 
Cell lysates were defrosted and the nitrocellulose membranes were blocked in Array Buffer 5 for 
60 minutes at room temperature on a rocking platform shaker. 400 µL of the cell lysate was 
combined with 1100 µL Array Buffer 1. After thawing, 20 µL of Detection Antibody Cocktail was 
added to each protein sample and mixed by pipetting. The protein samples were incubated for 
60 minutes at room temperature. Array Buffer 5 (blocking buffer) was aspirated from the 




overnight at 4°C on a rocking platform shaker. Membranes were washed three times for 
10 minutes in 1X Wash Buffer. The membranes were incubated with 2.0 mL streptavidin-HRP for 
30 minutes at room temperature on a rocking platform shaker. Membranes were washed three 
times for 10 minutes in 1X Wash Buffer. 1.0 mL Chemi Reagent Mix was distributed evenly over 
each membrane and imaged using the blot: chemi protocol on the ChemiDoc MP (Bio-Rad). 
Reference spots were included to demonstrate that the membrane had been incubated 
successfully with streptavidin-HRP during the assay procedure. 
 
2.8.3. Data analysis 
Spot intensity was measured in Image Lab software version 5.2.1. Average intensity of the pair of 
duplicate spots was determined for each kinase. Background signal was subtracted using the 
intensity of a clear area of the membrane (of equal size to each spot). 
 
2.9. Microarray 
2.9.1. Directly heat shocked and control cell preparation for RNA extraction 
The cells, that were either control treated (at 37°C) or heat shocked at 45°C to produce heat shock 
exosomes (section 2.2.2), were lysed for yielding RNA. This was following removal of cell 
conditioned media for exosome extraction.  
 
2.9.2. Heat shock or control exosome treatment of MCF-7 cells prior to RNA extraction 
MCF-7 cells were seeded at 125,000 cells/flask in T25 flasks. Control and heat shock exosomes 
were each extracted from 10 x T175 flasks of control or heat shocked MCF-7 cells (each flask 
contained approximately 2.0 × 106 cells) and were administered to the T25 flask of cells 24 hours 
after seeding (sections 2.2 and 2.2.2). This exosome treatment was repeated 48 hours after initial 
seeding to replicate the exosome treatments received by cells in the Matrigel trans-well invasion 
assay (section 2.7.1.1). Twenty-four hours after receiving the second dose of exosomes, the cells 
were harvested and RNA was extracted. 
 
2.9.3. RNA extraction from MCF-7 cells 
RNA was extracted from cells using the miRcury RNA cell and plant kit (300110, Exiqon). The cells 




(section 2.2.2). For each sample, media was aspirated from the cell monolayer and the cells were 
washed with PBS, spent PBS was removed. 350 µL of Lysis Solution (provided in the kit) was added 
directly to the culture plate and the cells were lysed by gently tapping and swirling the culture 
plate for five minutes or until all cells were immersed in the Lysis Solution. The lysate was then 
transferred to a clean microcentrifuge tube. To maximise cell lysis, the sample was vortex mixed 
for 15 seconds, or until the cell pellet had completely dissolved. 200 µL 100% ethanol was added 
to the lysate, and then the sample was vortex mixed for 10 seconds. An RNA extraction column 
was assembled with one of the provided collection tubes (one column was required per sample). 
The sample was transferred onto the column and centrifuged for 1 minute at 3500 × g. To ensure 
the entire sample had passed through the column, the column was centrifuged for a further 
minute at 14,000 × g in a Heraeus biofuge fresco centrifuge. The flowthrough was discarded and 
the column was reassembled with the collection tube. 400 µL Wash Solution was applied to the 
column and the column was centrifuged for 2 minutes at 14,000 × g. The flowthrough was 
discarded and the column was reassembled. 0.25 Kunitz unit/µL RNase-free DNase I working 
solution was prepared by combining 0.5 mL DNase I (AMPD1-1KT, SigmaAldrich) with 1.0 mL 
reaction buffer. 100 µL DNase I working solution was added to the column. The column assembly 
was centrifuged for 2 minutes at 200 × g to enable the DNase I to pass through the column. The 
flowthrough was transferred onto the surface of the column and it was incubated at 25°C for 15 
minutes on a heat block. Following the incubation period, the column was washed twice more 
with 400 µL Wash Solution followed by centrifugation for 1 minute at 14,000 × g. The flowthrough 
was discarded and the column was reassembled. The column was centrifuged for 2 minutes at 
14,000 × g to thoroughly dry the resin. At this point the collection tube was discarded. The 
column was placed into a clean 1.7 mL elution tube (provided in the kit). 50 µL of Elution Buffer 
was added to the column, and the column was centrifuged for 2 minutes at 200 × g followed 
immediately by 1 minute at 14,000 × g. The column was discarded and the purified RNA sample 
was stored at -80°C until use. 
 
2.9.4. cDNA synthesis 
Extracted RNA was measured for quality and quantity using the RNA protocol on the NanoDrop 
1000 (Thermo Fisher Scientific). The High Capacity cDNA Kit (Applied Biosystems) was used to 
make cDNA. A reaction tube for each sample was made (on ice) by combining 1.0 µg RNA, 1.0 µL 
20X reverse transcriptase enzyme mix, 2.0 µL 10X reverse transcriptase buffer, 0.8 µL 
deoxyribonucleotide triphosphates (dNTPs), 2.0 µL 10X random primers, and a sufficient quantity 
of nuclease free water to bring the total reaction volume to 20 µL. The tubes were sealed and 




reaction tubes were incubated in an MJ mini thermal cycler (Bio-Rad) at 25°C for 10 minutes, 
followed immediately by a 2 hour incubation period at 37°C, and finally a 5 minute incubation at 
85°C. The samples were then maintained at 4°C until they were moved to permanent storage 
(until use) at -20°. 
 
2.9.5. Agilent G3 Human Gene Expression 8 x 60K v3 microarray 
Experiments were performed as four biological replicates, samples were extracted using a Qiagen 
RNeasy miniprep kit and the RNA was DNase treated. The extracted RNA was quality verified on a 
2100 expert Agilent bioanalyzer, to confirm that all samples had an RNA yield greater than 30 μg 
and RIN values above 9. Samples were amplified and labelled with Agilent Low Input Quick Amp 
labelling two colour kit, hybridised to an Agilent G3 8plex x 60k gene Human transcriptome 
microarray, and washed to supplier’s protocol. The array slide was scanned at 3.0 μM and 20 bit 
Tiff file dynamic range on an Agilent Surescan G2565CA microarray scanner at 100% PMT gain for 
both red and green lasers, and exported TIFF images. The TIFF images were then aligned to their 
design files and converted into probe intensity values using the Agilent Feature Extraction 
Software. Using this software this data was probe and Loess normalised, and then quantile 
normalised for array variation using DNAstar (ArrayStar Inc.). 
 
2.9.6. DAVID analysis of genes involved in biological pathways 
All genes with statistically significantly differential expression between two samples (control 
MCF-7 cells, directly heat shocked MCF-7 cells, control exosome recipient MCF-7 cells or heat 
shock exosome recipient MCF-7 cells), represented by a p value of <0.05, were further analysed 
using the online functional annotation tool DAVID Bioinformatic Resources 6.7 (National Institute 
of Allergy and Infectious Diseases, National Institutes of Health, USA). The method described by 
Huang and colleagues (2009) was used to identify pathways affected by heat shock exosomes 
(Huang et al., 2009a; Huang et al., 2009b). Briefly, Entrez gene identification numbers of 
statistically significantly differentially expressed genes were pasted into the ‘Enter Gene List’ box. 
‘ENTREZ_GENE_ID’ was selected from the ‘Select Identifier’ options. ‘Gene List’ was selected as 
the ‘List Type’. In the ‘Annotation Summary Results’, ‘KEGG_PATHWAY’ was selected from the 
‘Pathways’ tab. The ‘Chart’ button was pressed to reveal the pathways affected by 
up-/down-regulation of the listed genes. The relevant pathway was selected to uncover a diagram 





2.10. Statistical methods 
2.10.1. Student’s one tailed T­test 
The one tailed T-test was used to determine the probability of two small sets of quantitative data 
(collected independently) being significantly increased or decreased compared with one another 
in terms of the difference between sample means; i.e. the probability that two populations were 
the same with regards to the variable being tested. This enabled acceptance or rejection of the 
hypothesis in question. 
 
2.10.2. Student’s two tailed T­test 
The Student’s two tailed T­test was used to determine the probability of two small sets of 
quantitative data (collected independently) being significantly different from one another in 
terms of the difference between sample means. 
 
2.10.3. Pearson’s correlation coefficient  
Pearson’s correlation coefficient was calculated to determine the strength of the linear 
relationship between two variables.  
 
2.10.4. Spearman’s rank correlation coefficient  
Spearman’s rank correlation coefficient is a nonparametric measure of statistical 
dependence between two variables. It was used to determine the monotonic relationship 
between two data sets. 
 
2.10.5. Grubbs’ test for outliers 
The Grubbs' test was used to identify outliers in datasets of >6 data points. The Grubbs' test 
detects one outlier at a time. Each outlier is removed from the dataset and the test is repeated 


















3. Exosome characterisation 
3.1. Introduction 
Characterisation of exosomes from different sources (e.g. cell lines or patients) under different 
biological conditions (e.g. stress or people with disease) will improve our understanding of their 
role in health and disease (Théry et al., 2002). Exosomes are currently distinguished from other 
EVs based primarily on size, but also using other characteristics including protein composition and 
density (Raposo and Stoorvogel, 2013). Exosomes have been reported to have a diameter of 30–
160 nm (Ludwig and Giebel, 2012; Théry et al., 2002; Théry, 2011), this along with enrichment in 
specific protein markers distinguishes them from Golgi bodies and vesicles derived from the 
endoplasmic reticulum (Raposo et al., 1996; van Niel et al., 2006). Exosome characterisation is 
challenging mainly because of their small size and time-consuming extraction procedures (Gould 
and Raposo, 2013). Several methods and techniques have been optimised over the past decade 
with exponential increase in the study of exosomes. Common exosome characterisation methods 
include: western blotting (WB), transmission electron microscopy (TEM), nanoparticle tracking 
analysis (NTA), and confocal microscopy (Gardiner et al., 2013; Théry et al., 2006). These 
techniques were used in this chapter to characterise exosomes and examine their purity. 
 
3.1.1. Western blotting 
In order to verify that the exosomal pellet obtained at the end of the exosome extraction 
procedure contains exosomes, and is not contaminated with apoptotic bodies and other EVs, the 
sample must be characterised. A highly purified exosome sample should be free from 
contaminants, such as protein components of the intracellular compartments (e.g. endoplasmic 
reticulum or mitochondria) that never come into contact with exosomes (Raposo and Stoorvogel, 
2013). WB has advantages over other exosome characterisation methods, as organelles and 
soluble contaminants, which cannot be identified by TEM, NTA, and confocal microscopy, can be 
detected (Webber and Clayton, 2013). 
 
3.1.2. Transmission electron microscopy 
In addition to WB, exosomes can be visualised using TEM, this technique is often used to examine 
exosome structure (Webber and Clayton, 2013). Exosomes are prepared as whole mount samples 




following negative staining with uranyl acetate. On electron micrographs exosomes appear as 
round dark spheres with diameters <200 nm (Raposo and Stoorvogel, 2013).  
 
3.1.3. Confocal microscopic analysis of exosomes 
Confocal microscopy can be used to visualise the interactions between fluorescently labelled 
exosomes and cells. Cells and exosomes are labelled with fluorescent dyes that are activated at 
different wavelengths to distinguish interactions between cell material and exosomal material 
(Escrevente et al., 2011; Franzen et al., 2014; Parolini et al., 2009).  
 
3.1.4. Nanoparticle tracking analysis 
To complement WB and TEM, NTA measures the size distribution and concentration of exosome 
samples (Soo et al., 2012). NTA measures particles in a liquid of 10 nm–1 µm in diameter using the 
rate of Brownian motion to determine particle size. A laser illuminates the particles in a sample 
causing dispersal of scattered light. The scattered light is detected and tracked. Brownian motion 
is affected by the viscosity of the liquid, the temperature, and the size of the particle. By 
measuring temperature and liquid viscosity NTA is able to establish the size of particles suspended 
in samples using their refractive index. Particles are automatically tracked, measured and 
quantified by the NTA instrument. This technology was first used for analysing exosomes by 
Dragovic and colleagues in 2011 (Dragovic et al., 2011) and has since become a well-established 







3.2.1. Exosomal marker detection by western blotting 
In order to distinguish exosome populations from their cellular derivatives, exosome samples 
required characterisation following extraction. The WB method was developed to identify: HSP70, 
a protein involved in MVB synthesis that is found enriched on the exosome surface (Mathew et 
al., 1995) and is also present in the cytosol of cells; cytochrome C oxidase, a mitochondrial marker 
(also found in apoptotic bodies) (Finucane et al., 1999; Siekevitz and Watson, 1956); the cell 
organelle markers: calnexin, found in endoplasmic reticulum (Wada et al., 1991), and GM130, a 
Golgi maker (Nakamura et al., 1995); and GAPDH, used as a control as it is a cytosolic protein 
expressed at high levels in both cells and exosomes (Seidler, 2013). The exosome marker HSP70 
was detected in both cell protein and exosome protein extracts, shown in two WB membranes in 
Figure 3.1. Cytochrome C oxidase was present in the cell sample but not in the exosome sample, 
suggesting that the exosome sample was not contaminated with either apoptotic bodies or 
cellular organelles, specifically, mitochondria. To further confirm that no contamination had 
occurred during the exosome extraction procedure, the cell organelle markers calnexin and 
GM130 were identified in cell protein lysate only. GAPDH was present in both cellular and 
exosomal protein samples and was therefore used as a control to check that the WB process had 
worked effectively. The results suggest that the characterised sample was free of cellular or 
organelle contamination and contained only EVs. 
87 
Figure 3.1: Exosome characterisation by western blotting. 10.0 µg MCF-7 cell protein lysate and 10.0 µg 
MCF-7-derived exosome protein lysate were characterised. Proteins identified were GAPDH, calnexin, and 
GM130 (cell markers), cytochrome C oxidase (mitochondrial marker also found in apoptotic bodies), and 
HSP70 (a known exosome component). Presence of GAPDH and HSP70 in the exosome protein lysates 
suggests that the sample contains exosomes. Absence of GM130 and calnexin in the exosome protein lysate 
suggests that the exosome sample had not been contaminated with intracellular organelles (Golgi and 
endoplasmic reticulum, respectively) during the sequential centrifugation extraction process. Absence of 





3.2.2. Exosome visualisation by transmission electron microscopy 
As exosomes are small in size, they are impossible to visualise using a standard light microscope 
therefore negative staining is used to visualise exosomes using TEM. To ensure that the exosome 
extraction procedure (section 2.2) is effective in isolating exosomes, TEM was performed on 
whole mount exosome samples extracted from MCF-7 cells (Figure 3.2). Exosomes within the 
expected size range were identified (Raposo et al., 1996). Because of failure to recognise that the 
formvar coated grids needed hydrophilising (with Glow Discharge treatment and subsequent 
magnesium acetate conditioning to give a negative charge), there is a lot of background staining 
on the electron micrograph. Hydrophobic surfaces inhibit the spreading of particles in suspension 
in negative staining solutions. Despite this, exosomes were identified and measured on the 
carbon coated grid. 
 
Figure 3.2: Electron micrograph of exosomes extracted from MCF-7 cells. A) Exosomes at x40,000 
magnification. B) Same image as A) but with data labels for vesicle diameter. Images taken using a Hitachi 
H7650 Transmission Electron Microscope at 100 kV. 
 
3.2.3. Confocal microscopic analysis of exosome-cell interactions 
Internalisation and trafficking of exosomes inside A-2780 cells that had their nuclei stained with 
DAPI was visualised (Figure 3.3). The clear co-localisation observed between exosomes and 
A-2780 cells suggested that the exosomes isolated during the sequential/differential 





Figure 3.3: Interaction between exosomes and A-2780 cells. PKH26 stained exosomes (red) were identified 
inside the A-2780 cells with DAPI stained nuclei (blue) after 60 minutes of co-incubation. Following this 
period they were fixed in 4% paraformaldehyde. Images were acquired using a Zeiss LSM 510 inverted 
confocal microscope, using x630 magnification. A) Image acquired using the 543 nm laser showing 
exosomes interacting with cells, most exosomes have been taken up by the cells. B) Image achieved using 
the 405 nm laser showing the nuclei of A-2780 cells stained with DAPI. C) Phase contrast image of the 






3.2.4. Exosome size determination by nanoparticle tracking analysis 
In addition to sample protein identification by WB, and visualisation by TEM, exosomes were also 
characterised by NTA. The mode average diameters of exosomes released by eight different 
ovarian cancer cell lines were determined using NTA. The mean average of three biological 
replicates of exosome diameter for eight ovarian cancer cell lines is shown in Figure 3.4, in 
descending order. The largest exosomes were extracted from MCP-1 cells (average exosome 
diameter of 149.17 nm) and the smallest from OVCAR-5 (average diameter of 127.10 nm). All 
exosomes were larger than particles detected in PBS (average diameter of 121.70 nm). There was 
no significant exosome size difference between the eight different ovarian cancer cell lines. The 
results suggest that exosomes of a similar size are produced from the eight ovarian cancer cell 
lines of interest.  
 
 
Figure 3.4: Average diameter of exosomes released per cell from eight different ovarian cancer cell lines.  
The mode average diameter of exosomes released by each cell line over 24 hours was determined by NTA. 
The exosome samples were resuspended in PBS and diluted 1 in 100, leading to particle concentrations of 
approximately 5.0 × 108/mL. There were three biological replicates for each cell line. For each biological 
replicate there were two technical replicates. Five 30 second videos of each technical replicate were 
recorded and from these exosome diameter (nm) was calculated. The bar graph represents the mode 
average diameter of exosomes calculated using three biological replicates that were collected on three days 
over a seven day period for each cell line. The error bars represent standard error of the mean. 
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3.2.5. Quantification of exosomes released by eight different ovarian cancer cell lines over a 
24 hour period by Nanoparticle Tracking Analysis 
After numerous attempts to label and subsequently quantify exosomes using fluorescent lipid 
dyes, cellular transfection of plasmids to induce expression of cytosolic fluorescent protein and 
protein radiolabelling, a decision was made to revert to NTA, a method used commonly for 
exosome quantification (Gardiner et al., 2013). To determine the concentration of exosomes 
released by eight different ovarian cancer cell lines, the exosome samples used to measure 
exosome size were also analysed for particle concentration by NTA (Figure 2.1). The highest 
concentration of exosomes released per cell were secreted by all eight ovarian cancer cell lines in 
biological replicate 3; the second most in biological replicate 1 and the least in biological replicate 
2. This may be caused by confounding experimental factors. To account for variation, exosome 
secretion level per cell was normalised to that of OVCAR-3 cells for each biological replicate of the 
other seven cell lines. OVCAR-3 was chosen as the normalisation reference because, when cell 
lines were ranked according to the average number of exosomes released per cell, OVCAR-3 was 
considered mid-range (fifth highest number of exosomes released per cell), and also because 
OVCAR-3 is the most commonly used cell line in preclinical research. The average number of 
exosomes present in the media after 24 hours of cell culture for the eight ovarian cancer cell lines 
of interest (as calculated by NTA) is shown in Figure 3.5 in descending order. There was no 
statistically significant difference between any of the eight cell lines; this was probably because of 
the high variability between biological replicates. However, IGROV-1 cells consistently secreted 





Figure 3.5: Average number of exosomes released per cell from eight different ovarian cancer cell lines, 
quantified by NTA. A) The average number of exosomes released per cell, quantified by NTA, from three 
biological replicates is demonstrated. Each biological replicate was collected on a different day over a seven 
day period. Values were normalised to OVCAR-3 levels of exosome secretion per cell; error bars represent 
the standard error of the mean of the average of three biological replicates. B) Screen shots of NTA videos 






In this chapter, exosomes extracted from both ovarian and breast cancer cell lines were 
characterised using four different methods available to our research group. These methods were 
WB, TEM, confocal microscopy, and NTA. There have been no reports of different ovarian cancer 
cell lines with distinct characteristics secreting exosomes of varying size or at a different 
concentration. Exosomes have been reported to be 30–160 nm in diameter (Ludwig and Giebel, 
2012; Théry et al., 2002; Théry, 2011), the EM and NTA data collected both show that exosomes 
from eight different ovarian cancer cell lines lie within this range (Figure 3.2 and Figure 3.4). Cells 
from which exosomes were extracted were conditioned in EFM therefore, the exosomes 
characterised were mostly of human origin, although it should be noted that the FBS clearing 
procedure is not 100% reliable therefore it is likely that the exosome samples were not 
completely free of bovine exosomes (section 3.3.1.2) (Webber and Clayton, 2013). Because of the 
ultracentrifugal exosome extraction procedure used in this project, it was possible that the vesicle 
population isolated contained microvesicles and possibly small apoptotic blebs that lie within the 
size range of exosomes. However, WB results showed that exosomes contained the specific 
exosome marker HSP70 and also the positive/loading control GAPDH. They were also free from 
organelle and apoptotic bleb contaminants (Figure 3.1). The confocal microscopic results suggest 
that the exosomes interacted with cells so were biologically viable following the extraction, 
fluorescent labelling, and short-term storage at -20°C (Figure 3.3).  
NTA has been used to assess the exosome output of three ovarian cancer cell lines (Zhang et al., 
2015), but in this project a more comprehensive analysis of exosome secretion levels of ovarian 
cancer cells was performed. NTA was used to determine the exosome secretion rates of eight 
ovarian cancer cell lines, this has not previously been reported in literature and provides valuable 
information for ovarian cancer researchers to assist future experimental/study design (Figure 
3.5). Exosome secretion from a single cell line and between different cell lines was inconsistent, 
this may have been because of the experimental conditions during each sample collection. 
However, NTA is known to have limitations, particularly when applied to exosome quantification; 
therefore it may not be the most appropriate method for exosome quantification. Despite 
detecting clean exosome preparations containing vesicles of the correct size and structure using 
four different exosome characterisation methods, there are limitations of the exosome isolation 






3.3.1. Current issues with exosome isolation, purification and nomenclature 
Exosomes are classified based upon size, density, and protein composition. However these 
properties are insufficient for clear distinction between different classes of EV (Bobrie et al., 
2011). All exosome preparations invariably contain different proportions of other membranous 
vesicles that co-purify with exosomes including microvesicles and apoptotic blebs (Tauro et al., 
2012). Only once the ability to interfere with molecular mechanisms required for EV formation are 
developed, will the origins of EVs be determined. This will also enable elucidation of the 
respective functions of different types of EV (Raposo and Stoorvogel, 2013).  
Confusion on the origin and nomenclature of EVs is evident throughout literature and is an issue 
that has still not been resolved (Raposo and Stoorvogel, 2013). Currently, the available 
purification methods, namely differential/sequential ultracentrifugation and density gradient 
centrifugation (Simpson and Mathivanan, 2012), isolate EVs by size and/or density and cannot 
distinguish between exosomes that are of endosomal origin, and microvesicles and apoptotic 
blebs that bud from the plasma membrane. This is a problem as microvesicles range in size from 
50–1000 nm (Théry et al., 2009), and exosomes are 30–160 nm in diameter (Ludwig and Giebel, 
2012), so there is an overlap in size between the two types of EV (Booth et al., 2006). Because 
exosome purification depends upon EV size, when ‘exosomes’ are isolated the population of 
vesicles represents a mixture of exosomes and other EVs. Hence, a major challenge that remains 
in the EV research field is to improve and standardise methods for exosome characterisation and 
analysis (Théry et al., 2006).  
 
3.3.1.1. Nomenclature 
The term ‘exosome’ is currently used in three different ways: (1) to refer to secreted vesicles of 
MVB/endosomal origin; (2) in a broader sense to describe EVs that have a biological function; and 
(3) to define vesicles that sediment only after centrifugation at ~70,000–120,000 × g (Booth et al., 
2006; Gould and Raposo, 2013; Johnstone et al., 1987; Raposo et al., 1996; Théry et al., 2006; 
Trams et al., 1981). Taking into account the issues discussed concerning exosome extraction 
procedure and nomenclature, throughout this project the term ‘exosome’ refers to EVs that are 
extracted from cell culture media following differential/sequential centrifugation with a final 






3.3.1.2. Exosome sample contamination 
Measurement of exosome sample purity is important for experimentation involving functional 
exosomes. Contamination by, for example, high levels of protein aggregates could affect 
experimental results, the effects seen may have been caused by the protein rather than exosomes 
themselves giving false positive results (Webber and Clayton, 2013). Bovine exosomes are 
another common contaminant of exosome samples extracted from culture media. Bovine 
exosomes form part of the FBS that supplements the media to support normal cell growth. 
Additionally bovine serum may contaminate exosome samples by introducing bovine proteins and 
RNAs that could interfere with functional, and proteomic or sequencing exosome experiments 
(Eitan et al., 2015), as mentioned in section 3.3. 
When quantifying exosomes using the BCA assay or NTA, bovine exosome contamination could 
lead to overestimation of exosome concentration (Eitan et al., 2015). Fluorescently labelled 
exosomes may be used on the NTA to ensure that only exosomes of interest are considered for 
the analysis. This can only be achieved by extracting exosomes from cells that stably express a 
fluorescent protein/exosomal marker fusion protein, fluorescent labelling would not selectively 
target human exosomes. It is possible to remove bovine exosomes completely by growing cells in 
SFM prior to extraction; however, serum starvation could induce a cellular response to stress that 
could affect the experimental results. This is particularly unfavourable for experiments performed 
to examine the effect of stressed cell-derived exosomes upon the stress response in the recipient 
cell (Fader et al., 2008). The best solution is to culture cells from which exosomes are to be 
extracted in media containing FBS cleared of exosomes (EFM) (by ultracentrifugation at 120,000 × 
g overnight). If exosome depleted FBS was used in media continually, cell growth may be affected, 
however, for short periods during exosomal experiments (typically a maximum of 48 hours), 
biological changes to cells cultured in the absence of bovine exosomes are minimal (Eitan et al., 
2015).  
All exosome extraction procedures carried out during this project involved culture of cells with 
EFM for 24 hours prior to exosome extraction. EFM was made by clearing FBS of exosomes by 
ultracentrifugation at 120,000 × g overnight at 4°C. This does not guarantee, however, that all the 
bovine exosomes had been removed from the FBS before it was added to the media (final 







3.3.2. Limitations of exosome characterisation techniques 
The techniques used in this project to characterise exosomes are used frequently in the EV 
research field however, there are limitations. Since the EV research field is still relatively young, 
the gold standard method(s) for exosome characterisation have not yet been established. 
 
3.3.2.1. Limitations of exosome quantification by WB 
HSP70 is a good marker for exosomes because it is well-regarded that HSP70 is involved in 
exosome biogenesis (Théry, 2011). Ideally other proteins known as exosome markers such as Alix 
and TSG101 would also have been identified by WB in the exosome samples. Unfortunately, these 
proteins were not optimised even though considerable efforts were made.  
The apoptotic body marker cytochrome C oxidase was used and its presence in whole cell protein 
lysates and absence in exosome samples suggests that apoptotic body concentration in the 
exosome samples was low. However, the exosome samples may have contained high levels of 
microvesicles.  
Most exosome research publications identify at least one of the exosome tetraspanin markers 
CD9, CD63 and/or CD81. At the present time, these tetraspanin markers are the best for 
characterising exosomes because they are amongst the most common proteins identified in 
exosomes (Mathivanan et al., 2012). Despite substantial efforts, it was not possible to optimise 
these exosome markers for WB in this project. Conversely, tetraspanin exosome markers are 
enriched in exosomes but are also found on the cell membrane so cannot be used as markers to 
distinguish exosomes from microvesicles. Knowledge within the EV research field of marker 
proteins to distinguish different types of EV is not yet sufficient for identification of exosomes 
(Raposo and Stoorvogel, 2013). 
 
3.3.2.2. Limitations of exosome quantification by TEM 
TEM is an indicator of the structure and size of exosomes extracted but may not represent the 
entire sample, especially in this project where the formvar coated grids were not prepared 
correctly by hydrophilisation to give a negative charge. This may have prevented a large fraction 
of the exosome sample from fixing to the grids and also gave high background signal making it 
difficult to distinguish exosome structure on some sections of the grids. This may also explain why 




3.3.2.3. Limitations of exosome quantification by NTA 
When quantifying exosomes it is important to note that exosomes are not only being released by 
cells but are also being taken up by recipient cells so the concentration represents the net 
number of exosomes that have been released but not internalised by neighbouring cells. 
Therefore, the calculated exosome concentrations may not represent the levels of exosome 
secretion by different cell types because some types of cells may take up more exosomes but 
secrete less, or vice versa. When measured by NTA, of the eight cell lines tested, IGROV-1 cells 
appeared to secrete the highest number of exosomes. IGROV-1 cells may secrete similar numbers 
of exosomes compared with other ovarian cancer cell lines but the rate of exosome uptake by 
IGROV-1 cells may be much lower, hence the higher concentration of exosomes detected in 
conditioned media. It is currently difficult to distinguish exosomes from other small particles in 
solution, including protein aggregates and other debris, when analysing exosome samples by NTA. 
The PBS control sample should account for this. However, without the ability to specifically tag 
exosomes for subsequent detection by NTA it is impossible to exclude non-exosomal particles. It 
is unclear whether the inconsistency in exosomes released per cell in the eight cell lines was 
because of true inconsistency in exosome release or because of limitations of the NTA method for 
quantifying exosomes.  
 
3.3.2.4. Limitations of exosome quantification by confocal microscopy 
Confocal microscopy is subjective, time consuming and allows for only a small fraction of the total 
cell number to be analysed (Franzen et al., 2014; Lässer et al., 2011). In terms of exosome 
characterisation, the major limitation of lipid dyes is that they are not specific to exosomes. They 
were designed to label cell membranes so the amount of dye leeching is difficult to determine. 
The best way to resolve this problem would be to specifically tag exosomes by creating 
fluorescent fusion proteins with exosome markers e.g. CD63-GFP. This is achieved by creating a 
stable CD63-GFP expressing cell line that will consequently produce CD63-GFP expressing 
exosomes (Koumangoye et al., 2011). This would enable visualisation of their activity by confocal 
microscopy. Because of the small diameter of exosomes (maximum of 160 nm [Ludwig and 
Giebel, 2012]) it may be difficult to visualise tagged proteins associated with exosomes. 
Furthermore, the number of proteins inside exosomes is unknown, CD63-GFP incorporation into 
exosomes must be great enough to give a signal that can be detected, i.e. it may not be possible 
to detect a single CD63-GFP protein on a single exosome.  
A major limitation of the use of confocal microscopy for visualisation of exosome activity is that 




exosomes that are typically 30–160 nm in diameter (Ludwig and Giebel, 2012), or clusters of 
exosomes that are less than 390 nm in diameter, would be indistinguishable from one another. 
This should not affect the general detection of exosome uptake inside recipient cells but may 
affect tracking and localisation analysis of individual exosomes.  
 
3.3.3. Additional exosome isolation techniques 
Differential/sequential ultracentrifugation was used throughout this project, however, additional 
exosome isolation procedures exist that may have been more suitable. Each technique has both 
benefits and limitations. 
 
3.3.3.1. Sucrose density gradient centrifugation 
In addition to ultracentrifugation, sucrose density gradient centrifugation has frequently been 
used to extract exosomes. This method exploits the buoyant density of exosomes for purification 
and can be used in either a continuous gradient (Raposo et al., 1996) or in a linear stepped 
gradient (sucrose cushion) (Lamparski et al., 2002). Sucrose density gradient centrifugation 
minimises protein contamination from large protein aggregates that co-sediment with exosomes 
during ultracentrifugation (Tauro et al., 2012). However, unless sucrose is substituted for 
iodoxanol (OptiPrep™, SigmaAldrich), this technique is unable to separate exosomes from viruses 
or large EVs with comparable sedimentation velocities (Cantin et al., 2008). The main limitations 
of this method are that sucrose gradients are difficult to make accurately, and following 
centrifugation it is difficult to remove separate fractions without mixing them. 
 
3.3.3.2. Immunoadsorption/immunoaffinity capture 
Immunoadsorption is an alternative exosome isolation technique (Wubbolts et al., 2003) using 
magnetic beads coated with a specific protein antigen that selects for exosomes with an outward 
orientation (as achieved during inward budding of the endosomal membrane during exosome 
biogenesis). Initially this technique was reported to yield high quality exosome samples enriched 
for exosome markers Alix, TSG101, and HSP70 (Tauro et al., 2012). However, since the technique 
utilises a specific membrane antigen, only exosomes with the antigen are isolated while the 
exosome population without the antigen are excluded (Simpson and Mathivanan, 2012). This 
could eliminate a substantial fraction of the exosome sample. The exosome sample would contain 




of the total exosome population. In order to use this immunoaffinity method to accurately 
separate different types of EVs, an antigen specific to each class of EV, that is always present, 
must be used. Many of the antigens present on the exosomal surface are common to other types 
of EV and the knowledge of the exosomal membrane within the EV research field is not adequate, 




Ultrafiltration is a method used to concentrate exosomes from biological fluids, typically urine 
(Cheruvanky et al., 2007). Exosomes in suspension (in culture media) are forced through a 
semi-permeable membrane that separates them from other components of the media including 
protein aggregates, which commonly contaminate exosome preparations (Nordin et al., 2015). 
This method has been used in some exosome research studies and has become more popular 
with exosome researchers over the last few years (Cheruvanky et al., 2007; Lamparski et al., 2002; 
Lobb et al., 2015). The method is less time consuming and does not require the use of an 
ultracentrifuge, however, would probably not be ideal for extracting exosomes from cell culture 
media because of the lower concentration of exosomes in culture media compared with biological 
fluids.  
 
3.3.3.4. Size exclusion chromatography 
Recently an investigation was performed to compare standard ultracentrifugation with 
ultrafiltration liquid chromatography (UF-LC) where the ultrafiltered exosomes were loaded onto 
a sephacryl column for subsequent size-exclusion fractionation. This method yielded exosome 
samples of higher concentration and purity than ultracentrifugation (Nordin et al., 2015). Data 
were also collected that suggested that exosomes fuse, erupt, and aggregate during the 
ultracentrifugation procedure, these issues were evaded with UF-LC (Nordin et al., 2015). 
 
3.3.3.5. Commercial ‘exosome’ isolation kits 
Because of the rapid and growing interest in exosomes as future biomarkers and their possible 
use in therapeutics, many commercially available kits have been designed for easy isolation of 
exosomes, which generally do not require ultracentrifugation. These kits usually extract all lipid 




(including apoptotic and membrane blebs of up to ~1000 nm in size) and membrane-free 
macromolecular aggregates (Raposo and Stoorvogel, 2013). 
 
3.3.4. Additional exosome characterisation methods 
In addition to the exosome characterisation methods used in this project, other methods exist. 
Ideally all characterisation methods would have been used but because of time and money 
constraints this was not possible.  
 
3.3.4.1. Cryo-electron microscopy 
Often exosomes have a cup-shaped morphology because the spherical structure collapses during 
the drying stage prior to the fixing process when preparing grids for TEM (Raposo et al., 1996). 
Rapidly frozen, vitrified exosomes visualised using cryo-electron microscopy are round in shape 
(they have not collapsed) (Conde-Vancells et al., 2008). This method may give a more 
representative depiction of exosome structure than standard TEM. 
 
3.3.4.2. High resolution flow cytometry 
Conventional flow cytometry cannot detect vesicles <300 nm in diameter (Raposo and Stoorvogel, 
2013). Currently available exosome characterisation methods allow analysis of exosomes in bulk 
but are not suitable for accurate quantification. They often fail to analyse single exosomes within 
a population, and do not examine phenotypic heterogeneity within exosome samples (Nolte-'t 
Hoen et al., 2012b). A high-throughput flow cytometric method for analysis of individual 
exosomes has recently been developed using PKH67-labelled exosomes (Nolte-'t Hoen et al., 
2012b; van der Vlist et al., 2012). The method was further optimised for selection of exosomes 
specifically expressing major histocompatibility complex class 2 (MHC-II) and milk-fat 
globule-epidermal growth factor 8 (MFG-E8) (Nolte-'t Hoen et al., 2012b). The main disadvantage 
of this method is that only exosomes expressing the specific proteins are selected, vesicles that 
are negative for the target proteins will not be analysed, therefore analysis may not be 
representative of the entire exosome sample. Additionally, specific antigens selected must only 
be present on the membranes of exosomes, our knowledge of EV protein components is limited 
at the present time, so it is difficult to select antigens that will specifically isolate the exosome 






Despite its limitations, sequential/differential ultracentrifugation is the most widely used method 
for exosome extraction (Zhang et al., 2014) and was used to isolate exosomes throughout this 
project. On reflection, it may have been better to isolate exosomes using iodoxanol density 
gradient centrifugation or UF-LC to minimise protein aggregate and viral contamination (Cantin et 
al., 2008; Nordin et al., 2015; Tauro et al., 2012). However, density gradient centrifugation does 
not prevent contamination of the exosome sample with other types of EV that have an equal 
density to exosomes. Strategies to separate EVs dependent upon their origin (endosomal or 
membranous) are yet to be robustly developed (Raposo and Stoorvogel, 2013; Théry et al., 2006). 
Future work should strive to characterise exosomes using as many of the characterisation 
techniques discussed in this chapter as possible, to ensure that the exosome sample has the 
desired characteristics and is free from impurities. Because of time and money constraints this is 
not always possible. 
Regardless of the limitations discussed in this chapter, throughout this project all exosome 
samples were characterised using four different methods: WB, TEM (on non-hydrophilised 
formvar grids), NTA, and confocal microscopy. All four methods recognised EVs with typical 
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4. The effect of exosomes on cell motility
4.1. Introduction 
4.1.1. Mechanisms of cell motility 
To facilitate metastasis, cancer cells must escape the primary tumour and relocate to a secondary 
site (section 1.2). In order for this to happen they must acquire an increased motile capacity 
(Brooks et al., 2010; Birchmeier et al., 2003; Friedl and Wolf, 2003). Invasive and migratory 
behaviours facilitate movement of cells from the primary tumour mass into the circulation or 
lymphatics for dissemination around the body (Figure 1.2 and Figure 1.3) (Shayan et al., 2006). To 
move within tissues and escape the primary tumour, neoplastic cells migrate in a similar way to 
cells during normal physiological processes, including: embryonic morphogenesis, wound-healing, 
and immune-cell trafficking (Friedl and Wolf, 2003). Cell migration occurs through a continuous 
cycle of four key steps, shown in Figure 4.1: (1) Firstly, the motile cell becomes polarised and 
elongates (Conklin and Keely, 2012), (2) as a result of projection of the leading edge, a long 
finger-like protrusion (known as a pseudopod) forms, (3) this attaches to the ECM through 
focal-adhesions and extends and contracts pulling the cell body forward, (4) a traction force is 
generated that causes gradual forward gliding of the cell body and its trailing edge across the ECM 





Figure 4.1: Mechanisms of cell motility. 1) The motile cell becomes polarised and elongates. Enzymes break 
down ECM making room for the cell to move forward. 2) As a result of projection of the leading edge, a long 
finger-like protrusion, known as a pseudopod, forms. 3) This attaches to the ECM through focal-adhesions 
and extends and contracts pulling the cell body forward. 4) A traction force is generated that causes gradual 
forward gliding of the cell body and its trailing edge across the ECM. A trail of damaged ECM is left behind 
the cell that has moved. 
 
In order for cell migration to occur, the cell body shape is altered and the cell interacts with the 
adjacent ECM. The ECM provides both a support scaffold for the cell to move along and also acts 
as a barrier to cell migration. The migrating cell destroys the ECM through the activity of 
interstitial collagenases, gelatinases, and stromelysins at the leading edge, as the cell body moves 
towards the ECM framework (Conklin and Keely, 2012; Friedl and Wolf, 2003). Whilst the cell 
body increases in volume, the ECM is degraded, which provides the space required for the cell to 
move forward. The motile cell leaves behind a trail of tube-like defects in the ECM along the 
migration path (Friedl et al., 1997), like a snail’s trail. Additional protein types involved in 
neoplastic cell migration include integrins, cell-cell adhesion molecules, and proteins involved in 




degradation is not essential to effective cell motility, some cancer cell types are able to physically 
deform their shapes to allow them to squeeze between cells of a complex tissue in the absence of 
protease activity (Brooks et al., 2010; Friedl and Wolf, 2003; Sahai, 2005; Sahai, 2007). 
Neoplastic cells migrate in several ways. Specifically, epithelial cancers migrate through single-cell 
migration collective/clustered cell migration or chain migration. Single-cell migration, as the name 
suggests, involves movement of single cancer cells. Collective/clustered migration involves 
movement of small clusters of cells or sheets of cells. This occurs in normal physiology during 
embryonic development, and development of glands and ducts in mammary tissue. Chain 
migration involves synchronised movement of a string of cells aligned between stromal fibres 
(Friedl and Wolf, 2003). Chain migration has been visualised in both breast (Roussos et al., 2011), 
and ovarian (Sood et al., 2001) cancers. In some cases, following extensive dedifferentiation, 
epithelial cancers migrate via mesenchymal migration where cells embrace a fibroblast-like 
spindle-shaped morphology (section 1.2). Other types of cancer cell migrate in a less adhesive, 
amoeboid-like manner, which allows them to crawl faster through tissues (Brooks et al., 2010; 
Friedl and Wolf, 2003).  
 
4.1.2. The scratch assay 
The scratch assay is a simple, cost-effective and well-established method used to measure basic 
cell migration factors such as speed, persistence, and polarity in vitro. A cell monolayer is grown 
to 100% confluency and a scratch is made using a pipette tip, scratch width is then observed at 
regular intervals (Todaro et al., 1965) (Figure 2.2). Cells at the wound edge polarise and migrate 
inwards, eventually the scratch heals. Aside from being both straightforward and economical, the 
major advantage of the scratch assay is that it generates a strong directional migratory response 
in the cells allowing for easy analysis of cell migration rates (Cory, 2011).  
 
4.1.2.1. The use of the scratch assay in exosome research 
The effect of exosomes on motility of human cells in vitro has been assessed using the scratch 
wound healing assay in many studies over the past six years (Salomon et al., 2013a). 
Cytotrophoblast-derived exosomes statistically significantly increased motility of first trimester 
extravillous trophoblast cells (Salomon et al., 2013a). Cancer studies have shown that exosomes 
influence the motile potential of recipient cells using the scratch assay. Motility of breast cancer 
cells and glioma cells was shown to increase in the presence of parent cell-derived exosomes in a 




fluid-derived exosomes were shown to increase the motility of human telomerase reverse 
transcriptase (hTERT)-immortalised human umbilical vein endothelial cells, this process was 
shown to be mediated by phosphatidylserine on the exosomal surface (Chugh et al., 2013). 
Exosomes derived from a colon adenocarcinoma cell line have been shown to increase 
proangiogenic motility of human dermal microvascular endothelial cells by 4.1 fold (Yoon et al., 
2014). Human embryonic kidney cell-derived exosomes positive for LMP1 were shown to increase 
movement of immortalised nasopharyngeal epithelial cells and an EBV-negative human 
nasopharyngeal carcinoma cell line (Aga et al., 2014). 
Exosome donor cells with increased drug resistance and metastatic potential have been explored 
as possible mediators of increased cell motility in cancer cells. Exosomes derived from human 
prostate cancer cells both resistant and sensitive to Docetaxel did not differentially affect cell 
motility (Corcoran et al., 2012). Even though the drug resistance status of a cell does not affect 
the ability of the exosomes it secretes to induce cell movement in recipient cancer cells, there is 
evidence to suggest that the metastatic capacity of an exosome’s parental cell can influence 
recipient cell motility (Harris et al., 2015). Exosomes derived from aggressive triple-negative 
breast cancer cells were able to increase motility of three breast cancer cell lines more than 
exosomes derived from their less invasive sister cell line (section 4.1.2.2) (O'Brien et al., 2013).  
 
4.1.2.2. The linear relationship between breast cancer exosome donor cell metastatic 
status and invasive capacity induced by exosomes 
A relationship has been established between increasing breast cancer cell motility and increasing 
metastatic capacity of exosome donor cells (Harris et al., 2015). Whereby, presence of highly 
metastatic breast cancer cell-derived exosomes increased motility the greatest, followed by 
intermediately metastatic cell-derived exosomes. Whereas, exosomes derived from cells with a 
low metastatic capacity had minimal effect on cell motility. This suggests an association between 
the metastatic potential of the exosome donor cells and the ability of exosomes to increase cell 
motility (Harris et al., 2015).  
 
4.1.3. Hypothesis 
As exosomes derived from cells with higher metastatic capacity have been shown to increase 
motility of breast cancer cells to a greater degree than exosomes isolated from less metastatic 
breast cancer cells (Harris et al., 2015), it was predicted that this mechanism may be active in 




from a range of ovarian cancer cell lines with different metastatic abilities upon motility of ovarian 
cancer cells was investigated using the scratch wound healing assay. It was hypothesised that 
exosomes derived from highly motile ovarian cancer cell lines increase the motile capacity of 
inherently less motile ovarian cancer cell lines. In addition to this, it was hypothesised that cells 








4.2.1. Scratch assay method optimisation 
The cell seeding concentration for the scratch assay was optimised for each different cell line 
(Figure 4.2). The optimum seeding concentrations are summarised in Table 2.2. Different tools to 
create the scratches were tested. P200 pipette tips were found to leave the least residual cells 
within the scratch region in comparison with the P20 and P2 pipette tips. The straight needle 
probe was insufficient for making a wide clean scratch (Figure 4.3).  
 
 
Figure 4.2: Optimising cell seeding concentration for scratch assay. Each cell line was seeded at different 
concentrations to find the optimum. The lowest concentration at which 100% confluency was achieved over 





Figure 4.3: Testing scratch making tools on a cell monolayer. A) P2 pipette tip, B) P20 pipette tip, C) P200 
pipette tip, and D) the straight needle probe were tested for their efficiency in creating a scratch on a 
monolayer of MCF-7 breast cancer cells. 
 
4.2.2. Motility and proliferation rates of nine ovarian cancer cell lines 
4.2.2.1. Motility rates of nine ovarian cancer cell lines 
The difference in motile capacity of these nine ovarian cancer cell lines has not previously been 
reported in literature. To assess the motility rates of different cancer cell lines, the scratch assay 
was used (Figure 2.2 and Figure 2.4). Cells were seeded in 24-well plates and left to settle and 
reach 100% confluency over 48 hours. A scratch was made down the centre of the cell monolayer 
using a P200 pipette tip, and the cells were visualised every 12 hours to determine rate of scratch 
closure. SKOV-3 cells were found to have the greatest motile capacity, closely followed by 
OVCAR-8. IGROV-1 cells moved the slowest (Figure 4.4A). The two tailed T-test calculations 
indicate that cell motility (in terms of normalised scratch closure width at the 24 hour time point) 
of all nine cell lines were statistically significantly different from one another, except for A-2780 
and MCP-1; A-2780 and OVCAR-4; CP-70 and OVCAR-3; CP-70 and OVCAR-4; IGROV-1 and MCP-1; 




nine ovarian cancer cell lines of interest. Average scratch closure rates show a similar pattern to 
the scratch closure curves in Figure 4.4A, except CP-70 cells were shown to move slower overall 
than OVCAR-3 cells in terms of average scratch closure rate (1.95%/hour and 2.18%/hour, 
respectively). The scratch closure curves in Figure 4.4A show that at the 120 hour time point the 
scratch was wider (i.e. the cells moved slower) for OVCAR-3 cells compared with CP-70 cells. See 
Appendix B (section 8.2) for raw motility data. 
 
Table 4.1: Two tailed T-test for cell motility in terms of average scratch closure speed (% area 






























3.24 × 10-5 5.75 × 10-4 0.442 0.009 0.311 3.37 × 10-5 7.94 × 10-6 7.70 × 10-8 
CP-70 
(solid tumour)  
3.05 × 10-6 0.010 0.289 0.051 2.47 × 10-4 2.58 × 10-5 2.63 × 10-7 
IGROV-1 
(solid tumour)   
0.117 2.11 × 10-4 0.001 3.62 × 10-6 2.03 × 10-6 1.52 × 10-8 
MCP-1 
(solid tumour)    
0.007 0.191 6.10 × 10-6 1.29 × 10-6 1.62 × 10-9 
OVCAR-3 
(malignant ascites)     
0.044 6.69 × 10-4 1.31 × 10-5 8.48 × 10-9 
OVCAR-4 
(malignant ascites)      
3.13 × 10-5 5.41 × 10-6 1.48 × 10-8 
OVCAR-5 
(malignant ascites)       
0.004 9.77 × 10-7 
OVCAR-8 
(unknown origin)        
0.005 
 P = >0.05        
 P = <0.05        
 
 
4.2.2.2. Proliferation rates of nine ovarian cancer cell lines 
The scratch assay is used to determine how fast cells move, however it is also important to 
appreciate that cell proliferation (i.e. increase in cell number) also contributes to closure of the 
scratch. To find the proliferation rates of the cell lines, cells were seeded at a known 
concentration at time = 0 and cell concentration was calculated every 24 hours over a period of 
120 hours. The proliferation curves of nine ovarian cancer cell lines are shown in Figure 4.4C. 
Despite healing the scratch the fastest, SKOV-3 cells proliferate slower than most of the cell lines 
(Figure 4.4A&C). Of the nine cell lines tested, SKOV-3 cells were the third slowest in terms of 
proliferation with a doubling time of 36.24 hours (Figure 4.4D). A-2780 cells, and the A-2780 sister 
cell lines MCP-1 and CP-70, were shown to proliferate the fastest of the nine cell lines tested 
(Figure 4.4C&D), however aside from IGROV-1, these cell lines were the least motile (Figure 
4.4A&B). The two tailed T-test values indicate that cell proliferation (in terms of doubling time 




A-2780 and SKOV-3; CP-70 and MCP-1; CP-70 and OVCAR-3; CP-70 and SKOV-3; MCP-1 and 
OVCAR-3; MCP-1 and OVCAR-4; MCP-1 and SKOV-3; OVCAR-3 and SKOV-3, were statistically 
significantly different from one another (Table 4.2). See Appendix B (section 8.2) for raw 
proliferation data. 
 






























0.084 0.401 0.086 1.55 × 10-4 0.048 0.276 0.315 4.70 × 10-4 
CP-70 
(solid tumour)  
0.433 0.030 3.45 × 10-4 0.060 0.406 0.435 0.001 
IGROV-1 
(solid tumour)   
0.376 0.647 0.737 0.521 0.533 0.573 
MCP-1 
(solid tumour)    
0.002 0.042 0.205 0.242 0.003 
OVCAR-3 
(malignant ascites)     
0.454 0.330 0.436 0.025 
OVCAR-4 
(malignant ascites)      
0.194 0.266 0.214 
OVCAR-5 
(malignant ascites)       
0.945 0.629 
OVCAR-8 
(unknown origin)        
0.744 
 P = >0.05        






























































































































































































































































































































































































































































































































































































































































































4.2.3. Scratch closure speed normalised to cell proliferation rates 
Once scratch closure speed (Figure 4.4B) and cell proliferation rates, in terms of cell 
concentration doubling time (Figure 4.4D), had been determined for all nine cell lines, scratch 
closure speed was normalised to cell proliferation levels (Figure 4.5). Generally, scratch closure 
speed was not greatly affected by cell proliferation rate because SKOV-3 cells remained the most 
motile (0.23), followed by OVCAR-8 (0.19) and OVCAR-5 (0.13). IGROV-1 remained the least motile 
cell line (0.02) (Figure 4.4B and Figure 4.5). Cell proliferation was shown to have minimal effect 
upon MCP-1 cell motility with a normalised scratch closure speed of 0.11. Of the nine cell lines 
tested they were the fourth most motile (Figure 4.5) as opposed to the second slowest as 
indicated by average scratch closure speed (Figure 4.4B).  
Scratch closure speed normalisation to proliferation rate suggested that OVCAR-3 (0.05) was the 
equal third slowest cell line in terms of cell motility (Figure 4.5) contrasting with fourth fastest 
when motility was assessed by average scratch closure speed only (Figure 4.4B). Similar results 
were found with the OVCAR-4 cell line when scratch closure speed was normalised to 
proliferation, a value of 0.04 represented the second slowest moving cell line of the nine lines 
tested whereas, when cell proliferation was not considered, OVCAR-4 cells were regarded as the 
fourth slowest cell line. These results suggest that for both OVCAR-3 and OVCAR-4 cell lines, cell 
proliferation contributed to closure of the scratch, more so than for the other cell lines tested. 
 
Figure 4.5: Scratch closure speed normalised to cell proliferation rates. Average scratch closure speed was 
divided by cell doubling time to give normalised values for scratch closure speed for each cell line. There 


















































































































The correlation between cell proliferation and motility rate shows that there was lack of 
correlation between these two cellular phenotypes (Figure 4.6). The motility rate of each cell line 
was assessed in terms of both scratch width after 24 hours, and percentage scratch area 
reduction per hour. For doubling time plotted against scratch width after 24 hours for each cell 
line (Figure 4.6A), the regression line represents a Pearson’s correlation coefficient of 0.200 
(p = 0.606), demonstrating that there was a weak relationship between the two sets of data. The 
R2 value of 0.040, and Spearman’s rank correlation coefficient of 0.949 indicate that the variables 
have a weak linear but strongly monotonic relationship. For doubling time plotted against 
percentage scratch area reduction per hour for each cell line (Figure 4.6B), the Pearson’s 
correlation coefficient was calculated as -0.081 (p = 0.836) indicating that there was a weak 
relationship between these cellular characteristics. The R2 value of 0.007 suggests that cell 
motility, and exosome secretion rates have no linear relationship. Spearman’s rank correlation 
coefficient was calculated as 0.898, further indicating a weak linear, but moderately monotonic 
relationship. This shows that irrespective of whether cell motility is analysed in terms of scratch 
width after 24 hours, or percentage scratch area reduction per hour, cell motility is not greatly 
influenced by cell proliferation.  
The Grubbs’ test indicated that there were no outliers in the data sets for both cell motility (in 
terms of both average scratch closure speed and scratch width at 24 hours) and proliferation 
(doubling time) rates. This results suggests that there was no association between cell motility 
and cell proliferation. The speed at which cells replicated did not affect their ability to close the 







Figure 4.6: Correlation between motility and proliferation capabilities of nine ovarian cancer cell lines. 
Nine cancer cell lines were assessed for their motile capacity using the scratch assay and their proliferation 
rate by calculating cell number increase over 120 hours (five days). Average doubling time between 0–96 
hours was used as a measure of cell proliferation. The relationship between cell proliferation and cell 
motility was determined in terms of A) scratch width at 24 hours and B) percentage scratch area reduction 
per hour. The correlation between the two cellular phenotypes for each cell line is shown. R2 and p values 






4.2.4. The relationship between cell motility and exosome secretion rates 
It is possible that exosome secretion from cells that migrate more rapidly is elevated because of 
the increased need for cell-cell communication. An increase in circulating exosome concentration 
has been linked with poorly differentiated tumours and shorter overall survival (Silva et al., 2012). 
Since a greater motile capacity is also a characteristic of more aggressive and well developed 
tumours (Guarino, 2007; Huber et al., 2005), it was hypothesised that more motile cells secrete 
more exosomes. To investigate this, the relationship between exosome secretion and motility 
rate was determined by plotting exosome secretion and motility rates against one another. The 
correlation between exosome secretion and motility rate shows that there was no relationship 
between these two cellular phenotypes (Figure 4.7).  
Where motility rate was assessed in terms of percentage scratch area reduction per hour, a 
Pearson’s correlation coefficient of ­0.303 (p = 0.465) suggests a weak negative correlation 
between the variables, this is represented by the regression line in Figure 4.7A. The R2 value of 
0.092 indicates that the data points had a weak linear relationship. The Spearman’s rank 
correlation coefficient of 0.610 indicates an intermediary monotonic relationship between 
motility rate (in terms of percentage scratch area reduction per hour) and exosome secretion 
rates. 
These results suggest a moderate relationship between cell motility and exosome secretion. The 
Grubbs’ test was applied to identify outliers. The Grubbs’ test confirmed that in terms of average 
number of exosomes released per cell, IGROV-1 was an outlier. When the IGROV-1 anomalous 
data point was removed, the direction of the relationship between exosome secretion and cell 
motility (in terms of both average scratch closure speed and scratch width at 24 hours) changed 
from positive to negative, or vice versa. For this reason, the IGROV-1 data point was not included 
in the analysis.  
When the IGROV-1 data point was removed (Figure 4.7B), the R2 value was 0.238, the Pearson’s 
correlation coefficient was 0.488 (p = 0.536), and the Spearman’s rank correlation coefficient was 
0.337, suggesting a weak, positively correlated, mildly monotonic relationship between cell 
motility and exosome secretion.  
Many publications use scratch width at 24 hours to assess cell motility (Kaur et al., 2012; Liu et al., 
2013; Yang et al., 2010), so the data was also analysed in terms of normalised percentage scratch 
width at 24 hours. The relationship between cell motility in terms of scratch width at 24 hours and 
exosome secretion is presented in Figure 4.7C. The Pearson’s correlation coefficient was 
calculated as 0.457 (p = 0.255) suggesting a moderate positive correlation. The R2 value of 0.208 




coefficient was 0.670 suggesting an intermediary monotonic relationship between cell motility (in 
terms of scratch width at 24 hours) and exosome secretion. When the IGROV-1 anomaly was 
removed (Figure 4.7D), the Pearson’s correlation coefficient was re­calculated to -0.617 
(p = 0.140) suggesting a moderate negative correlation between the variables. The R2 value of 
0.380 suggests a weak linear relationship between cell motility and exosome secretion. 
Spearman’s rank correlation coefficient was 0.041 indicating absence of a monotonic relationship 































































































































































































































































































































































































































































































































4.2.5. The effect of exosomes derived from highly motile cells on less motile cells 
It was predicted that exosomes may have the ability to transfer signals to recipient cells to 
increase their metastatic behaviour, in particular, cell motility. Having established the most motile 
cell lines from the least motile, exosome swapping experiments were performed where ovarian 
cancer cells were cultured in EFM. Twenty-four hours prior to, and immediately after the scratch 
was created, exosomes derived from more/less motile cells were administered, and their effect 
on cell motility was explored. To determine the effect of exosomes on motility of OVCAR-5 cells, 
exosomes were extracted from OVCAR-5 and SKOV-3 cells and applied to OVCAR-5 cells (Figure 
2.3). OVCAR-5 cells were selected as their motile capacity was in the middle of the range of the 
ovarian cancer cell lines tested (Figure 4.4A&B), so their motility could be increased or decreased 
by exosome treatment. It was predicted that their motile capacity may be enhanced by 
SKOV-3-derived exosomes because SKOV-3 cells had the greatest motile capacity. 
Exosomes were collected from media that had conditioned approximately 6 million cells over a 24 
hour time period and applied to cells in the scratch assay. OVCAR-5 and SKOV-3-derived 
exosomes enhanced motility of OVCAR-5 cells resulting in faster closure of the scratch, but the 
effect induced did not reach significance. Despite the differences in the motility rate curve (Figure 
4.8A) and increase in average scratch closure speed (Figure 4.8B), the T-test of normalised scratch 
width at 24 hours and average scratch closure speed, showed that neither OVCAR-5 nor SKOV-3 
exosomes statistically significantly increased cell motility (Table 4.2). The experiment was 
repeated three more times to generate a total of 12 biological replicates (Figure 4.9), but 
significance was not reached (Table 4.4). It was hypothesised that SKOV-3 exosomes would 
increase motility more than exosomes derived from other cell lines because SKOV-3 cells are the 
most motile. However, the results suggest that SKOV-3 cell-derived exosomes do not increase the 
motility of OVCAR-5 cells. Also, OVCAR-5 cell-derived exosomes, used as a control, did not 
increase OVCAR-5 cell motility, indicating that increased exosome concentration also does not 





Table 4.3: Two tailed T­test results for exosome ‘swapping’ treatments on OVCAR­5 cells shown in Figure 
4.8. 
Average scratch closure speed (% area 
reduction/hour) 
 



































Figure 4.8: The effect of OVCAR-5 and SKOV-3-derived exosomes on motility of OVCAR-5 cells. A) The 
curve represents scratch closure rate of OVCAR-5 cells that received no exosomes, or OVCAR-5 or SKOV-3 
cell-derived exosomes. B) Average scratch closure speed in terms of percentage scratch area decrease per 
hour. Each sample group contained three biological replicates, within each replicate there were three 
technical replicates. Error bars represent standard error of the mean of three biological replicates. C) 
Representative images of the cells at different time points showing the effect that exosomes had on cell 
movement. Each exosome treatment contained exosomes secreted by approximately 2 million cells over 24 






Table 4.4: Two tailed T­test results for 12 replicates of exosome ‘swapping’ treatments on OVCAR­5 cells 
shown in Figure 4.9. 
Average scratch closure speed (% area 
reduction/hour) 
 

































Figure 4.9: The effect of OVCAR-5 and SKOV-3-derived exosomes on motility of OVCAR-5 cells with 12 
biological replicates. A) The curve represents scratch closure rate of OVCAR-5 cells that received no 
exosomes, or OVCAR-5 or SKOV-3 cell-derived exosomes. B) Average scratch closure speed in terms of 
percentage scratch area decrease per hour. Each sample group contained 12 biological replicates, within 






4.2.6. The effect of exosomes derived from less motile cells on highly motile cells 
To investigate the effect of exosomes on motility of SKOV-3 cells, exosomes were extracted from 
OVCAR-5 and SKOV-3 cells and applied to SKOV-3 cells (as shown in Figure 2.3, except SKOV-3 
cells were the recipient cells instead of OVCAR-5 cells). It was hypothesised that OVCAR-5 
exosomes may have the ability to reduce the motility of SKOV-3 cells because the parent cells had 
a lower motile capacity.  
As above in Figure 4.8, exosomes were collected from media that had conditioned approximately 
6 million cells over a 24 hour time period. Both OVCAR-5 and SKOV-3-derived exosomes increased 
motility of SKOV-3 cells resulting in faster closure of the scratch (Figure 4.10). The T-test of 
normalised average scratch closure speed indicates that both SKOV-3 and OVCAR-5 exosomes 
statistically significantly increased SKOV-3 cell motility, with p values of 0.001 and 0.012, 
respectively (Table 4.5). As shown in OVCAR-5 cells, both SKOV-3 and OVCAR-5 exosomes induced 
a similar effect upon SKOV-3 cell motility. This suggests that the signal responsible for increased 
motility was transferred by exosomes, but was not necessarily provided by exosomes derived 
from cells that have a more motile phenotype. Increased motility may be caused more generally 
by cancer-derived exosomes, independent of the motility status of the cells from which they were 
derived. 
 
Table 4.5: Two tailed T­test results for exosome ‘swapping’ treatments on SKOV-3 cells shown in Figure 
4.10. 





















Figure 4.10: The effect of SKOV-3 and OVCAR-5-derived exosomes on motility of SKOV-3 cells. A) The 
curve represents scratch closure rate of SKOV-3 cells that received no exosomes, or SKOV-3 or OVCAR-5 
cell-derived exosomes. B) Average scratch closure speed in terms of percentage scratch area decrease per 
hour. Each sample group contained three biological replicates, within each replicate there were three 
technical replicates. Error bars represent standard error of the mean of three biological replicates. P values 
were calculated using the two tailed T-test. C) Representative images of the cells at different time points 
showing the effect that exosomes had on cell movement. Each exosome treatment contained exosomes 
secreted by approximately 2 million cells over 24 hour period, there were approximately 350,000 cells in 







4.3.1. Establishment of ovarian cancer cell line motile capacity 
Prior to this project, adherent epithelial ovarian cancer cell lines had been used in many 
experiments to study cancer in vitro (Comamala et al., 2011; Flate and Stalvey, 2014; Zhao et al., 
2012). However, a comprehensive comparison of cell motility within a panel of ovarian cancer cell 
lines had not been carried out. Nine ovarian cancer cell lines (Table 2.1) were ranked in order of 
motile capacity using the scratch assay, with SKOV-3 cells found to be the most motile, and 
IGROV-1 cells the least motile (Figure 4.4). Establishment of the cellular motility status of these 
cell lines will assist ovarian cancer researchers in the future by influencing cell line choice in 
experimental design. 
 
4.3.2. The association between cellular motile capacity, proliferation, and exosome secretion 
rates 
The effect of cell proliferation on the ability of cells to heal the wound in the scratch assay was 
established (Figure 4.5). The speed at which cells grow and replicate was shown not to influence 
motility rates (Figure 4.6). In addition, there was no association between cellular motility and 
exosome secretion rates (Figure 4.7). These findings are important for the ovarian cancer 
research field. Investigation into the relationship between cell motility, proliferation, and 
exosome secretion rates will save researchers time, money and resources in the future; and will 
assist with selection of cell lines suitable for the experimental design. It was important to 
determine the effect of proliferation on cell motility to validate the use of the scratch assay for 
analysis of motile capacity of cell lines. 
 
4.3.3. The effect of exosomes from motile cell lines on recipient cell motility rates 
Exosomes derived from both OVCAR-5 and SKOV-3 cells were shown to increase the motility 
(assessed using the scratch assay) of SKOV-3 cells (Figure 4.10). A trend was established whereby 
exosomes derived from both OVCAR-5 and SKOV-3 cells were shown to increase the motility of 
OVCAR-5 cells (Figure 4.8) (although not to a statistically significant degree). However when the 
experiment was repeated in OVCAR-5 cells, to generate 12 biological replicates, the same results 
were not attained. When all 12 biological replicates were considered, OVCAR-5 and SKOV-3 
exosomes did not consistently increase the motility of OVCAR-5 cells (Figure 4.9), despite the 
initial increase with three biological replicates shown in Figure 4.8. It was concluded that OVCAR-5 




In addition, several exosome swapping experiments with different exosome donor cell lines and 
different recipient cell lines were performed, but statistically significant differences in cell motility 
between control and exosome-treated cells were not found (results not shown). This suggests 
that more motile cell line-derived exosomes did not increase the motile capacity of less motile 
recipient cells, and vice versa.  
Further experimentation with more scratch replicates would confirm whether exosomes from 
more motile cells can affect motility of recipient cells. Additionally, the trans-well migration assay 
(Figure 2.6) may provide an alternative method for analysis of cell migration and may generate 
more accurate results.  
 
4.3.4. The effect of cell origin and chemotherapeutic resistance status on cell motility 
4.3.4.1. Cell origin 
The origin of each of the ovarian cancer cell lines is shown in Table 2.1. In terms of motility 
(average scratch closure speed), all nine cell lines were statistically significantly different from one 
another (calculated using the two tailed T-test) (Table 4.1), except for CP-70 (solid tumour) and 
OVCAR-3 (ascites); IGROV-1 (solid) and MCP-1 (ascites); A-2780 (solid) and OVCAR-4 (ascites); 
MCP-1 (solid) and OVCAR-4 (ascites). This indicates that the origin of the cell line does not affect 
its motile capacity. However, SKOV-3 and OVCAR-5, two of the most motile cell lines were derived 
from ascites whereas IGROV-1, the least motile cell line, was derived from the solid tumour mass. 
It was predicted that cells with a greater motile capacity would originate from the ascites as 
opposed to the solid tumour mass because these cells have acquired the ability to detach from 
the primary tumour; this phenotype is associated with cells of a metastatic nature (Brooks et al., 
2010). 
 
4.3.4.2. Resistance to chemotherapeutics 
A-2780 cell line was derived from a solid untreated ovarian tumour (Godwin et al., 1992), MCP-1 
were generated by culturing A-2780 cells in the presence of cisplatin and therefore have a 
moderate resistance to cisplatin (Anthoney et al., 1996), CP-70 were also generated by culturing 
A-2780 cells in the presence of cisplatin but have a higher resistance to cisplatin than MCP-1, 
10-fold greater than their A-2780 parental cell line (Louie et al., 1985). CP-70 were statistically 
significantly more motile than both A-2780 and MCP-1 cell lines suggesting that with increased 
resistance to chemotherapeutics, cells acquire a more aggressive and migratory phenotype, this 




be further tested with different cell lines with varying resistance to different chemotherapeutic 
agents. 
 
4.3.5. Experimental limitations 
4.3.5.1. Constraints of using SKOV-3 cells for assessing the effect of exosomes on cell 
motility 
Of the nine cell lines assessed, SKOV-3 cells have the greatest motility (Figure 4.4B and 
Figure 4.5). Because of their highly motile phenotype, it may be difficult to identify the effects 
caused by different types of exosomes. This could have been resolved, perhaps, by taking 
measurements of scratch area at more regular intervals, for example, every two hours. However, 
the four hour time interval was initially chosen for SKOV-3 cells as a compromise between 
collection of more frequent data points and the impact that regularly removing the cells from the 
incubator would have on the experimental results. To alleviate the issue of SKOV-3 cells healing 
the wound too quickly (before the effect of exosomes could be determined) OVCAR-5 cells, that 
have a reduced motile capacity compared with SKOV-3 cells, were used for most experimentation 
to investigate the effect of exosome swapping on cell motility. 
 
4.3.5.2. Limitations of the scratch assay 
There are a number of limitations of the scratch assay in comparison to other available methods 
to measure cell motility e.g. the trans-well migration/chemotaxis assay. The main disadvantage is 
that direct physiological relevance is poor (Cory, 2011). The Boyden chamber trans-well migration 
and invasion (Matrigel) assays are more representative of the processes undertaken by 
metastasizing tumour cells in vivo (Marshall, 2011).  
Additionally, the assay is relatively long, 48 hours are required for growth of the cell monolayer 
and then a further 48 hours for scratch closure, for most cell lines (Liang et al., 2007). Another 
disadvantage is that it is impossible to create the same size scratch twice, therefore all scratches 
were of varying widths (Liang et al., 2007). Despite accounting for this during calculation of 
scratch width (by normalising data so that the time = 0 value equalled 100%), this prevented 
attainment of consistent results and created variation between scratches, even though multiple 
points along the same scratch were measured. For these reasons it was difficult to obtain the 
required number of replicates to reduce the amount of error to an acceptable level.  
Furthermore, scratching the cell monolayer causes damage to the cells at the edge of the wound, 




cell migratory activity (Sammak et al., 1997). In spite of these limitations, the in vitro scratch assay 
is the preferred method for analysis of cell migration as it is easy to establish, inexpensive, does 
not require any specialist materials and, most importantly, provides a good measure of cell 
motility (Liang et al., 2007). 
 
4.3.5.3. Excessive concentration of exosomes 
The physiological concentration of exosomes in peripheral blood of healthy donors is currently 
predicted to be 5–50 µg/mL (Hunter et al., 2008; Lee et al., 2014; Müller, 2012). Efforts were 
made to determine exosome protein concentration prior to administration onto cells so that the 
amount of exosomes administered fell within this range. However, this involved multiple 
freeze-thaw cycles, which it is best to avoid so that the biological viability of the exosomes is not 
lost (Théry et al., 2006). A decision was made not to quantify the exosomes prior to 
administration, and instead fresh exosomes were used immediately following extraction, with the 
anticipation that in future experimentation, the exosomes would be quantified following 
collection of preliminary data that supported the theory that exosomes from more motile cells 
had an effect upon recipient cell motility. Unfortunately lacking confidence in the data collected 
meant that this experiment was not optimised further. 
Since the exosome dose administered to the cells in the scratch assay exceeded the predicted 
physiological concentration, one third of the exosomes extracted from a T175 flask (exosomes 
secreted from approximately 3 million cells in 24 hours) was administered to a single well of a 
24-well plate (seeded at 220,000 OVCAR-5 cells or 350,000 SKOV-3 cells). Since SKOV-3 cells were 
the most motile cell line tested, an increase in SKOV-3 cell motility may have suggested that the 
effect of exosomes upon motility was concentration dependent, rather than specific to the cell 
line that the exosomes were derived from.  
 
4.3.5.4. Scratch width at 24 hours is not an accurate measure of cell motility 
Scratch width at 24 hours is a commonly used method for assessing cellular motile capacity 
(Funari et al., 2013; Wang et al., 2013). The statistical analysis performed to describe the 
relationship between exosome secretion rates, and cell motility in terms of scratch width at 24 
hours, involved two points (for SKOV-3 and OVCAR-8) where the scratch width at 24 hours was 0 
because the cells were very motile and healed the wound within this time period. It may have 




cell lines tested, the differences in cell motility were not distinguishable between the different cell 
lines using the 12 hour time point. 
 
4.3.6. Experimental improvements 
4.3.6.1. Time-lapse visualisation 
Had the technology been available in our department, it would have been ideal to make 
time-lapse video recordings of the cells moving throughout the scratch assay. An environmental 
control chamber that would maintain the cells at 37°C and 5% CO2 was required to collect this 
data. This would have allowed the identification of cells that moved the fastest, that moved first 
(following scratch creation), and those that moved the slowest or did not move among the 
population that were associated with each scratch. This would also have made it easier to identify 
whether scratch closure was because of cell proliferation rather than cell movement. 
Alternatively, more regular observations of scratch width could have been made to better 
estimate cell motility, 12 hours between data collection points (6 hours for SKOV-3 cells) may not 
have been sufficient to accurately determine cell motility. 
 
4.3.6.2. Immunocytochemistry 
To investigate the phenotypes of motile cells further, immunocytochemical analysis of EMT 
markers may have revealed a relationship between more motile cell lines and less motile cell 
lines. E-cadherin is a tumour suppressor gene that also acts as a marker of EMT and is regularly 
used not only in academic research, but also in the clinic to determine patient prognosis 
(section 1.2.2.1) (Takai et al., 2014). Additionally vimentin, a marker of mesenchymal cells, is used 
to recognise mesenchymal-like cells and can identify cells that have undergone or are in the later 
stages of EMT (section 1.2.2.1). Increased vimentin expression has been associated with increased 
motility and invasiveness of prostate cancer cells. Furthermore, in the same study E-cadherin and 
vimentin expression had an inversely linear relationship (Zhao et al., 2008).  
It would be interesting to investigate whether more motile cells associated with the scratch 
express greater levels of vimentin compared with E-cadherin. Additionally, cells may alter their 
phenotype in response to creation of the scratch, e.g. cells along the scratch edge may start to 
express more vimentin. Perhaps, in the cell lines that have a more stationary phenotype 
E-cadherin expression is greater than vimentin. These questions could be answered using this 





Because of the inconsistency in statistically significant results when treating OVCAR-5 and SKOV-3 
cells with OVCAR-5 and SKOV-3 exosomes, and the inability to detect changes in cell motility as a 
result of other exosome swapping experiments, the hypothesis that exosomes derived from 
highly motile ovarian cancer cell lines increase the motile capacity of inherently less motile 
ovarian cancer cell lines was not supported. Exosomes, irrespective of their cell of origin, had no 
clear effect on cell migration. It appears that unlike in breast cancer (Harris et al., 2015), more 
motile ovarian cancer cell line-derived exosomes do not affect motility of less motile ovarian 
cancer cell lines. An explanation for this may be that ovarian cancer metastasis has a similar, yet 
distinct, mode of action to breast cancer metastasis. Ovarian cancer metastasis occurs when 
metastatic cells evade the ovarian tumour into the peripheral environment and travel to 
secondary organs in the peritoneal fluid (Figure 1.3, section 1.2.3). Whereas metastatic breast 
cancer cells must develop the ability to hijack the circulation in order to access to secondary sites 
(Figure 1.2, section 1.2.1). Although these metastatic mechanisms differ, they both rely greatly 
upon cancerous cells increasing their motile capacity compared with healthy cells. It is likely that 
exosomes derived from more motile cells affect less motile cells through a different mechanism, 
possibly their invasive capacity is affected. The trans-well migration/chemotaxis assay assesses 
the invasive capacity of cells, and is possibly more physiologically relevant than the scratch assay 
in terms of testing cell motility and invasive potential (Cory, 2011; Liang et al., 2007), therefore 
this assay may be more suitable for determining the effect of exosomes upon cell migration. 
 
4.4.1. Future direction 
Exosomes derived from cells that have undergone stress have been shown to affect recipient cells 
in various ways. In collaboration with Professor Munira Kadhim, our group were the first to show 
that exosomes are involved in mediating radiation-induced bystander effect, whereby 
non-irradiated cells that received exosomes derived from irradiated cells exhibited DNA damage 
characteristics corresponding to those of irradiated cells (Al-Mayah et al., 2012). Other studies 
have shown that exosomes derived from cells stressed by radiation, hypoxia and oxidative stress 
contribute to neighbouring cell resilience to stress (Arscott et al., 2013; Eldh et al., 2010; Salomon 
et al., 2013b). Until now, there have been no published studies that investigate the effect of heat 
shock cell-derived or chemotherapy treated cell-derived exosomes upon recipient cell invasive 
capacity. Therefore the hypothesis that cells stressed by heat shocking or chemical stress 
(chemotherapeutics) have the ability to increase cell migration in recipient cells was investigated 
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5. The effect of stressed cell-derived exosomes upon the invasive 
capacity of cancer cell lines in vitro 
5.1. Introduction 
5.1.1. Cellular stress response 
Tissue homeostasis ensures that equilibrium is maintained between cell proliferation and death 
rates (Lockshin and Zakeri, 2007). Stress stimuli imbalance this physiological mechanism causing 
potential harm to the organism because excessive loss or gain of tissue is fatal. Cellular stress 
response is the term used to describe a number of different mechanisms that occur inside the cell 
as a result of environmental stress. The most common stressors include extremes of temperature 
and exposure to toxins. Cells respond to stress in various different ways. One approach is to 
activate mechanisms to promote cell survival; alternatively, programmed cell death pathways are 
triggered to eliminate damaged cells (Fulda et al., 2010). There is an immediate stress response 
that has the purpose of maximising imminent cell survival, minimising damage to overall cell 
integrity, and helping the cell recover from the insult. If the toxic stimulus is unresolved and 
exceeds the stress resilience threshold then cell death processes are activated (Perkins and 
Gilmore, 2006; Weston and Davis, 2007). There is also is long-term cellular stress response that 
increases cellular resilience to subsequent exposure to environmental stresses (Fulda et al., 2010).  
 
5.1.2. Stress proteins 
Cellular stress is tackled by a family of proteins called ‘stress proteins’. Stress proteins often are 
not restricted to function during periods of stress, many are also essential to the function of cells 
in a normal environment (Calabrese et al., 2010). Since a cell’s survival depends on its ability to 
mount an appropriate response to environmental or intracellular stress, stress proteins are well 
conserved across phyla. Similarities in the expression pattern of stress proteins is maintained from 
singular prokaryotic cells through to cells of complex eukaryotic organisms (Fulda et al., 2010).  
 
5.1.3. The heat shock response 
The heat shock response is a protective response activated by extreme temperature but also by 
other types of stress. It was originally described as a response to mild increases in temperature of 
only 3–5°C above normal (Craig, 1985; Lindquist and Craig, 1988). Heat stress causes protein 




increases chaperone protein, namely HSP, activity inside the cell, which improves the protein 
folding capacity of the cell. Misfolded proteins are refolded, alleviating protein aggregation; 
hence, cell survival is promoted. This process confers transient protection, otherwise known as 
thermotolerance, whereby cells become more resistant to subsequent stress stimuli (Fulda et al., 
2010; Pallepati and Averill-Bates, 2011). 
 
5.1.4. Heat shock proteins 
HSPs (also exosome marker proteins, section 1.4.3.2) are a group of evolutionary conserved 
proteins that are either constitutively expressed e.g. HSP90 or are inducible e.g. HSP70. HSP90 not 
only has chaperone duties but also prevents premature folding of nascent polypeptides (Lindquist 
and Craig, 1988). HSP70 is expressed at low basal levels and expression increases in response to 
stressors (Samali and Orrenius, 1998). HSP70 has been shown to protect the cell from induction of 
controlled cell death by directly inhibiting cell death pathways and indirectly by pro-survival 
protein refolding activity (Hartl and Hayer-Hartl, 2002). HSP70 also inhibits downstream c-Jun 
N-terminal kinases (JNK)-pro-apoptotic activity (Gabai et al., 2000; Mosser et al., 1997; Park and 
Liu, 2001). 
 
5.1.5. DNA damage response 
Stress conditions caused by chemotherapeutic agents induce DNA damage as an initial response. 
DNA double-strand breaks (DSBs) are considered a key lesion in activation of the DNA damage 
response. Depending upon the type of lesion, DNA damage initiates one of several repair 
pathways. Following a DSB, two major mechanisms responsible for DNA repair are 
non-homologous end joining (which involves the DNA-PK repair protein), and homologous 
recombination. These processes restore the continuity of the DNA double strand (Jackson, 2002; 
Valerie and Povirk, 2003). Mismatch repair subsequently corrects any mistakes made during DNA 
repair (Stojic et al., 2004). Cisplatin is a crosslinking agent that forms platinum-DNA adducts and 
subsequently produces DSBs; as a result, cell division is disrupted and induction of apoptosis 
ensues (Roos and Kaina, 2006; Takahara et al., 1995). Cisplatin is a standard chemotherapy drug in 






5.1.6. The role of exosomes in transferring stress-tolerance to neighbouring cells 
Our research group has shown that CP-70 cisplatin-resistant cells can transfer resistance to 
A-2780 cisplatin-sensitive cells via exosomes (Pink et al., 2015). These results initiated the theory 
that protection against other types of cell stress may also be communicated between cells 
through exosomes. Other research groups have published data that supports this concept, as 
described below. 
 
5.1.6.1. Radiation stress 
Our group (in collaboration with Professor Munira Kadhim) have shown that exosomes extracted 
from irradiated MCF-7 cells can transfer resilience to radiation stress to naïve MCF-7 cells, via 
exosomes, in a RNA dependent manner (Al-Mayah et al., 2012). DNA damage increased in cells 
that had not been irradiated but had received exosomes from irradiated cells (Al-Mayah et al., 
2012). A similar study in glioblastoma cells and normal astrocytes also showed that exosomes 
released by cells that had been exposed to radiation stress were able to increase cell migration in 
recipient cells (Arscott et al., 2013).  
 
5.1.6.2. Hypoxia 
It has been shown that under hypoxic conditions epidermoid (Park et al., 2010), breast (Wang et 
al., 2014), and prostate (Ramteke et al., 2015) cancer cells produce exosomes that have the ability 
to stimulate invasion and metastasis in recipient cells. More than 50% of the proteins secreted by 
epidermoid cancer cells under hypoxia were found to be associated with the exosome population. 
Additionally, many of these proteins were identified to have functions in the control of 
metastasis, hence, it was predicted that exosomes derived from cells under hypoxic conditions 
may support increased metastatic activity in recipient cells (Park et al., 2010). Hypoxia increased 
the concentration of exosomal C4.4A; a protein known for its involvement in wound healing, 
tissue remodelling and cell motility (Ngora et al., 2012). Prostate cancer exosomal proteome 
analysis identified a higher protein concentration in hypoxic exosomes (160 proteins) compared 
with control exosomes (62 proteins). Hypoxic exosome proteins were mostly associated with the 
remodelling of epithelial adherens junction pathway. This protein signature encompasses proteins 
that have the ability to increase cellular invasiveness and modulate the microenvironment; thus, 
supporting prostate cancer progression (Ramteke et al., 2015). 
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5.1.6.3. Oxidative stress 
Pre-treating cells with exosomes derived from cells that had undergone oxidative stress provided 
protection against subsequent oxidative stress in the recipients, measured as an attenuated loss 
of cell viability (Eldh et al., 2010). Furthermore, microarray analysis identified that exosomal 
mRNA content differs between exosomes derived from cells grown under conditions of oxidative 
stress compared with normal conditions (Eldh et al., 2010). 
5.1.7. Inhibition of stress exosome induced responses 
5.1.7.1. Exosome uptake inhibition 
Several agents have been used by other research groups to inhibit exosome uptake (Mulcahy et 
al., 2014) including Heparin (Christianson et al., 2013; Franzen et al., 2014) and proteinase K 
(Escrevente et al., 2011). These agents were chosen for optimisation in our lab to investigate the 
effects of inhibition of stress exosome uptake. 
5.1.7.2. Inhibition of the DNA-PK protein 
NU7441, an inhibitor of DNA-PK, was used in this project to inhibit the non-homologous end 
joining and homology-directed repair pathways of DNA repair that are mediated by DNA-PK 
(Smith and Jackson, 1999). 
5.1.8. Evidence for increased exosome secretion following stress 
There is substantial evidence to suggest that the concentration of exosomes secreted by cancer 
cells increases with disease progression (Muralidharan-Chari et al., 2010), but the molecular 
mechanisms regulating the biogenesis of exosomes have not been described. The concentration 
of exosomes secreted by stressed cells has been shown to increase in response to heat stress 
(Clayton et al., 2005), exposure to anti-cancer drugs (Lv et al., 2012), irradiation (Al-Mayah et al., 
2015; Jella et al., 2014), and hypoxia (King et al., 2012; Ngora et al., 2012; Salomon et al., 2013a; 
Wang et al., 2014); suggesting that exosomes have a functional role in intercellular 
communication following stress. Stress-induced exosome release has been shown to occur within 
20 minutes (Koumangoye et al., 2011). Further molecular studies are required to determine 
whether there are qualitative differences in cargo carried by exosomes generated in stressed cells 




5.1.9. Cellular invasive capacity 
One of the rate-limiting steps of the metastatic cascade is basement membrane penetration 
(Brooks et al., 2010; Volk et al., 1984). Invasion results from a combination of abnormal cell 
motility, reduced cellular cohesion, and production of proteolytic enzymes (Chambers et al., 2002; 
Fidler, 2003); metastasis follows, where formation of secondary tumours at distant sites occurs.  
 
5.1.9.1. Proteolytic enzymes 
Protease activity is tightly regulated under normal conditions and is typically required for 
processes including ovulation (Hulboy et al., 1997) and mammary gland involution (Wiesen and 
Werb, 2000). These control mechanisms are lost during metastasis enabling ECM degradation and 
subsequent cell invasion (section 4.1.1). Binding of the tumour cell to the basement membrane 
triggers signal transduction pathways that result in the release of several hydrolytic enzymes that 
are responsible for ECM breakdown (Brooks et al., 2010). These enzymes are either released by 
the tumour cells themselves, or by neighbouring cells (Price et al., 1997). Examples of proteolytic 
enzymes associated with metastasis include: urokinase-type plasminogen activator protein (Danø 
et al., 2005; Duffy et al., 1999; Duffy, 2004), cathepsins (Price et al., 1997), and several MMPs 
(Blood and Zetter, 1990; Brown, 1999; Deryugina and Quigley, 2006; Egeblad and Werb, 2002). 
 
5.1.10. Matrigel trans-well assay 
To establish the invasive capacity of nine ovarian cancer cell lines the Matrigel trans-well invasion 
assay was used. Matrigel is a solubilised basement membrane formulation encompassing mostly 
laminin, collagen IV, and heparan sulphate proteoglycan extracted from the 
Engelbreth-Holm-Swarm mouse sarcoma (Kleinman et al., 1982). Matrigel is coated onto the 
trans-well membranes with 8.0 µm pores and acts as a barrier to invading cells. Metastatic cells 
are able to attach and invade the Matrigel, and subsequently pass through the 8.0 µm pores 
(Marshall, 2011). The trans-well Matrigel invasion assay assesses the invasive capacity of cells and 
is more physiologically relevant than the scratch assay in terms of testing cell motility and 
metastatic potential (Cory, 2011; Kenny et al., 2009; Liang et al., 2007). This assay has been used 
extensively in cancer research to investigate the complex mechanisms that contribute to cell 






Exosomes derived from metastatic cells have been shown to influence the invasive capacity of 
recipient cells. Additionally, previous studies have shown that exosomes can transfer protection 
to stress from cells that have experienced stress to naïve cells. Since the adaptive response of 
cells to stress correlates with cell fate, it is likely that cells undergoing stress communicate with 
their neighbours to help prepare them for adverse environmental stimuli and, hence, promote 
survival of the organism. It was hypothesised that exosomes mediate transfer of signals that 
increase invasiveness in recipient cells and provide a vehicle for transfer of stress precautionary 







5.2.1. Invasive capacity of cancer cell lines  
In addition to the scratch motility assay, the trans-well migration and trans-well invasion assays 
were performed to further investigate some aspects of the invasive potential of the nine ovarian 
cancer cell lines of interest. The MCF-7 breast cancer cell line was also assessed using the 
trans-well migration and invasion assays. The trans-well migration assay, like the scratch assay, 
also assesses cell motility but in terms of the cell’s ability to pass through a membrane with 
8.0 µm pores as opposed to the ability of the cells to close a scratch. This migration assay also 
assesses cellular chemotaxis, in terms of the movement of cell towards an environment with a 
higher concentration of serum. The trans-well invasion assay investigates the same principle, 
however, the cells must also have the ability to adhere to, then sufficiently degrade and invade an 
artificial ECM barrier, in addition to passing through the semi-permeable membrane. 
Cells were seeded in trans-wells that had membranes with 8.0 µm pores. Uncoated membranes 
were used for the trans-well migration assay, whilst ECM invasion-testing membranes were used 
for the trans-well invasion assay, these were supplied pre-coated in Matrigel (BD Biosciences). 
Cells were left to migrate/invade over a 24 hour period. The cells that successfully passed through 
the membrane were stained and counted. Migration/invasion was calculated by counting the 
number of cells on the base of the membrane following the migration/invasion period. A diagram 
of the Matrigel trans-well assay is shown in Figure 2.6. The invasive capacity of ten cancer cell 
lines was established using the Matrigel invasion assay. Cell invasion through uncoated 
membranes was indicative of the proportion of cells that had the ability to compress and pass 
through membranes. Cells that can pass through Matrigel coated membranes have the additional 
capacity to sufficiently degrade and invade ECM. CP-70, MCP-1, OVCAR-4, OVCAR-5, OVCAR-8, 
and SKOV-3 cells were all statistically significantly more capable of invading uncoated membranes 
than Matrigel coated membranes. This was calculated using the one tailed T-test that generated 
p values of 3.39 × 10-5, 5.39 × 10-6, and 5.73 × 10-6, respectively (Figure 5.1). This indicates that 
these cell lines have the capacity to pass through porous membranes but have reduced ability to 
degrade and invade ECM. OVCAR-5 and SKOV-3 cells were both more invasive than the other cell 
lines through both uncoated and Matrigel membranes. When seeded at 100,000 cells/trans-well 
insert, on average 21,272 SKOV-3 cells invaded Matrigel membranes. For OVCAR-5 cells an 
average of 8525 cells had the capacity to invade Matrigel membranes (Figure 5.1A). This suggests 
that of the ten cell lines, OVCAR-5 and SKOV-3 cells are the most invasive through both porous 




allowing for subsequent membrane invasion. See Appendix B (8.2) for raw migration and invasion 
data. 
Aside from OVCAR-5 and SKOV-3 cells, the other cell lines had reduced invasive capacity. This is 
shown in Figure 5.1B, where data for OVCAR-5 and SKOV-3 was removed to show the differences 
between the eight less invasive cell lines more clearly.  
CP-70, MCP-1, OVCAR-4, and OVCAR-8 cells have intermediate capacity to invade membranes, of 
the ten cell lines tested, and this was statistically significantly prevented by artificial ECM 
(Matrigel). CP-70 cells were approximately 35 times more efficient at crossing uncoated 
membranes than Matrigel coated membranes, with 2828 cells on average capable of penetrating 
uncoated membranes and 81 cells capable of penetrating Matrigel membranes. An average of 
2731 MCP-1 cells were capable of migrating across the uncoated membrane and 112 through the 
Matrigel membrane. On average, 6176 OVCAR-8 cells penetrated the uncoated membrane 
compared with 307 that invaded the Matrigel membrane. IGROV-1 cells were approximately 
three times more effective at migrating through uncoated membranes, with 2725 invasive cells 
compared with an average of 895 cells capable of invading Matrigel membranes. OVCAR-4 cells 
were the third most invasive cells, after OVCAR-5 and SKOV-3 cells, with 10,616 cells on average 
capable of crossing the uncoated membrane and 67 capable of penetrating the Matrigel 
membrane. 
A-2780, MCF-7, and OVCAR-3 cell lines were the least invasive, and the presence of the ECM layer 
did not have a great effect on invasion (Figure 5.1). For MCF-7 cells, the number of invasive cells 
was greater in the presence of the Matrigel layer, with an average of 303 cells invading the 
uncoated membrane and 527 cells penetrating the Matrigel membrane. For A-2780 cells, there 
was little difference in the number of cells capable of invading the uncoated and Matrigel 
membranes with an average of 528 and 450, respectively. OVCAR-3 cells were the least invasive 
with an average of 99 and 50 invasive cells for uncoated and Matrigel membranes, respectively. 
Representative images of the trans-well membranes further support these results. It is clear to 
see that SKOV-3 cells were the most migratory (Figure 5.1C) and invasive (Figure 5.1D), followed 
by OVCAR-5 cells, then OVCAR-4 cells. OVCAR-3 cells were the least invasive. 
After investigating some aspects of the invasive potential of the cells using the scratch, trans-well 
migration and trans-well invasion assay, it was confirmed that SKOV-3 cells were both the most 
motile and invasive, and IGROV-1 cells were both the least motile and invasive (Figure 4.4A&B 






Figure 5.1: Invasive capacity of ten cancer cell lines. Cells were starved of FBS for 24 hours prior to being 
seeded at 100,000 cells/trans-well. Trans-wells had membranes with 8.0 µm pores coated in Matrigel or 
uncoated membranes. 10.0% FBS was used as chemoattractant; cell invasion over 24 hour period was 
calculated. A) The average number of cells with migratory and invasive capacities of each cell line through 
uncoated and Matrigel coated membranes. B) Zoomed in version of graph shown in A) without OVCAR-5 
and SKOV-3 cell lines. C) Representative images of the Matrigel and uncoated membranes following the 
invasion period and crystal violet staining. Each sample group contained six biological replicates, within 
each replicate there were five technical replicates. Error bars represent standard error of the mean of the 
biological replicates. P values were calculated using the one tailed T-test.  
 
5.2.2. Correlation between cell invasiveness, migratory phenotype, and motile capacity 
The correlation between cell invasiveness and migration rate shows that there was a strong 
relationship between these two cellular phenotypes (Figure 5.2A). The regression line represents 




relationship between the two sets of data. The R2 value of 0.987 and Spearman’s rank correlation 
coefficient of 0.394 indicate that the invasion and migration rates have a strong linear but weakly 
monotonic relationship. The Grubbs’ test was applied to identify outliers between cell 
invasiveness and migration rate. The Grubbs’ test confirmed that in terms of cell invasiveness, 
OVCAR-5 and SKOV-3 cells were outliers; in terms of migration rate, OVCAR-4, OVCAR-5, and 
SKOV-3 cells were outliers. When the OVCAR-4, OVCAR-5, and SKOV-3 anomalous data points 
were removed, the relationship between cell invasiveness and migration rate changed from 
positive to neutral (no clear relationship) (Figure 5.2B). The R2 value was <0.001, the Pearson’s 
correlation coefficient was -0.013 (p = 0.978), and the Spearman’s rank correlation coefficient was 
-0.036, suggesting no correlation between cell invasiveness and migration rate once the outliers 
had been removed.  
For cell invasiveness versus motility (Figure 5.2C), the Pearson’s correlation coefficient was 
calculated as 0.786 (p = 0.012) indicating that there was a moderately positively correlated 
relationship between these cellular characteristics. The R2 value of 0.618 suggests that cell 
motility and invasiveness have a weak linear relationship. Spearman’s rank correlation coefficient 
was calculated as 0.233, further indicating a weakly monotonic relationship. The Grubbs’ test 
identified no outliers in the motility dataset, but OVCAR-5 and SKOV-3 cell data points were 
outliers in the cell invasiveness dataset. When the OVCAR-5 and SKOV-3 anomalous data points 
were removed, the relationship between cell invasiveness and motile capacity changed from 
moderately positive to weakly positive. The R2 value was 0.094, the Pearson’s correlation 
coefficient was 0.306 (p = 0.504), and the Spearman’s rank correlation coefficient was 0.214, 
suggesting weak positive correlation between cell invasiveness and motile capacity, once the 
outliers had been removed.  
For cell migratory phenotype versus motile capacity (Figure 5.2E), the regression line represents a 
Pearson’s correlation coefficient of 0.805 (p = 0.009) signifying a positively correlated relationship 
between these cellular characteristics. The R2 value of 0.649 indicates that cell motility and 
migratory rates have a weak linear relationship. Spearman’s rank correlation coefficient was 
calculated as 0.600, indicating a moderately monotonic relationship. Since increased cell motility 
is required for increased cell migration, an association between these two cellular characteristics 
was anticipated. When the OVCAR-4, OVCAR-5, and SKOV-3 anomalous data points were 
removed, the positive correlation between cell migration rate and motile capacity became slightly 
weaker. The R2 value was 0.611, the Pearson’s correlation coefficient was 0.782 (p = 0.066), and 
the Spearman’s rank correlation coefficient was 0.257, suggesting weak positive correlation 




Cell invasiveness, migratory abilities and motility are acquired by cells as they become more 




Figure 5.2: Correlation between invasion with migration and motility rates of nine ovarian and one breast 
cancer cell lines. Nine ovarian and one breast cancer cell lines were assessed for their invasive capacity 
using the Matrigel trans-well invasion assay, migratory capacity was determined using the trans-well 
migration/chemotaxis assay and motile capacity using the scratch assay. A) The relationship between cell 
invasiveness and migratory phenotype in terms of the ability of cells to cross semi-permeable membranes. 
B) Correlation between cell invasiveness and migratory phenotype excluding the OVCAR-4, OVCAR-5, and 
SKOV-3 anomalies. C) The relationship between cell invasiveness and motile capacity in terms of the speed 
at which cells could close a scratch. D) Correlation between cell invasiveness and motile capacity excluding 
the OVCAR-5 and SKOV-3 anomalies. E) The relationship between cellular migratory phenotype and motile 
capacity in terms of the speed at which cells could close a scratch. F) Correlation between cellular migratory 
phenotype and motile capacity excluding the OVCAR-4, OVCAR-5, and SKOV-3 anomalies. The correlation 
between the different cellular characteristics for each cell line is shown. R2 and p values were calculated 





5.2.3. Heat stress method validation by western blotting 
Hyperthermia is a treatment for cancer, used alongside other anti-cancer therapies because heat 
shocking malignant cells has been shown to increase their sensitivity to radiation and some 
chemotherapy drugs. Heat is applied to a small area, in the form of microwaves, radiowaves, 
or ultrasound. The location of the tumour influences the heat-shocking method used (van der Zee, 
2002; Wust et al., 2002). People with cancer who have received heat treatment have been shown 
to have increased five year survival rates (Colombo et al., 2011). However, high heat also 
traumatises and damages cells, often leading to cell death. This is ideal when the tumour cells are 
affected; however there may also be off-target effects in neighbouring cancer cells and 
surrounding tissues (Wust et al., 2002). To determine the effect of exosomes derived from heat 
shocked cells on recipient cancer cells, a number of trans-well invasion experiments were 
performed. 
To verify that the heat shocking procedure was sufficiently stressing cells and inducing a cellular 
response to increased temperature, heat shocked cell protein lysates were probed for HSP70 (and 
GAPDH as a positive/loading control). Three protein samples of heat shocked and control cells 
were loaded into a gel and electrophoresis was performed (Figure 5.3A). The protein was 
transferred from the gel (Figure 5.3B) onto a membrane (Figure 5.3C) and the membrane was 
probed for HSP70 first (Figure 5.3D), followed by detection of GAPDH as a positive/loading control 
(Figure 5.3E) to show that the protein samples were viable. The HSP70 band had partially washed 
away during probing for GAPDH. The blot shows that HSP70 is more concentrated in the heat 
shocked cells. GAPDH was comparable across the six cell samples, indicating that HSP70 was 
upregulated in the heat shocked cells as part of the stress response. 
The relative intensities of WB bands (Figure 5.3) were quantified using Image Lab software 
version 5.2.1. Control cell band intensity was used as the reference band for each antibody. This 
confirmed that heat shocking MCF-7 cells at 45°C for 1 hour was sufficient to induce the heat 
shock response, since the p value was 0.001 for the difference in intensity of the HSP70 bands in 
control cells compared with heat shocked cells (Table 5.1). The positive/loading control GAPDH 
bands were not statistically significantly different in intensity suggesting that the increased band 
intensity observed in HSP70 bands for the heat shocked cells is because of an increase in protein 





Table 5.1: The relative intensities of HSP70 and GAPDH bands on Figure 5.3 western blots of heat shocked 

















Control 1 1.00   1.00   








Heat shock 1 2.16  0.81  
Heat shock 2 2.50 0.84 















Figure 5.3: Validation of heat shocking stress procedure by western blotting. A) Gel electrophoresis of 
three heat shocked and three control cell protein samples, 2.829 second exposure of stain-free gel. B) 
Polyacrylamide gel after transfer of protein onto PVDF membrane, 2.829 second exposure of stain-free gel. 
C) Stain-free PVDF membrane after protein transfer. D) Blot after probing with anti-HSP70 antibody. E) Blot 






5.2.4. The effect of heat shocked cell-derived exosomes on invasive behaviour of cancer cells  
The effect of heat shocked cell-derived exosomes (heat shock exosomes) on invasive capacity of 
four cancer cell lines: MCF-7, IGROV-1, OVCAR-5, and SKOV-3, was investigated. To determine 
whether heat stress exosomes can increase invasive capacity of cells, parental cells were 
incubated at 45°C for 1 hour then returned to 37°C atmosphere for 23 hours; exosomes were 
collected from the tissue culture media and incubated with serum-starved cells for 24 hours. The 
stress exosome collection procedure was repeated 24 hours later and a second batch of heat 
shock exosomes were added to the cells immediately after they had been seeded in the Matrigel 
trans-well assay. The effect of heat stress exosomes on invasive capacity compared with cells 
treated with control cell-derived exosomes (control exosomes) was established. A one tailed 
T-test value of 0.015 confirmed that invasive capacity of MCF-7 cells increased in the presence of 
heat shock exosomes compared with cells that received control exosomes (Figure 5.4). Invasive 
capacity of three other cell lines (IGROV-1, OVCAR-5, and SKOV-3) showed the same trend but the 
increase in invasiveness was not significant. These results suggest that following heat-induced 
stress response the exosomes released by MCF-7 cells have the ability to induce greater invasive 
potential in neighbouring cells.  
  
149 
Figure 5.4: The effect of heat shocked cell-derived exosomes upon the invasive capacity of four cancer cell 
lines. The Matrigel trans-well invasion assay was used to determine the effect of heat shocked cell-derived 
exosomes on invasive potential of four cancer cell lines. Exosomes were extracted from approximately 
6 million cells that had been heat shocked 24 hours prior to exosome extraction and 6 million control cells 
that had been maintained at 37°C, for each cell line. Extracted exosomes were administered to 
approximately 1 million cells. 24 hours later the exosome extraction procedure was repeated to harvest 
more heat shocked and control cell-derived exosomes. 100,000 cells were distributed into each insert of the 
trans-well assay. Following extraction exosomes were immediately transferred into Matrigel trans-wells 
(the dose was equivalent to exosomes extracted from 6 million cells). Cells invaded Matrigel membranes 
over 24 hours. Matrigel membranes were cleared of non-invasive cells and invasive cells were stained with 
crystal violet. The number of invasive cells on each membrane was counted, where it was impossible to 
count the total number of cells five representative areas were counted. The counts were used to accurately 
calculate the total number of invasive cells. The graphs represent fold change in terms of the total number 
of cells that invaded the Matrigel membrane following treatment with either control or heat shocked 
cell-derived exosomes. Each sample group contained either three, six or nine biological replicates 
depending upon the cell type. Error bars represent standard error of the mean of the biological replicates. P 
values were calculated using the one tailed T-test. The images represent the Matrigel membranes following 




5.2.5. Characterisation and further investigation into the effect of heat shocked cell-derived 
exosomes on invasive behaviour of MCF-7 cells  
Heat shocked MCF-7 cell-derived exosomes were characterised by WB (Figure 5.5A). HSP70, a 
marker of exosomes, and GAPDH were both identified in the exosome samples. Cytochrome C 
oxidase and calnexin were not detected by WB in the exosome samples indicating that the 
samples contained exosomes and were not contaminated by intracellular organelles or other 
types of EV during the extraction process. All four proteins were identified in the MCF-7 cell 
samples indicating that the WB procedure was effective. HSP70 was upregulated in cells that had 
experienced heat shock and in the exosomes derived from these cells.  
The relative intensities of WB bands (Figure 5.5A) for protein samples extracted from directly heat 
shocked and control MCF-7 cells, and their secreted exosomes, were quantified using Image Lab 
software version 5.2.1. Control cell band intensity was used as the reference band for each 
antibody. The results show that HSP70 was enriched in heat shock exosomes with a band intensity 
of 0.13 compared with 0.08 for control exosomes (Table 5.2). HSP70 was also enriched in heat 
shocked cells (1.30) compared with control cells (1.00). The positive/loading control GAPDH bands 
were more intense in control cells (1.00) compared with heat shocked cells (0.88), and in heat 
shock exosomes (0.34) compared with control exosomes (0.05). Calnexin was detected in control 
and heat shocked cells (1.00 and 0.67, respectively), as expected, but was also present in heat 
shocked exosomes (0.18) (although the band is not visible on the blot [Figure 5.5A]). This was 
unexpected because calnexin is an endoplasmic reticulum marker. Cytocrome C oxidase, a marker 
of apoptotic bodies and mitochondria, was present in both heat shocked and control cells (1.00 
and 1.11, respectively) and absent in both exosome samples, as anticipated (Table 5.2). This 
indicates that the exosome samples contained low levels of apoptotic bodies. 
 
Table 5.2: The relative intensities of HSP70, GAPDH, calnexin, and cytochrome C oxidase bands on 
Figure 5.5A western blots of directly heat shocked MCF-7 cells and exosomes derived from heat shocked 
MCF-7 cells compared with control MCF-7 cells and exosomes. 
Sample 
Relative intensity 
HSP70 GAPDH Calnexin 
Cytochrome C 
oxidase 
Control cells 1.00 1.00 1.00 1.00 
Control exosomes 0.08 0.05 0.00 0.01 
Directly heat 
shocked cells 









Since exosomes were not quantified prior to being added to cells, it was speculated that the 
increase in cell invasiveness in the presence of heat shock exosomes may have been because of 
increased exosome concentration, i.e. cells release more exosomes into the environment in 
response to heat stress, and it was the number, rather than a specific component of heat shock 
exosomes, that caused an increase in cellular invasive behaviour. NTA was performed on three 
samples of control exosomes and three samples of heat shock exosomes derived from MCF-7 
cells. The six T175 flasks were seeded at equal concentration of MCF-7 cells and once 70% 
confluency was reached three of the flasks were heat shocked for 1 hour at 45°C; the remaining 
three flasks were maintained at 37°C. Exosomes were extracted the following day and exosome 
concentration was determined by NTA. There was no significant difference between the 
concentration of exosomes released by control MCF-7 cells (32.33 × 108 particles/mL) compared 
with heat shocked MCF-7 cells (39.72 × 108 particles/mL) (Figure 5.5B). This indicates that 
exosomes transfer a stress-induced signal to recipient cells that in turn causes increased cell 
invasiveness. 
TEM identified vesicles within the size range of exosomes (30–160 nm) for both control and 
heat-shock exosomes (Figure 5.5C&D). Previous reports have identified smaller sized exosomes 
secreted by stressed cells (de Jong et al., 2012). In our group, for example, cells irradiated with 
2.0 Gy secrete exosomes that are statistically significantly smaller in diameter than those released 
by non-irradiated cells (Jacobs et al., unpublished). Consistent with this, heat shocked MCF-7 cells 
also released exosomes that were statistically significantly smaller in diameter than those 
secreted by control cells (p = 0.047). 
To further investigate the effect of exosome concentration upon MCF-7 cell invasiveness, the 
Matrigel invasion experiment was repeated with control exosomes (1X) (exosomes extracted from 
approximately 6 million cells, cultured for 24 hours in EFM), doubled concentration of control 
exosomes (2X) (exosomes extracted from approximately 12 million cells, cultured for 24 hours in 
EFM), and heat shock exosome treatments. This time an additional control was added: control 
cells that received no exosomes (Figure 5.5E). Treatment with control exosomes did not affect 
MCF-7 cell invasiveness regardless of exosome concentration. Despite an increase in fold change 
from 1.00 for cells with no exosome treatment to 1.88 for cells treated with 1X control exosomes 
and a fold change value of 4.13 for cells treated with 2X control exosomes, none of the 
differences in MCF-7 cell invasiveness were statistically significantly different. Heat shock 
exosomes increased MCF-7 cell invasiveness by 46 fold. Despite the increase in fold change, the 
effect of heat shock exosomes on MCF-7 cell invasiveness was not statistically significantly 
different from other exosome treatments. This was because of one of the heat shocked exosome 




(no exosomes, 1X control exosomes and 2X control exosomes). Representative images of the 
Matrigel membranes are shown in Figure 5.5F. Low numbers of invasive cells are shown on the 
three control types (no exosomes, 1X control exosomes and 2X control exosomes) but areas of 
the heat shock exosome treated cell membranes have a higher concentration of invasive cells. 






Figure 5.5: Characterisation of heat shock and control exosomes derived from MCF-7 cells and their effect 
on invasive behaviour on naïve MCF-7 cells. A) Control and heat shocked cell and exosome protein lysates 
were characterised by western blotting, samples were probed for GAPDH, calnexin, HSP70, and cytochrome 
C oxidase. B) Quantification of exosomes secreted by control and heat shocked MCF-7 cells by nanoparticle 
tracking analysis. C) Images of electron microscopy grids of control and heat shock exosomes visualised by 
transmission electron microscopy. D) Average diameter of exosomes secreted by heat shocked and control 
MCF-7 cells measured on electron microscopy grids (C). There were two biological replicates containing 
diameter measurements of 50 exosomes. The p value was calculated using the two tailed T-test. E) Matrigel 
assay performed to investigate the effect of exosome concentration and heat shock exosomes upon 
invasive capacity of MCF-7 cells. 1X control exosomes was equivalent to exosomes extracted from 
approximately 6 million cells, cultured in exosome-free media for 24 hours. 2X control exosomes was 
equivalent to exosomes extracted from 12 million cells. F) Representative images of Matrigel membranes 
showing invasive MCF-7 cells following treatment with different concentrations and types of exosomes (in 






5.2.6. The effect of heat stress cell conditioned media on motility of MCF-7 cells 
In addition to enhanced cell invasiveness, increased cell motility is another important factor in 
cancer metastasis. Because of the significant increase in invasiveness caused by heat shock 
exosomes (Figure 5.4 and Figure 5.5E), their effect on cell motility was also investigated using the 
scratch assay. Exosomes were not isolated from the heat shock cell conditioned media, as in 
previous experiments that investigated the effects of exosomes on cell motility; whole media 
transfer was performed instead of directly adding exosomes to naïve cells. Control MCF-7 cells 
that did not receive heat shocked cell conditioned media had a similar motility rate curve to those 
that received heat shocked cell conditioned media (Figure 5.6A). Directly heat shocking cells 
slowed their motility rate (Figure 5.6); this was expected as the cells had become damaged and 
were recovering from the heat stress. The average percentage scratch closure per hour (Figure 
5.6B) was not statistically significantly different between the three different treatment types: 
control, heat shocked cell conditioned media transfer and direct heat shocking; rates were 
2.03%/hour, 2.41%/hour and 1.55%/hour, respectively. To determine whether the different 
treatments affect cell motility immediately after their administration or whether the response 
occurs a few hours after the stress alert has been received, the average scratch closure rate per 
hour was calculated for the time periods between each data collection point (Figure 5.6C). Again, 
there was no statistically significant difference between the motility rates of the three different 
treatment types (control, heat shocked cell conditioned media and direct heat shocking) 
suggesting that heat shocked cell conditioned media, and hence, heat shocked cell-derived 







Figure 5.6: Scratch assay performed to investigate the effect of heat shock media transfer and direct heat 
shocking upon motility of MCF-7 cells. A) The curve represents scratch closure rate of MCF-7 cells that 
were treated with heat shocked cell conditioned media or were directly heat shocked compared with 
control cells that received no treatment. B) Average scratch closure speed in terms of percentage scratch 
area decrease per hour over the entire assay. C) Average scratch closure speed was analysed for the time 
periods between each data collection point. Each sample group contained six biological replicates, within 
each replicate there were three technical replicates. Error bars represent standard error of the mean of six 
biological replicates. 
 
5.2.7. The role of kinases in heat shock exosome mediated increase in MCF-7 cell invasiveness 
With the aim of improving our understanding of the mechanism responsible for increased cell 
invasiveness induced by heat shock exosomes, the proteome profiler human phospho-MAPK 
array was used. The assay simultaneously determined the relative phosphorylation levels of 26 
kinases (including nine mitogen-activated protein kinases [MAPKs]) of MCF-7 cells treated with 
either control exosomes or heat shock exosomes. Each cell lysate was combined with a cocktail of 
biotinylated detection antibodies and incubated overnight on a nitrocellulose membrane (spotted 
with capture and control antibodies in duplicate). Antibody signal was detected using 
streptavidin-HRP and chemiluminescent reagents (Figure 5.7A). The signal intensity at each 
capture spot represented bound phosphorylated protein and was used to calculate relative 
phosphorylation levels of each kinase. Significant differences in protein kinase phosphorylation 




significantly downregulated in the cell treated with heat shock exosomes compared with control 
exosome treatment. The downregulated kinases were: Akt2 (p = 0.033), CREB (p = 0.046), HSP27 
(p = 0.0037), p38γ (p = 0.031), and p53 (p = 0.0081) (Figure 5.7B). This result indicates that 
down-regulation of the protein kinases Akt2, CREB, HSP27, p38γ, and p53 may have a role in the 
mechanism responsible for heat shock exosome-induced increased MCF-7 cell invasiveness. 
 
 
Figure 5.7: Relative phosphorylation levels of 26 kinases in MCF-7 cells following treatment with either 
control or heat shock exosomes determined using the proteome profiler human phospho-MAPK array. A) 
Blots showing intensity for each kinase on duplicate spots for each exosome treatment. B) Intensity levels of 
each kinase in MCF-7 cells treated with either control or heat shock exosomes. P values were calculated 






5.2.8. Gene expression microarray indicates pathways possibly involved in exosome mediated 
increased cell invasiveness 
To explain the increased invasiveness of heat shock exosome recipient MCF-7 cells analysis of the 
relative gene expression profiles of control MCF-7 cells, directly heat shocked MCF-7 cells, control 
exosome recipient MCF-7 cells, and heat shock exosome recipient MCF-7 cells was performed. In 
order to identify genes that were up- or down-regulated, following each treatment type, total 
RNA was extracted, amplified, and labelled using the Agilent Low Input Quick Amp labelling two 
colour kit, hybridised to an Agilent G3 8plex × 60k gene human transcriptome microarray, 
processed and scanned, converted to probe intensity, and Loess- and quartile-normalised. Fold 
change and p values were calculated using ArrayStar software (DNASTAR®, Madison, USA). Gene 
expression correlation between experiments were generated by plotting hybridisation signal 
values for each analysed gene. All four gene expression correlations showed strong positive 
correlation indicating that differential gene expression between experiments was minimal (Figure 
5.8), as expected with such a large number of genes, and show reliable dye normalisation. The 
green lines represent hybridisation signal fold change threshold of 2.0. The number of genes that 
had differential expression of more than two-fold between the experiments are shown above and 







Figure 5.8: Scatter plots of gene expression correlation in MCF-7 cells. A) Control cells versus directly heat 
shocked cells. B) Control exosome recipient cells versus heat shock exosome recipient cells. C) Control cells 
versus control exosome recipient cells. D) Directly heat shocked cells versus heat shock exosome recipient 
cells. The red 45° line marks the line of best-fit for all probe signals. The green lines represent 2-fold change 
thresholds for hybridisation signal. 
 
5.2.9. Gene expression most greatly affected by heat shock exosomes and directly heat 
shocking MCF-7 cells 
Typically, only genes with 2.0 or greater fold change in gene expression and a significant p value 
of ≤0.05 are regarded as exhibiting differential expression. However, for directly heat shocked 
MCF-7 cells versus heat shock exosome recipient MCF-7 cells, only five genes held both of these 
attributes, and no genes for the other three treatment comparisons (control MCF-7 cells versus 
directly heat shocked MCF-7 cells, control exosome recipient MCF-7 cells versus heat shock 




cells). Because of the low number of differentially expressed genes with fold change greater than 
2.0, genes were ranked in descending order of fold change to determine the 20 greatest 
up-regulated genes and the 20 greatest down-regulated genes for each gene expression sample 
set comparisons (Table 5.3).  
  
Table 5.3: The 20 greatest up- and down-regulated genes for each gene expression comparison in MCF-7 
cells. A) Control cells versus directly heat shocked cells. B) Control exosome recipient cells versus heat shock 
exosome recipient cells. C) Control cells versus control exosome recipient cells. D) Directly heat shocked 
cells versus heat shock exosome recipient cells. Highlighted genes were most greatly up-/down-regulated in 
more than one sample comparison. The colours represent the same genes that are most 
up-/down-regulated in more than one experiment comparison. 
A) Control MCF-7 cells versus directly heat shocked MCF-7 cells 
Up-regulated in directly heat shocked cells  Down-regulated in directly heat shocked cells 
Gene name Fold change P value  Gene name Fold change P value 
HTRA3 3.341921 0.384 
 
XLOC_009974 0.405076 0.799 
ITGAL 2.796371 0.284 
 
DSC1 0.403809 0.308 
LOC100130849 2.709529 0.744 
 
CXCL2 0.399461 0.509 
TRIM55 2.679796 0.119 
 
XLOC_007302 0.393999 0.448 
XLOC_l2_009510 2.665921 0.412 
 
XLOC_010238 0.386404 0.712 
CD70 2.661669 0.153 
 
XLOC_l2_000138 0.38567 0.381 
FLJ32255 2.635503 0.167 
 
PCSK1 0.383093 0.414 
PTGES 2.624374 0.167 
 
XLOC_008708 0.379768 0.384 
AGBL2 2.616214 0.306 
 
LOC100507156 0.373974 0.728 
XLOC_011633 2.610768 0.115 
 
XLOC_010163 0.373097 0.384 
LOC100506421 2.59553 0.167 
 
TP53AIP1 0.371366 0.511 
GOLGA6L6 2.582582 0.130 
 
XLOC_005263 0.366258 0.628 
XLOC_005531 2.581694 0.152 
 
LIMS3L 0.362595 0.299 
ESYT3 2.581647 0.139 
 
SLCO1A2 0.358111 0.306 
ZNF3 2.578119 0.598 
 
SLITRK2 0.356211 0.105 
RRAGD 2.553797 0.621 
 
PPP1R1A 0.350085 0.664 
PSG8 2.542537 0.237 
 
KISS1R 0.323405 0.290 
NPPB 2.53951 0.290 
 
GAB3 0.316999 0.091 
LOC100132356 2.525886 0.217 
 
ABCC4 0.217219 0.719 
PSAT1 2.51985 0.132 
 
UGT3A1 0.210625 0.360 
  
 
   
 
B) Control exosome recipient MCF-7 cells versus heat shock exosome recipient MCF-7 cells 
Up-regulated in heat shock exosome recipient 
cells  
Down-regulated in heat shock exosome 
recipient cells 
Gene name Fold change P value  Gene name Fold change P value 
NSUN7 4.352195 0.216 
 
XLOC_007277 0.392912 0.275 
MAK16 3.554827 0.178 
 
TRAPPC6B 0.391662 0.659 
GZF1 3.550008 0.131 
 
OR52L1 0.389641 0.118 
LOC286149 3.199528 0.447 
 
XLOC_l2_012388 0.389072 0.137 
LOC100128922 3.155415 0.511 
 
XLOC_l2_008313 0.385202 0.145 
XLOC_000909 3.144326 0.324 
 




XLOC_l2_011924 3.04401 0.224 
 
ARL10 0.378097 0.769 
ENG 2.970951 0.367 
 
PTGS2 0.371292 0.380 
XLOC_013795 2.855058 0.281 
 
XLOC_012079 0.370785 0.786 
XLOC_004426 2.760932 0.203 
 
DUSP26 0.363442 0.077 
XLOC_007420 2.749519 0.395 
 
XLOC_l2_001138 0.361445 0.102 
MARCO 2.713181 0.527 
 
TNF 0.35333 0.068 
BAALC 2.70135 0.786 
 
PEG3 0.35049 0.132 
PGCP1 2.551168 0.562 
 
XLOC_l2_014423 0.348687 0.155 
XLOC_l2_000696 2.526436 0.545 
 
XLOC_l2_005692 0.3438 0.244 
DEFB107A 2.511197 0.734 
 
LAMA1 0.338534 0.143 
XLOC_l2_015288 2.504192 0.353 
 
DAGLA 0.333836 0.362 
XLOC_l2_010897 2.495157 0.191 
 
LBH 0.33187 0.362 
NDP 2.466298 0.176 
 
XLOC_009893 0.326386 0.750 
CTTNBP2NL 2.43161 0.346 
 
ANP32A 0.314603 0.133 
  
 
   
 
C) Control MCF-7 cells versus control exosome recipient MCF-7 cells 
Up-regulated in control exosome recipient 
cells  
Down-regulated in control exosome recipient 
cells 
Gene name Fold change P value  Gene name Fold change P value 
XLOC_l2_003911 21.0027 0.323 
 
XLOC_l2_014024 0.08197 0.321 
TM4SF19 19.73313 0.291 
 
XLOC_002049 0.081768 0.342 
LINC00290 18.72338 0.284 
 
XLOC_l2_008321 0.081471 0.357 
PRDM9 18.14694 0.323 
 
LOC100293612 0.081142 0.357 
LOC400756 17.98568 0.226 
 
DDTL 0.080851 0.336 
LBH 17.86589 0.314 
 
XLOC_001795 0.079146 0.365 
XLOC_l2_001011 17.32759 0.284 
 
SERPINE1 0.077292 0.379 
XLOC_001776 16.31838 0.281 
 
FAM190A 0.0753 0.320 
LOC643723 16.25609 0.282 
 
XLOC_002174 0.074166 0.394 
XLOC_l2_015037 16.18181 0.353 
 
XLOC_005194 0.073272 0.326 
ARL10 16.1636 0.301 
 
AKD1 0.072093 0.296 
GUCY2F 15.23669 0.287 
 
GAB3 0.071955 0.320 
XLOC_012079 15.22509 0.340 
 
CHST10 0.070909 0.390 
XLOC_l2_002761 15.18733 0.287 
 
XLOC_002049 0.068169 0.295 
XLOC_004851 14.43412 0.319 
 
GUCY2D 0.067104 0.348 
LOC100133123 14.27681 0.280 
 
XLOC_005081 0.065717 0.356 
PPIH 14.04792 0.280 
 
XLOC_000133 0.058433 0.325 
SNORD115-37 14.00694 0.286 
 
XLOC_002134 0.055497 0.321 
OR51S1 13.93371 0.324 
 
XLOC_009974 0.055082 0.355 
CLEC4GP1 13.86039 0.280 
 
SULT1C3 0.052455 0.355 
  
 
   
 
D) Directly heat shocked MCF-7 cells versus heat shock exosome recipient MCF-7 cells 
Up-regulated in heat shock exosome recipient 
cells  
Down-regulated in heat shock exosome 
recipient cells 
Gene name Fold change P value  Gene name Fold change P value 
MARCO 16.93904 0.334 
 
XLOC_l2_007656 0.106307 0.347 
XLOC_008358 13.28133 0.350 
 
FAM190A 0.102325 0.378 
FBN3 11.88516 0.351 
 




LOC100129894 11.57543 0.312 
 
FASLG 0.097355 0.415 
XLOC_004851 11.41059 0.320 
 
XLOC_005081 0.097065 0.336 
XLOC_l2_008124 11.11305 0.417 
 
XLOC_l2_014024 0.096003 0.154 
XLOC_004851 10.33849 0.316 
 
ZNF3 0.094102 0.336 
KIAA0556 10.3313 0.314 
 
HIST2H4A 0.09292 0.308 
XLOC_000550 10.32035 0.360 
 
TACR3 0.090907 0.376 
NEFL 9.869531 0.311 
 
SULT1C3 0.084926 0.372 
GSTP1 9.59684 0.316 
 
CHST10 0.079697 0.264 
XLOC_009912 9.547468 0.398 
 
LOC100130849 0.078929 0.267 
XLOC_l2_015037 9.535888 0.417 
 
XLOC_l2_008321 0.078702 0.300 
XLOC_l2_003911 9.447515 0.456 
 
SERPINE1 0.077911 0.412 
BHMT2 9.340737 0.317 
 
LOC100293612 0.073924 0.286 
TM4SF19 9.327131 0.421 
 
RCAN3 0.070968 0.264 
XLOC_l2_000696 9.220111 0.287 
 
FP588 0.070215 0.232 
XLOC_010714 8.822661 0.395 
 
MIB2 0.063713 0.268 
XLOC_000505 8.783594 0.315 
 
APLNR 0.063397 0.316 
CACNA1B 8.603439 0.372 
 
AKD1 0.061339 0.333 
 
 
5.2.10. Cellular biological and molecular functional pathways implicated in heat shock exosome 
recipient MCF-7 cells and by directly heat shocking MCF-7 cells 
In order to accurately predict the pathways that are activated by heat shock exosomes or by 
directly heat shocking MCF-7 cells, approximately 100 genes are required. Typically genes that 
have at least a 2-fold change in their expression, and a p value of ≤0.05 are selected for accurate 
prediction of the pathways activated in the different experiments. However, when these 
thresholds were applied to the genes, there were not enough genes to perform an accurate 
analysis. Therefore, all genes with p values of ≤0.05 were selected (irrespective of their fold 
change); there were 15 differentially expressed genes for directly heat shocked cells versus 
control cells, 120 for control exosome recipient cells versus heat shock exosome recipient cells, 
326 genes for control cells versus control exosome recipient cells, and 481 for directly heat 
shocked cells versus heat shock exosome recipient cells. These gene lists were input into DAVID 
Bioinformatics Resources 6.7 and KEGG Pathways were selected for each gene expression sample 
set comparison. 
Enriched molecular functions in each list of differentially expressed genes were identified by this 
tool. The gene ontology (GO) terms are shown with their corresponding p values. For control 
MCF-7 cells versus directly heat shocked MCF-7 cells, two genes that participate in 
calcium-dependent phospholipid binding were identified to have differential gene expression with 




the SNARE interactions in vesicular transport pathway (Figure 5.9) were identified to have 
differential gene expression with a statistically significant p value of 5.4 × 10-4.  
Eight GO terms were recognised for containing differentially expressed genes between control 
exosome recipient MCF-7 cells versus heat shock exosome recipient MCF-7 cells (Table 5.6). The 
p53 signalling pathway (Figure 5.10) was also identified to have differential gene expression 
between these two experiments, with a statistically significant p value of 5.7 × 10-2, expression of 
three genes were affected (Table 5.7).  
Ten GO terms (Table 5.8) and ten KEGG pathways (Table 5.9) were identified to be affected in 
control exosome recipient MCF-7 cells compared with control MCF-7 cells. Seven of the identified 
KEGG pathways were related to cancer and the endocytosis pathway was also influenced by 
control exosomes.  
Fourty-one GO terms (Table 5.10) and ten KEGG pathways (Table 5.11) were also identified to be 
affected in directly heat shocked MCF-7 cells versus heat shock exosome recipient MCF-7 cells. 
GO terms identified included ‘heat shock protein binding’ (p = 6.0 × 10-2) and ‘damaged DNA 
binding’ (p = 7.8 × 10-2). Four of the KEGG pathways were related to cancer and the lysosome and 
phagocytosis pathways were also influenced by heat shock exosomes compared with direct heat 
shocking. 
 
Table 5.4: GO terms and the number of differentially expressed genes associated with each term for 
control MCF-7 cells versus directly heat shocked MCF-7 cells. 
GO Term (molecular function) Gene count P value 
calcium-dependent phospholipid binding 2 1.6 × 10-2 
 
 
Table 5.5: KEGG pathways associated with differentially expressed genes in control MCF-7 cells versus 
directly heat shocked MCF-7 cells. 
KEGG Pathway Differentially expressed genes P value 
SNARE interactions in vesicular 
transport 
1) Blocked early in transport 1 homolog (S. 
cerevisiae)-like (Bet-1) 
2) Synaptosomal-associated protein, 23kDa (SNAP23) 
3) Vesicle-associated membrane protein 4 (VAMP4) 








Figure 5.9: The SNARE interactions in vesicular transport KEGG pathway generated by DAVID 
Bioinformatics Resources 6.7 (Huang et al., 2009a; Huang et al., 2009b). The pathway shows the 
interaction of various genes in cellular vesicular transport. The red stars represent the differentially 






Table 5.6: GO terms and the number of differentially expressed genes associated with each term for 
control exosome recipient MCF-7 cells versus heat shock exosome recipient MCF-7 cells. 
 GO Term (molecular function) Gene count P value 
1 phosphatase activity 6 8.6 × 10-3 
2 laminin-1 binding 2 1.5 × 10-2 
3 
oxidoreductase activity, acting on the CH-NH group of donors, oxygen as 
acceptor 
2 1.5 × 10-2 
4 protein phosphatase regulator activity 3 3.0 × 10-2 
5 phosphatase regulator activity 3 3.3 × 10-2 
6 laminin binding 2 5.5 × 10-2 
7 cAMP-dependent protein kinase regulator activity 2 7.8 × 10-2 
8 protein domain specific binding 5 8.8 × 10-2 
 
 
Table 5.7: KEGG pathways associated with differentially expressed genes in control exosome recipient 
MCF-7 cells versus heat shock exosome recipient MCF-7 cells. 
KEGG Pathway Differentially expressed genes P value 
p53 signalling pathway 
1) Fas (TNF receptor superfamily, member 6)  
2) insulin-like growth factor binding protein 3 (IGF-BP3) 
3) phosphatase and tensin homolog (PTEN); phosphatase and 
tensin homolog pseudogene 1 (PTENP1) 









































































































































































































































































 Table 5.8: GO terms and the number of differentially expressed genes associated with each term for 
control MCF-7 cells versus control exosome recipient MCF-7 cells. 
 GO Term (molecular function) Gene count P value 
1 protein phosphatase regulator activity 5 6.2 × 10-3 
2 phosphatase regulator activity 5 7.5 × 10-3 
3 cadherin binding 3 2.3 × 10-2 
4 cytoskeletal protein binding 14 2.3 × 10-2 
5 enzyme binding 14 3.0 × 10-2 
6 protein transporter activity 5 3.3 × 10-2 
7 promoter binding 4 4.4 × 10-2 
8 beta-N-acetylhexosaminidase activity 2 5.4 × 10-2 
9 cell adhesion molecule binding 3 6.5 × 10-2 
10 microtubule binding 4 7.8 × 10-2 
 
 
Table 5.9: KEGG pathways and the number of differentially expressed genes in each pathway for control 
MCF-7 cells versus control exosome recipient MCF-7 cells. 
 KEGG Pathway 
Number of genes 
up-/down-regulated 
P value 




6 4.9 × 10-2 
 3 Pathways in cancer 11 4.9 × 10-2 




5 5.7 × 10-2 
 6 Non-small cell lung cancer 4 6.3 × 10-2 
 7 Prostate cancer 5 6.3 × 10-2 
 8 Vibrio cholerae infection 4 6.8 × 10-2 
 9 Thyroid cancer 3 8.6 × 10-2 







Table 5.10: GO terms and the number of differentially expressed genes associated with each term for 
directly heat shocked MCF-7 cells versus heat shock exosome recipient MCF-7 cells. 
 GO Term (molecular function) Gene count P value 
1 cation-transporting ATPase activity 7 7.0 × 10-5 
2 proton-transporting ATPase activity, rotational mechanism 6 7.6 × 10-5 
3 hydrogen ion transporting ATP synthase activity, rotational mechanism 5 2.3 × 10-4 
4 ATPase activity, coupled to transmembrane movement of ions 8 6.7 × 10-4 
5 P-P-bond-hydrolysis-driven transmembrane transporter activity 9 3.1 × 10-3 
6 primary active transmembrane transporter activity 9 3.1 × 10-3 
7 
oxidoreductase activity, acting on the CH-NH group of donors, NAD or 
NADP as acceptor 
4 5.1 × 10-3 
8 ATPase activity, coupled to transmembrane movement of substances 8 6.1 × 10-3 
9 ATPase activity, coupled to movement of substances 8 6.5 × 10-3 
10 
hydrolase activity, acting on acid anhydrides, catalyzing transmembrane 
movement of substances 
8 6.8 × 10-3 
11 unfolded protein binding 8 8.2 × 10-3 
12 inorganic cation transmembrane transporter activity 9 1.1 × 10-2 
13 monovalent inorganic cation transmembrane transporter activity 7 1.8 × 10-2 
14 NF-kappaB binding 4 2.0 × 10-2 
15 oxidoreductase activity, acting on the CH-NH group of donors 4 2.0 × 10-2 
16 
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in 
linear amides 
5 2.8 × 10-2 
17 identical protein binding 21 3.1 × 10-2 
18 hydrogen ion transmembrane transporter activity 6 3.4 × 10-2 
19 aldo-keto reductase activity 3 3.5 × 10-2 
20 protein homodimerization activity 13 3.6 × 10-2 
21 peptidyl-prolyl cis-trans isomerase activity 4 3.7 × 10-2 
22 cis-trans isomerase activity 4 4.2 × 10-2 
23 cytoskeletal protein binding 17 4.5 × 10-2 
24 protein serine/threonine kinase activity 15 5.0 × 10-2 
25 RNA binding 22 5.1 × 10-2 
26 transcription factor binding 17 5.1 × 10-2 
27 FAD binding 5 5.6 × 10-2 




29 TPR domain binding 2 5.9 × 10-2 
30 heat shock protein binding 5 6.0 × 10-2 
31 SMAD binding 4 6.4 × 10-2 
32 structure-specific DNA binding 7 7.0 × 10-2 
33 nucleoside-triphosphatase regulator activity 14 7.1 × 10-2 
34 protein dimerization activity 17 7.6 × 10-2 
35 damaged DNA binding 4 7.8 × 10-2 
36 iron-sulfur cluster binding 4 7.8 × 10-2 
37 metal cluster binding 4 7.8 × 10-2 
38 guanyl-nucleotide exchange factor activity 7 8.4 × 10-2 
39 4 iron, 4 sulfur cluster binding 3 8.8 × 10-2 
40 ATPase activity, coupled 10 9.5 × 10-2 
41 pyrroline-5-carboxylate reductase activity 2 9.6 × 10-2 
 
 
Table 5.11: KEGG pathways and the number of differentially expressed genes in each pathway for directly 
heat shocked MCF-7 cells versus heat shock exosome recipient MCF-7 cells. 
 KEGG Pathway 
Number of genes 
up-/down-regulated 
P value 
 1 Vibrio cholerae infection 7 1.9 × 10-3 
 2 
Epithelial cell signaling in Helicobacter 
pylori infection 
7 5.1 × 10-3 
 3 Lysosome 9 6.1 × 10-3 
 4 Acute myeloid leukemia 6 1.1 × 10-2 
 5 Steroid biosynthesis 3 6.0 × 10-2 
 6 Fc gamma R-mediated phagocytosis 6 7.3 × 10-2 
 7 Bladder cancer 4 7.6 × 10-2 
 8 Pathways in cancer 13 8.5 × 10-2 
 9 Pancreatic cancer 5 8.9 × 10-2 
 10 
Natural killer cell mediated 
cytotoxicity 







5.2.11. The effect of cisplatin treated cell-derived exosomes on invasive behaviour of ovarian 
cancer cells  
After establishing that heat shock exosomes increase the invasive capacity of MCF-7 cells, the 
effect of exosomes derived from cells stressed in a different way, by treatment with a 
chemotherapeutic drug, was investigated. The hypothesis was that invasive capacity of cancer 
cells increased in response to exosomes derived from cells that had been stressed by several 
different types of stressor and was not limited to heat stress exosomes. To test this hypothesis, 
cisplatin treated cell-derived exosomes (cisplatin exosomes) were extracted and their effect on 
the invasive capacity of two ovarian cancer cell lines, A-2780 and IGROV-1, was explored. To 
generate cisplatin exosomes, parental cells were incubated in 40 µM cisplatin for 2 hours. This 
concentration of cisplatin (40 µM) was optimised in our research group in A-2780 cells by Dr Priya 
Samuel. Dr Samuel determined the ideal concentration and duration of stress induction by 
calculating the IC50 (the concentration at which cisplatin reduced cellular metabolic activity by 
half) using the MTT assay. Chemotherapy-containing media was removed, the cells were washed 
in PBS, and fresh EFM was added to the cells. The cells were incubated for a further 2 hours, then 
the media was replaced with EFM once more. This step removes cisplatin pumped out of the cells 
following the treatment period. 20 hours later exosomes were collected from the tissue culture 
media and incubated with serum-starved cells for 24 hours. The stress exosome collection 
procedure was repeated 24 hours later, and a second batch of heat shock exosomes were added 
to the cells immediately after they had been seeded in the Matrigel trans-well assay. The effect of 
cisplatin exosomes on invasive capacity compared with control cells was established. A one tailed 
T-test value of 0.0082 confirmed that the invasive capacity of A-2780 cells increased in the 
presence of cisplatin exosomes compared with cells that received no exosomes (Figure 5.11). 
Cisplatin exosomes also increased invasive activity compared with control exosome treatment (p 
= 0.0067). There was not a significant difference between invasiveness of control cells treated 
with no exosomes, and cells treated with control exosomes (p = 0.218).  
The invasive capacity of IGROV-1 cells also increased in response to cisplatin exosomes compared 
with control cells that received no exosomes (p = 0.042), and in comparison to control exosome 
treatment (p = 0.039). There was no significant difference between invasiveness of control cells 
treated with no exosomes, and cells treated with control exosomes (p = 0.436).  
These results suggest that following cisplatin-induced stress response the exosomes released by 
both A-2780 and IGROV-1 cells have the ability to induce greater invasive potential in 
neighbouring recipient cells. Increased invasive capacity was induced by exosomes derived from 





Figure 5.11: The effect of cisplatin treated cell-derived exosomes upon the invasive capacity of ovarian 
cancer cell lines. The Matrigel trans-well invasion assay was used to determine the effect of cisplatin 
treated cell-derived exosomes on invasive potential of two ovarian cancer cell lines. Exosomes were 
extracted from approximately 6 million cells that had been cisplatin treated 24 hours prior to exosome 
extraction and 6 million control cells, for each cell line. Extracted exosomes were administered to 
approximately 1 million cells. 24 hours later the exosome extraction procedure was repeated to harvest 
more cisplatin treated and control cell-derived exosomes. 100,000 cells were distributed into each insert of 
the trans-well assay. Following extraction exosomes were immediately transferred into Matrigel trans-wells 
(the dose was equivalent to exosomes extracted from 6 million cells). Cells invaded Matrigel membranes 
over 24 hours. Matrigel membranes were cleared of non-invasive cells and invasive cells were stained with 
crystal violet. The number of invasive cells on each membrane was counted. The graphs represent fold 
change in terms of the total number of cells that invaded the Matrigel membrane following treatment with 
either control or cisplatin treated cell-derived exosomes. Each sample group contained six biological 
replicates. Error bars represent standard error of the mean of the biological replicates. P values were 
calculated using the one tailed T-test. The images represent the Matrigel membranes following the cell 
invasion period after the cells received either control or heat shock exosomes. 
 
5.2.12. Characterisation and further investigation into the effect of cisplatin treated cell-
-derived exosomes on invasive behaviour of A-2780 cells  
Cisplatin treated A-2780 cell-derived exosomes were characterised by WB (Figure 5.12A). As for 
the heat shock exosomes, HSP70 (an exosome marker) and GAPDH (a cytoplasmic marker) were 
both identified in the cisplatin and control exosome samples. Cytochrome C oxidase and calnexin 
were not detected by WB in the exosome samples indicating that the samples were not 
contaminated by intracellular organelles or other types of EV during the extraction process. All 
four proteins were identified in the A-2780 control and cisplatin treated cell samples signifying 




The relative intensities of WB bands (Figure 5.12A) for protein samples extracted from directly 
cisplatin treated and control A-2780 cells, and their secreted exosomes, were quantified using 
Image Lab software version 5.2.1. Control cell band intensity was used as the reference band for 
each antibody. The results show that HSP70 expressed at approximately equal levels in both 
cisplatin (0.08) and control exosomes (0.09) (Table 5.12). HSP70 was detected in both cisplatin 
treated and control cells (0.74 and 1.00, respectively). The positive/loading control GAPDH bands 
were more intense in control cells (1.00) compared with cisplatin treated cells (0.71), and in 
cisplatin exosomes (0.42) compared with control exosomes (0.17). Calnexin was detected in 
control and cisplatin treated cells (1.00 and 0.36, respectively), as expected, and at very low levels 
in control and cisplatin exosome samples (0.01 and 0.04, respectively). Cytocrome C oxidase was 
present in both cisplatin treated and control cells (0.43 and 1.00, respectively), and absent in both 
exosome samples (0.00 and 0.02), as predicted (Table 5.12). 
 
Table 5.12: The relative intensities of HSP70, GAPDH, calnexin, and cytochrome C oxidase bands on Figure 
5.12A western blots of directly cisplatin treated A-2780 cells and exosomes derived from cisplatin treated 
A-2780 cells compared with control A-2780 cells and exosomes. 
Sample 
Relative intensity 
HSP70 GAPDH Calnexin 
Cytochrome C 
oxidase 
Control cells 1.00 1.00 1.00 1.00 
Control exosomes 0.09 0.17 0.01 0.00 
Directly cisplatin 
treated cells 




0.08 0.42 0.04 0.02 
 
 
To determine the effect of cisplatin treatment on exosome secretion levels, NTA was performed 
on three samples of control exosomes and three samples of cisplatin exosomes derived from 
A-2780 cells. Six T175 flasks were seeded at equal concentration of A-2780 cells, and once 70% 
confluency was reached, three of the flasks were cisplatin treated for 2 hours at a concentration 
of 40 µM. The remaining three flasks were maintained at 37°C and used as control exosome 
donating cells. Exosomes were extracted the following day, and exosome concentration was 
determined by NTA. There was no significant difference between the concentration of exosomes 
released by control A-2780 cells (13.00 × 108 particles/mL) compared with cisplatin treated A-2780 
cells (17.22 × 108 particles/mL) (Figure 5.12B). This indicates that stress-induced by cisplatin does 




TEM identified vesicles within the size range of exosomes (30–160 nm) for both control and 
cisplatin exosomes (Figure 5.12C&D). In addition to irradiation and heat shocking 
(Figure 5.5C&D), cisplatin exosomes were also shown to be statistically significantly smaller in 
diameter than control A-2780 cell-derived exosomes (p = 2.112 × 10-8). 
To check that the increase in cell invasion was caused specifically by cisplatin exosomes rather 
than increased exosome number induced by the cisplatin treatment, the Matrigel invasion assay 
was repeated with A-2780 cells treated with 1X control exosomes (exosomes extracted from 
approximately 10 million cells, cultured for 24 hours in EFM), 2X control exosomes (exosomes 
extracted from approximately 20 million cells, cultured for 24 hours in EFM), or 1X cisplatin 
exosomes (Figure 5.12E). This experiment generated different results to those obtained 
previously. Compared with 1X control exosome treatment, both 2X control and 1X cisplatin 
exosome treatments caused statistically significantly fewer invasive A-2780 cells (p = 0.001 and 
p = 0.0003, respectively). This suggests that doubling the concentration of exosomes administered 
does not increase invasive behaviour of A-2780 cells. However on this occasion, cisplatin 
exosomes were not capable of increasing A-2780 cell invasive capacity.  
Representative images of the Matrigel membranes are shown in Figure 5.12F. The highest 
number of invasive cells were found on the Matrigel membranes that contained cells treated with 
1X control exosomes. Lower numbers of invasive cells are shown on membranes treated with 






Figure 5.12: Characterisation of cisplatin and control exosomes derived from A-2780 cells and their effect 
on invasive behaviour on naïve A-2780 cells. A) Control and cisplatin treated cell and exosome protein 
lysates were characterised by western blotting, samples were probed for GAPDH, calnexin, HSP70, and 
cytochrome C oxidase. B) Quantification of exosomes secreted by control and cisplatin treated A-2780 cells 
by nanoparticle tracking analysis. C) Images of electron microscopy grids of control and cisplatin exosomes 
visualised by transmission electron microscopy. D) Average diameter of exosomes secreted by cisplatin 
treated and control A-2780 cells measured on electron microscopy grids (C). There were two biological 
replicates containing diameter measurements of 50 exosomes. E) Matrigel assay performed to investigate 
the effect of exosome concentration and cisplatin exosomes upon invasive capacity of A-2780 cells. 1X 
control exosomes was equivalent to exosomes extracted from approximately 10 million cells, cultured in 
exosomes-free media for 24 hours. 2X control exosomes was equivalent to exosomes extracted from 20 
million cells. F) Representative images of Matrigel membranes showing invasive A-2780 cells following 
treatment with different concentrations and types of exosomes (in the Matrigel invasion experiment, E). 





5.2.13. Optimisation of exosome uptake inhibition with heparin and proteinase K 
To further confirm that cisplatin exosomes increase invasiveness of recipient cells, experiments 
were planned to show reversal of this effect by inhibiting exosome uptake. Heparin and 
proteinase K were chosen for optimisation in our lab. Heparin pre-treatment of cells and 
exosomes at 10.0 mg/mL heparin for 30 minutes at 37°C prior to exosome administration onto 
cells, and proteinase K pre-treatment of exosomes prior to their administration onto cells at 1.0 
mg/mL proteinase K for 30 minutes at 37°C were both successful methods for inhibition of 
exosome uptake. The average volume of PKH26-exosomes identified inside cells following 
exosome uptake inhibition was statistically significantly reduced from 11.00 µm3 to 0.09 µm3 for 
heparin treatment and from 143.26 µm3 to 0.50 µm3 for proteinase K treatment (Figure 5.13). 
Heparin binds many ECM proteins (Sarrazin et al., 2011) so is not a suitable exosome uptake 
inhibitor for invasion experiments involving Matrigel. Therefore, proteinase K was selected for 



























































































































































































































































































































































































































































































































































































































































5.2.14. The effect of exosome uptake and DNA repair inhibitors on the ability of cisplatin 
exosomes to increase invasiveness of A-2780 cells 
In an attempt to describe, at least in part, the mechanism responsible for cisplatin 
exosome-mediated increase in cellular invasive capacity, proteinase K (previously shown to inhibit 
exosome uptake [Figure 5.13]) and the DNA-PK inhibitor NU7441 were used. Proteinase K was 
added to cisplatin exosomes for 30 minutes, then inhibited by boiling for 10 minutes, prior to 
their administration onto cells. In addition to cisplatin exosomes, 10.0 µM NU7441 was 
administered to cells over a 24 hour treatment period. Proteinase K and NU7441 treatments 
occurred both 24 hours before and immediately after cells were seeded in the Matrigel trans-well 
inserts. Compared with control A-2780 exosome treatments, cisplatin exosomes did not increase 
cellular invasiveness (Figure 5.14), unlike in previous experiments (Figure 5.11). Inhibiting 
cisplatin exosome uptake with proteinase K was predicted to reduce cellular invasiveness, 
however, invasiveness did not decrease compared with cells treated with control exosomes or 
cisplatin exosomes (Figure 5.14). NU7441 treatment in addition to cisplatin exosomes statistically 
significantly reduced cellular invasiveness in comparison with cells treated with control exosomes, 





Figure 5.14: The effect of inhibiting exosome uptake and DNA-PK activity upon the ability of cisplatin 
exosomes to influence invasive capacity of A-2780 ovarian cancer cells. A) Matrigel assay performed to 
investigate the effect of A-2780 cell invasiveness following cisplatin exosome uptake inhibition with 
proteinase K and DNA-PK inhibition with NU7441 in cisplatin exosome recipient cells. B) Representative 
images of Matrigel membranes showing invasive A-2780 cells following treatment with different 
compounds and types of exosomes (in the Matrigel invasion experiment, A). There were three biological 
replicates for each treatment type, all of the cells were counted on each Matrigel membrane. P values were 






5.2.15. The role of kinases in cisplatin exosome mediated increase in A-2780 cell invasiveness 
With the aim of improving our understanding of the mechanism responsible for increased cell 
invasiveness induced by cisplatin exosomes, the proteome profiler human phospho-MAPK array 
was used. The relative phosphorylation levels of 26 kinases was determined for A-2780 cells 
treated with either control exosomes or cisplatin exosomes. The signal intensity at each capture 
spot represented bound phosphorylated protein and was used to calculate relative 
phosphorylation levels of each kinase (Figure 5.15A). Phosphorylation of each kinase was 
measured in duplicate (two spots for each kinase). Significant differences in protein kinase 
phosphorylation between samples were calculated using the two tailed T-test. Seven kinases had 
statistically significantly different relative levels of phosphorylation between the cells treated with 
cisplatin exosomes and the control exosome treatment. The downregulated kinases were: CREB 
(p = 0.019), extracellular signal-regulated kinases (ERK) 2 (p = 0.050), and TOR (p = 0.0021); 
upregulated kinases were: JNK2 (p = 0.00087), JNKpan (p = 0.044), p38α (p = 0.038), and p53 
(p = 0.015) (Figure 5.15B). These results indicate that CREB, ERK2, TOR, JNK2, JNKpan, p38α, and 
p53 may have a role in the mechanism responsible for cisplatin exosome-induced increased 
A-2780 cell invasiveness. 
Statistically significant down-regulation of CREB phosphorylation levels was consistent between 
heat shock exosome treated MCF-7 cells and cisplatin exosome treated A-2780 cells (compared 
with control exosome treated cell equivalents). p53 expression was different in both types of 
stress exosome treated cells but was statistically significantly increased in cisplatin exosome 








Figure 5.15: Relative phosphorylation levels of 26 kinases in A-2780 cells following treatment with either 
control or cisplatin exosomes determined using the proteome profiler human phospho-MAPK array. A) 
Blots showing intensity for each kinase on duplicate spots for each exosome treatment. B) Intensity levels of 
each kinase in A-2780 cells treated with either control or cisplatin exosomes. Differences in kinase 








There is evidence to suggest that exosomes can transfer protection to stress from cells that have 
experienced stress to naïve cells (Al-Mayah et al., 2012; Arscott et al., 2013; Eldh et al., 2010; 
Ngora et al., 2012; Park et al., 2010; Ramteke et al., 2015; Wang et al., 2014). Cells undergoing 
stress may send signals to their neighbours to help them respond to adverse environmental 
conditions, and as a result improve their chance of survival. Increased recipient cell motility and 
invasive capacity as a consequence of receipt of such a signal would enable cells to escape the 
potential threat. It was predicted that stress alerts are transferred between cells via exosomes. In 
support of this idea, results in this chapter demonstrate that exosomes derived from both heat 
shocked (Figure 5.4) and cisplatin treated cells (Figure 5.11) increase the invasiveness of some 
lines of recipient cancer cells. 
 
5.3.1. Stressed cell derived exosomes increase recipient cell invasiveness 
Exosomes were extracted from heat shocked cells and applied to cells in the Matrigel invasion 
assay. This experiment showed that heat shock exosomes statistically significantly increased the 
invasiveness of MCF-7 cells (Figure 5.4). A-2780 and IGROV-1 cells were treated with cisplatin, 
then exosomes were extracted from these stressed cells, and applied to cells in the Matrigel 
invasion assay. This experiment showed that cisplatin exosomes statistically significantly 
increased the invasiveness of A-2780 cells (Figure 5.11).  
 
5.3.2. Establishment of cancer cell line invasive capacity 
With the purpose of distinguishing more invasive ovarian cancer cell lines from less invasive cell 
lines, the Matrigel invasion assay was used. Prior to commencement of this project a comparison 
between the invasive capacities of a range of ovarian cancer cell lines had not been made, despite 
the Matrigel invasion assay being used as an in vitro model for analysis of cellular invasive 
competence. This project established that SKOV-3 cells were the most invasive, of the nine 
ovarian cancer cell lines tested, and A-2780 and OVCAR-3 cell lines were the least invasive (Figure 
5.1). The ECM layer did not affect the invasive capacity of A-2780, IGROV-1 nor OVCAR-3 cells. 
However, CP-70, MCP-1, OVCAR-4, OVCAR-5, OVCAR-8, and SKOV-3 cell invasive capacities were 
statistically significantly reduced by the ECM barrier. This suggests that these cell lines migrate 
easily across semi-permeable membranes but their ECM-degradation ability restricts the number 
of cells that can invade the membrane. The invasive competence of the breast cancer cell line 




membranes coated in Matrigel was similar to that of A-2780 and OVCAR-3 ovarian cancer cell 
lines (Figure 5.1). Analysis of gene expression differences between the cell lines may explain 
differences in their invasive capacities. The establishment of cellular invasive competencies will 
provide a useful tool for ovarian cancer researchers in the future for more sophisticated 
experimental design. 
 
5.3.3. Optimisation of the heat shocking procedure 
Heat shocking cells for 1 hour was shown to increase cellular protein expression of HSP70 (Figure 
5.3) and therefore strongly suggested that cells were sufficiently heat shocked, inducing a cellular 
stress response. The GO terms ‘heat shock protein binding’ and ‘damaged DNA binding’ were 
identified by differential gene expression data for heat shock exosome recipient cell versus 
directly heat shocked cells (Table 5.10). This may be a consequence of the exposure of the cells to 
the extreme temperature of 45°C. Up-regulation of components of these pathways further 
suggest that the heat shocking procedure was sufficiently stressing cells. 
 
5.3.4. Stress exosome characterisation 
Heat shock exosomes derived from MCF-7 cells, and cisplatin exosomes derived from A-2780 cells 
were characterised by WB, TEM, and NTA. WB results showed that heat shock exosomes 
contained HSP70 at an elevated level compared with control exosomes (Figure 5.5A). An increase 
in exosomal HSP70 concentration has also been shown by Clayton and colleagues in 2005, where 
exosomes were collected after heat shocking B-cells for 3 hours at 42°C (Clayton et al., 2005). 
These results indicate that the method used in this project, of heat shocking cells at 45°C for 1 
hour, also increases expression of HSP70 in heat stressed cells resulting in a higher concentration 
of HSP70 in the exosomes secreted by these cells. Cisplatin exosomes contained the exosome 
marker HSP70 and the positive/loading control protein GAPDH (present in both cells and 
exosomes) (Figure 5.12A). Heat shock and cisplatin exosome samples were also free of organelle 
and apoptotic body contamination. TEM identified exosomes within the expected size range, 30–
160 nm (Ludwig and Giebel, 2012), but stress (both heat shock and cisplatin) exosomes were 
statistically significantly smaller in diameter (Figure 5.5C&D and Figure 5.12C&D). These results 
are consistent with previous findings in our research group, where Dr Laura Jacobs showed that 
exosomes secreted by irradiated MCF-7 cells were also significantly smaller than those secreted 





5.3.5. The effect of exosome concentration on cellular invasiveness 
Previous studies (section 5.1.8) have shown that stress causes an increase in exosome secretion 
concentration (Al-Mayah et al., 2015; Clayton et al., 2005; Jella et al., 2014; King et al., 2012; Lv et 
al., 2012; Ngora et al., 2012; Salomon et al., 2013a; Wang et al., 2014). Therefore, one 
explanation for the observed increase in cell invasiveness in response to stress (both heat shock 
and cisplatin) exosome treatment was a higher exosomal dose instead of specific components of 
stress exosomes. To investigate this, exosome secretion following stress was compared with 
secretion under control conditions. Exosomes were extracted and quantified using NTA 
(Figure 5.5B and Figure 5.12B) – stress did not cause an increase in exosome secretion. To further 
confirm this, cell invasiveness was measured using the Matrigel invasion assay to compare 
treatment with control exosomes extracted from 6 million cells with treatment with control 
exosomes extracted from 12 million cells. The difference in cellular invasiveness was not 
statistically significantly different (Figure 5.5E and Figure 5.12E). This indicates that a specific 
exosome component of heat shock and cisplatin exosomes, rather than exosome concentration, is 
responsible for the increased invasive capacity observed in cancer cell lines. For the heat shock 
exosome treatment, cellular invasiveness was increased, although did not quite reach significance 
(because of high intra-assay variability) (Figure 5.5E). However, cisplatin exosomes did not 
increase cellular invasiveness in this experiment (Figure 5.12E); this may have been caused by 
accumulation of mutations as a result of successive passaging of the A-2780 cell line (causing 
alterations to cellular characteristics), insufficient cisplatin exposure of parental cells caused by 
discrepancy in cisplatin administration, or expired cisplatin. 
Microarray data suggests that relative expression levels of three genes: Bet-1, SNAP23, and 
VAMP4 (Figure 5.8A and Table 5.5), were statistically significantly different in MCF-7 cells that 
were directly heat shocked compared with control cells. These genes are all involved in SNARE 
interactions in vesicular transport (Figure 5.9). These results are consistent with previous studies 
that provide evidence for increased secretion of exosomes following cellular stress (section 5.1.8) 
(Al-Mayah et al., 2015; Clayton et al., 2005; Jella et al., 2014; King et al., 2012; Lv et al., 2012; 
Ngora et al., 2012; Salomon et al., 2013a; Wang et al., 2014). 
 
5.3.6. Invasive cell distribution on Matrigel membranes 
The invasive cells were observed on the Matrigel coated membranes, small clusters of MCF-7 cells 
were shown on the membranes, suggesting that MCF-7 cells invade more effectively in groups 




membranes was more uniform (Figure 5.12F) suggesting that they are more capable of invading 
as single cells. 
 
5.3.7. The effect of heat shock exosomes on cell motility 
To determine whether heat shock exosomes had the same effect on cell motility as they do on cell 
invasiveness, the scratch assay was used. Twenty-four hours after heat shocking, the media was 
aspirated, filtered, and administered to naïve cells. Then 24 hours later, the scratch assay was 
performed, and a second dose of heat shocked cell media was added to the cells. For comparison, 
and to confirm cellular damage, cell motility was also analysed in directly heat shocked cells using 
the scratch assay. As expected, directly heat shocked cells were less motile than control and heat 
shock media transfer recipient cells. This is likely to result from the damage caused during the 
heat shocking procedure. Heat shock media transfer did not affect the motility of recipient cells 
compared with control cells, suggesting that, unlike cellular invasiveness, heat shock exosomes 
(that were suspended in the conditioned media) did not affect cell motility (Figure 5.6). Had an 
effect been observed, this experiment would have been repeated but heat shock exosomes would 
have been extracted from the media and administered directly onto MCF-7 cells to determine 
whether that the increase in cell motility was caused by heat shock exosomes or another 
component of the heat shock media. 
 
5.3.8. Exosome uptake inhibition experiment 
In order to show that cellular invasiveness induced by stress exosomes is reversed when exosome 
uptake is inhibited, an experiment was optimised to inhibit exosome uptake using heparin (Figure 
5.11A&B). Heparin has been used as an inhibitor of exosome uptake in previous studies 
(Christianson et al., 2013; Mulcahy et al., 2014; Svensson et al., 2013). However, exosome uptake 
inhibition needed to be used in synchrony with the Matrigel invasion assay, since heparin binds 
with HSPG components of the Matrigel it was not suitable for this experiment. Therefore, 
proteinase K was optimised as an alternative exosome uptake inhibitor (Figure 5.12C&D). Protein 
interactions are key for exosomal uptake, and proteinase K has been shown to abrogate 
internalisation of EVs (Escrevente et al., 2011). Both heparin and proteinase K statistically 





5.3.9. The role of cisplatin exosomes in the increased invasiveness of A-2780 cells 
Following the discovery of increased A-2780 invasiveness in response to cisplatin exosomes, 
exosome uptake inhibition by pre-treatment of cisplatin-exosomes with proteinase K was 
expected to reduce cellular invasion compared with cells treated only with cisplatin exosomes as 
exosome uptake had been inhibited. Had this result been obtained, it would have further 
indicated that cisplatin exosomes are responsible for increased cellular invasion. However, on this 
occasion, cisplatin exosomes did not increase invasiveness of recipient cells significantly more 
than control exosomes, and a reduction in invasiveness was not induced by proteinase K 
treatment (Figure 5.14). Reasons for this include: (1) exosome uptake may not be required to 
increase cell invasiveness; (2) exosome-cell protein-protein interactions are necessary for transfer 
of the signal from stress exosomes to cells to induce a more invasive phenotype; (3) the 
interaction on the cell surface between the cell and exosomal membranes may be sufficient for 
signal transduction (Rana and Zöller, 2011; Record et al., 2014); (4) the A-2780 cell line had been 
passaged too many times so the characteristics of the cell line had evolved, and their response to 
cisplatin exosomes changed. 
 
5.3.10. Elucidating the mechanism responsible for stress exosome-mediated increases in 
cellular invasiveness 
5.3.10.1. The role of DNA-PK 
DNA-PK is a nuclear serine/threonine protein kinase, an essential participant in the DNA repair 
pathway. It has an important role in the DNA damage response and maintenance of genomic 
stability. DNA-PK is activated upon association with DNA (Smith and Jackson, 1999), and 
recognises and then re-joins DSBs in DNA through non-homologous end joining (Smith and 
Jackson, 1999; Yoo and Dynan, 1999). DNA-PK expression has been shown to be significantly 
elevated in patients with advanced disease and has been correlated with decreased therapeutic 
response to DNA-damaging agents in several malignancies (Beskow et al., 2009; Bouchaert et al., 
2012). This suggests that DNA-PK-mediated DNA repair is a mechanism involved in tumour cell 
survival and cancer development. High DNA-PK levels have also been associated with poor 
prognosis in the absence of DNA-damaging therapies (Evert et al., 2013; Willmore et al., 2008), 
suggesting a DNA damage response-independent role for DNA-PK in human cancers. DNA-PK has 
been identified as a mediator of cancer-promoting pathways distinct from DNA repair, including 
hypoxia, metabolism, inflammatory response, and transcriptional regulation (Goodwin and 
Knudsen, 2014). Goodwin and colleagues (2015) have shown that DNA-PK has a pivotal role in 




et al., 2015). In the same study, suppression of DNA-PK inhibited prostate cancer metastasis 
(Goodwin et al., 2015). It is possible that DNA-PK is active in other solid tumours. The stress 
exosome-associated increase in cancer cell invasiveness may be activated via a DNA-PK 
dependent pathway. To test this, DNA-PK was inhibited with NU7441 in cisplatin exosome 
recipient cells. Invasion was statistically significantly reduced in these cells in comparison with 
cells treated with cisplatin exosomes (Figure 5.14). However, since cells treated with cisplatin 
exosomes and proteinase K (to inhibit exosome uptake) and control exosomes were not 
statistically significantly less invasive than those treated with cisplatin exosomes, it is possible that 
the decreased cellular invasion observed was because of the NU7441 concentration being too 
high or the treatment period too long i.e. cell integrity caused reduced cell invasiveness. Because 
of time constraints, NU7441 concentration and treatment period were not optimised prior to 
performing the Matrigel invasion experiment, and the experiment was not repeated with altered 
conditions. Therefore, further experimentation is required to determine the role of DNA-PK in 
stress exosome-mediated increased cellular invasiveness. 
 
5.3.10.2. Potential pathways involved in stress exosome-mediated increased cellular 
invasiveness 
Carcinogenesis is a consequence of the disrupted balance between cell proliferation and 
apoptosis (programmed cell death). Therefore, proteins that regulate cell proliferation, 
differentiation, development, and apoptosis sustain oncogenic changes more frequently than 
molecules involved in other signalling pathways (Fresno Vara et al., 2004). During cancer 
progression, the phosphorylation status of three major families of MAPKs: ERK1/2, JNK1–3, and 
different p38 isoforms (α/β/δ/γ), influence the aggressiveness of the tumour (Sebolt-Leopold and 
Herrera, 2004). Expression levels of signal transduction regulatory proteins, including: Akt, GSK-3, 
p70 S6 Kinase, TOR, p53, and CREB, which mediate cell development and proliferation, also 
indicate the pathways that are active inside the cell (Robinson and Cobb, 1997).  
 
5.3.10.2.1. Effects upon the MAPK and PI-3K pathways in response to heat shock exosomes in 
MCF-7 recipient cells 
Microarray data suggested that relative expression levels of three genes: Fas, IGF-BP3, and PTEN 
and/or PTENP1 (Figure 5.8B and Table 5.7), were statistically significantly different in MCF-7 cells 
that received heat shock exosomes compared with control exosomes. These genes are all 




human phospho-MAPK array identified Akt2, CREB, HSP27, p38γ, and p53 as statistically 
significantly less phosphorylated in MCF-7 cells treated with heat shock exosomes compared with 
cells that received control exosomes (Figure 5.7). Akt2 overexpression is associated with a more 
malignant and aggressive phenotype in ovarian and pancreatic tumours (Cheng et al., 1992; 
Cheng et al., 1996). This protein kinase is capable of phosphorylating a number of known proteins. 
HSP27 is involved in stress resistance (Garrido et al., 1997; Huot et al., 1996; Wang et al., 2002), 
its expression is induced by environmental stress, and the protein translocates from the 
cytoplasm to the nucleus upon stress induction (Bryantsev et al., 2007). p53 is an essential 
tumour suppressor protein that responds to a diverse range of cellular stressors to regulate 
expression of cell cycle arrest, apoptosis, senescence, DNA repair, and metabolism (Levine et al., 
1991; Liu et al., 2014b). p53 is mutated or deleted in 60–70% of cancers (Hollstein et al., 1991; 
Levine et al., 1991; Liu et al., 2014b). p38 regulates cellular activity including proliferation, 
differentiation, transcription regulation, and development (Koul et al., 2013). This kinase is 
triggered under conditions of environmental stress and its stimulation requires its 
phosphorylation by MAP kinase kinases or autophosphorylation (Raingeaud et al., 1995; Zarubin 
and Han, 2005). p38 modulates stress-induced transcription and cell cycle regulation, with 
substrates of this kinase including many transcription regulators; one such protein is the tumour 
suppressor p53 (Koul et al., 2013). Down-regulated p53 phosphorylation in heat shock exosome 
recipient MCF­7 cells may explain the reduction in p38γ phosphorylation levels. 
Akt2, CREB, p38γ, and p53 have roles in cancer and its progression to invasive disease and HSP27, 
p38γ, and p53 participate in the stress response. Phosphorylation of all of these proteins was 
statistically significantly reduced in MCF-7 cells that received heat shock exosomes compared with 
control exosomes, therefore, the results obtained were unanticipated. Since heat shock exosomes 
increased invasive capacity of MCF-7 cells in previous experiments (Figure 5.4 and Figure 5.7E), it 
was expected that phosphorylation of proteins involved in both cell invasiveness and stress 
response would increase. 
 
5.3.10.2.2. Effects on the MAPK and PI-3K pathways in response to cisplatin exosomes in 
A-2780 recipient cells 
The proteome profiler human phospho-MAPK array identified ERK2 and TOR as statistically 
significantly less phosphorylated, and JNK2, JNKpan, p38α, p53 had statistically significantly 
greater phosphorylation in A-2780 cells treated with cisplatin exosomes compared with cells that 
received control exosomes (Figure 5.15). ERK2 acts as an integration point for multiple 




development. ERK2 mutations can drive the development of cancer (Samatar and Poulikakos, 
2014; Dhillon et al., 2007). TOR is a kinase that regulates the cellular stress response. It 
participates in cell cycle arrest following DNA damage (Shen et al., 2007). JNK2 and JNKpan are 
closely related kinases that target specific transcription factors, which mediate immediate-early 
gene expression in response to cellular stimuli (Hirsch and Stork, 1997). Both of these kinases 
participate in UV radiation induced apoptosis that has been shown to be associated with the 
cytochrome C-mediated cell death pathway (Staples et al., 2010; Wu et al., 2002). JNK2 inhibits 
ubiquitination of p53 that stabilises p53 in non-stressed cells (Fuchs et al., 1998).  
Disruption of CREB, ERK2, JNK2, JNKpan, p38α, and p53 expression have detrimental effects on 
cells and contribute to the development of aggressive cancers. TOR, p38α, and p53 participate in 
the stress response. Despite this, phosphorylation of CREB, ERK2, and TOR was statistically 
significantly reduced in A-2780 cells that received cisplatin exosomes compared with control 
exosomes. This result was unexpected because of the results obtained previously showing that 
cisplatin exosomes had the ability to increase invasiveness of A-2780 cells compared with control 
exosomes (Figure 5.11 and Figure 5.12), and also because of the roles that these proteins have in 
both cancer development and the stress response pathways. JNK2, JNKpan, p38α, and p53, 
however, were upregulated. This may explain, at least in part, the mechanism responsible for 
increased invasive activity of cells following treatment with cisplatin exosomes. All four of these 
up-regulated proteins are involved in the MAPK signalling pathway and the phosphoinositide 
3-kinase (PI-3K) cascade. The MAPK signalling pathway and the PI-3K cascade are essential 
pathways for the regulation of the cell cycle. They modulate proliferation, quiescence, apoptosis, 
migration, and cancer. Deregulation of these pathways contributes considerably to cancer 
progression (Dhillon et al., 2007; Fresno Vara et al., 2004). 
Increased cellular invasiveness in response to stress exosomes is not solely induced by activation 
of the MAPK and PI-3K pathways. Other pathways may also influence the increased invasion 
following stress exosome administration, but phosphorylation levels of proteins involved in 
only the MAPK signalling pathway were analysed. 
 
5.3.11. Experimental limitations and future directions 
5.3.11.1. The reliability of cell cultures 
After initially becoming more invasive following treatment with stress exosomes (Figure 5.4 and 
Figure 5.11), stress exosomes failed to increase invasive competency of MCF-7 and A-2780 cells in 




(both MCF-7 and A-2780) were maintained for the duration of stress exosome experimentation, 
from initial establishment of an increase in cellular invasiveness induced by stress exosomes, 
throughout exosome uptake inhibition experiment optimisation, scratch assay experimentation to 
determine the effect of stress exosomes on cell motility, and also for investigations into the 
possible mechanism responsible for stress exosome-induced increased invasiveness. Using the 
cells for this length of time (approximately 40 passages), may have contributed to the 
inconsistency in the results because of selective pressures and genetic drift that cell lines can 
exhibit, and reduced or altered functions when kept in culture for too long (Hughes et al., 2007). 
Cell lines with high passage numbers have often acquired a substantial number of mutations 
meaning that they no longer represent reliable models of their original source material (Yu et al., 
1997). Long-term sub-culturing forces selective pressure within the cell population, for example, 
rapidly dividing cells will eventually outcompete slower proliferating cells. Two of the main issues 
are that it is impossible to determine the age of a cancer cell in culture, and there is no marker 
that depicts a cell’s age or how many times it has divided (Hughes et al., 2007).  
Then again, 40 passages is not generally regarded as a high passage number. Cells of this age 
would not typically have acquired enough mutations to induce substantial changes to their 
normal functions. The same batch of cells were used throughout because it was suspected that 
changing the batch of cells may have increased variation in experimental results. Retrospectively, 
more consistent results may have been achieved using cells with the same passage number (i.e. 
the cells were of similar age), and the cells should have been characterised not only visually but 
also by short tandem repeat polymorphism profiling (Nims et al., 2010). 
 
5.3.11.2. More evidence required to support increased metastatic capacity in stress 
exosome recipient cells 
The effect of stress exosomes on cell invasiveness was tested using two experimental procedures, 
the Matrigel assay that examines cell invasiveness and also the scratch assay that determines cell 
motility (stressed cell conditioned culture media was introduced to recipient cells instead of 
isolated stress exosomes). Invasiveness increased in response to stress exosomes (Figure 5.4 and 
Figure 5.11), however stressed cell conditioned culture media did not affect the motility of 
recipient cells. In order to further validate the results additional analysis of stress exosome 
recipient cells should be performed. Three-dimensional culture systems arguably better mimic the 
tumour microenvironment and tumour cell activity (Breslin and O'Driscoll, 2013), therefore this 
technique could be used to further determine how stress exosomes affect metastatic activity of 




changes in cellular characteristics. Attempts were made to show differences in phosphorylation 
levels of various MAPKs to help understand the pathways involved in increased invasiveness 
caused by stress exosomes (Figure 5.7 and Figure 5.15), but future work should aim to specifically 
identify the proteins involved, enabling confident proposal of a suitable mechanism. 
Experimentation should not be restricted to the MAPK signalling pathway. Microarray data 
identified the genes Fas, IGF-BP3, and PTEN and/or PTENP1, which are all active in the p53 
signalling pathway, differentially expressed between cells that received heat shock exosomes 
compared with control exosomes (Figure 5.8B). This concept should be investigated further 







The results in this chapter have provided evidence to show that exosomes extracted from two 
different cancer cell lines of different organs that were stressed using two different types of 
stressor, increase invasive capacity of some recipient cells. This is novel work to the cancer and 
exosome research fields. The results presented have great potential for further research. Future 
experiments should focus on investigating the effect of different types of environmental stressors 
(not restricted to heat shock and drug treatment) on exosome composition, and the effects of 
different types of stress exosomes upon cellular invasiveness. It is of primary importance to define 















6.1. Novel contributions and impact of this project 
This project was the first to provide evidence to suggest that exosomes secreted from stressed 
cells can increase the invasive capacity of cells that internalise and process them. Invasion of 
recipient cells was assessed using the Matrigel trans-well invasion assay and showed that heat 
shocked cell-derived exosomes had the ability to statistically significantly increase invasiveness of 
MCF-7 breast cancer cell line (Figure 5.4), and cisplatin treated cell-derived exosomes were able 
to increase invasiveness of A-2780 and IGROV-1 ovarian cancer cell lines (Figure 5.11). These 
results are interesting because tumour cells that resist, but become stressed during 
administration of cancer therapy, could be expelling exosomes that increase the invasiveness of 
neighbouring cancer cells. The effect of stress exosomes upon healthy cells was not investigated 
in this project but should be considered for future research.  
 
6.1.1. The potential impact of heparin on ovarian cancer metastasis 
Heparin is a molecule typically used as an anti-coagulant (Hirsh et al., 1998), although, its use as 
an exosome uptake inhibitor has recently been discovered (Christianson et al., 2013; Franzen et 
al., 2014; Svensson et al., 2013). It was used in this project to confirm exosome uptake inhibition 
but could not be used in conjunction with the Matrigel trans-well invasion assay because it 
interacts with components of the Matrigel. Therefore, the effect of inhibition of cisplatin exosome 
uptake using heparin in recipient ovarian cancer cells could not be analysed. However, the use of 
heparin alongside chemotherapy for the treatment of ovarian cancer has shown improved patient 
survival (Mousa et al., 2006, Stevenson et al., 2007).  
Low molecular weight heparin is routinely used for anti-thrombotic treatment of cancer patients 
(Lee et al., 2003). Retrospective analysis of clinical data implied that heparin treatment, reduced 
metastasis, alongside other prognostic advantages, and hence, provided a survival benefit for 
patients with cancer (Hettiarachchi et al., 1999); this was later confirmed by numerous 
prospective clinical trials (Akl et al., 2008; Akl et al., 2014; Noble, 2014). Decreased metastasis 
following chemotherapeutic treatment alongside heparin has been associated with increased 
efficacy of chemotherapeutics, whereby heparin reduces interstitial pressure that improves the 
accessibility of tumour tissue to anti-cancer drugs (Bendas and Borsig, 2012; Gil-Bernabé et al., 
2013). It is also possible that the exosome uptake inhibition activity of heparin may also 
contribute to the reductions in metastasis observed in patients following chemotherapy and 




of exosomes secreted by cisplatin treated cells be confirmed, the value of heparin administration, 
alongside chemotherapeutics, would be recognised and could potentially be used as a standard 
frontline treatment option for patients with ovarian cancer. 
 
6.2. Exosome extraction optimisation 
Although there has been substantial progress in exosome research, the best method for isolating 
biologically intact exosomes is yet to be agreed upon within the exosome research field. 
Differential ultracentrifugation is the standard protocol for exosome isolation and is the most 
frequently used extraction technique within the field (Théry et al., 2006). Problems associated 
with ultracentrifugation for exosome isolation have been identified, including low yields and 
operator-dependent inconsistencies in efficiency (Momen-Heravi et al., 2013). Alternative 
strategies including sucrose density gradient centrifugation (Cantin et al., 2008), immuno-affinity 
capture (Tauro et al., 2012), and polymer based precipitation (Alvarez et al., 2012) have 
limitations also, e.g. vesicle disruption, and co-purification of non-vesicular protein aggregates 
(Momen-Heravi et al., 2013). Development of an exosome isolation method that consistently 
yields high recovery of functional exosomes is essential for progression of exosome research. In 
this project exosomes were extracted using classic differential ultracentrifugation; this may not be 
the most ideal method since this method does not eliminate impurities e.g. protein aggregates 
and other material that also pellet at 120,000 × g. Future work should strive to make use of more 
sophisticated exosome extraction techniques, where possible, to improve the quality of the 
exosome samples yielded. 
 
6.3. Characterisation of exosomes 
Secretion of a variety of types of EVs from cells has become appreciated over the past 20 years. 
Despite the release of apoptotic bodies during apoptosis being well-established (Hristov et al., 
2004), the concept that healthy cells also shed vesicles from their plasma membrane (now 
referred to as microvesicles) has only recently become widely acknowledged (Cocucci et al., 2009; 
György et al., 2011; Raposo and Stoorvogel, 2013). The definition of an ‘exosome’ has become 
more strict over the past few years, they are now widely regarded as vesicles 30–160 nm in 
diameter that are secreted from cells and specifically are of endosomal origin (Gould and Raposo, 
2013). 
Exosome characterisation remains a major challenge for the exosome research field (Théry et al., 




ongoing. There are no standard methods in place that have been agreed upon by the field’s 
experts (Raposo and Stoorvogel, 2013; Taylor, 2015). Instead, exosome characterisation is carried 
out using as many techniques as feasibly possible with small sample quantities of exosomes 
(~50 µL). This often leaves minimal volume of the exosome sample remaining for functional 
experimentation. In this project exosomes were characterised by WB, TEM, NTA, and their 
biological viability was assessed by fluorescent staining coupled with confocal microscopy. 
With the methods currently available, different types of EVs can be differentiated by size and 
density but it is impossible to distinguish their intracellular origins. Because of their small size, 
there is limited quantities of protein, mRNA, and miRNA material available to analyse for 
membrane or organelle markers. Additionally, there is cross-over between membrane and 
organelle markers, no single designated markers for each type of EV that can uniquely distinguish 
them have been identified (Kalra et al., 2013; Tauro et al., 2012). Until this issue has been 
overcome, exosomes are best characterised based on multiple techniques (Yáñez-Mó et al., 
2015).  
Because of the current insufficient means for distinguishing different types of EVs, it is quite 
inaccurate to describe vesicles of 30–160 nm in diameter as exosomes because it is possible that 
vesicles within this size range did not originate in the endosome. Microvesicles and apoptotic 
bodies could also lie within this range. Nevertheless, throughout this thesis the term ‘exosome’ 
has been used to refer to material (vesicles) of less than 200 nm in size that were extracted by 
filtering of culture media through 0.22 µm filters and subsequent ultracentrifugation at 
120,000 × g. The intracellular origin of the vesicles used throughout this project was not 
determined. 
 
6.3.1. Distinct characteristics of stressed cell-derived exosomes 
Stressed cell derived exosomes in this project were identified to be statistically significantly 
smaller than exosomes secreted by control (non-stressed) cells. Stressors included heat shocking 
(Figure 5.5D) and cisplatin treatment (Figure 5.12D). Previous data collected by Dr Laura Jacobs, a 
member of our research group, supports this. She discovered that when MCF-7 cells were 
irradiated under a 2.0 Gy dose, secreted exosomes were statistically significantly smaller (Jacobs 
et al., unpublished data). It would be of interest to investigate whether smaller exosomes are 
secreted by cells in response to a variety of stressors, or whether this effect is limited to stress 




In addition, HSP70 (known for its activity during the stress response – particularly in the cell’s 
reaction to extreme heat [section 5.1.3]) was more enriched in heat shock exosomes compared 
with control exosomes (Figure 5.5A). Cisplatin exosomes were not enriched for HSP70, this may 
suggest that cisplatin treatment does not activate the heat shock response pathway to the same 
degree as extreme heat, and as a result the components loaded into stress exosomes are 
dependent upon the stress type.  
 
6.4. Motility, invasion, proliferation, and exosome secretion rates of different cancer 
cell lines 
Motility, invasion, proliferation, and exosome secretion rates of different cancer cell lines were 
established during this project (Figure 4.4 and Figure 5.1). These properties of the cell lines have 
not previously been determined and recorded. This information provides a useful tool for cancer 
researchers, they could use this information to enhance their experimental design. Cell lines with 
desirable characteristics, whether it be that they secrete high levels of exosomes, or they have a 
very motile phenotype, could be selected for their suitability to the desired experimental design. 
The data collected in this project could be expanded to create a database that could be used by 
researchers worldwide. The number of cell lines and number of cellular characteristics analysed 
could be increased, the data would not need to be limited to cancer cell lines, and information 
about a range of different cell lines of different origins could be recorded. The database could be 
designed in a similar way to ExoCarta where researchers deposit their own experimental results 
to populate the database (Keerthikumar et al., 2016; Mathivanan and Simpson, 2009; Mathivanan 
et al., 2012; Simpson et al., 2012). One of the major limitations of the scratch assay is unreliability 
and inconsistency in the results, generation of a public database would improve the reliability of 
the results because of accumulation of an increased number of biological replicates. As for the 
ExoCarta database, researchers would need to provide their methods to ensure that the 
experimental results can be compared and summarised.  
 
6.5. The mechanism responsible for stress exosome-induced increased invasiveness of 
recipient cells 
The mechanism responsible for increased invasiveness following receipt of stress exosomes needs 
to be further investigated. Experiments performed in this project suggest the involvement of 
members of the MAPK family of protein kinases (Figure 5.7 and Figure 5.15), and the p53 




proteins and gene expression components. There are an extensive number of proteins that were 
not investigated for their potential role. qPCR experimentation should be performed to further 
confirm the down-/up-regulation of genes contributing to the effect. The increased invasiveness 
of recipient cells could also be a result of exosome mediated transfer of mRNA and miRNA to 
recipient cells. 
 
6.5.1. The role of miRNA in exosome-mediated metastasis 
Various studies have shown that exosomal transfer of miRNAs increases metastasis, e.g. miR-21 in 
oesophageal squamous cell carcinoma (Tanaka et al., 2013), let-7 miRNAs in gastric cancer 
(Ohshima et al., 2010), miR-10b in breast cancer (Singh et al., 2014), miR-223 transferred by 
tumour-associated macrophages-derived exosomes in breast cancer (Yang et al., 2011), miR-126 
in chronic myelogenous leukaemia (Taverna et al., 2014), and miR-192 in lung cancer (Valencia et 
al., 2014). The RNA content of stress exosomes should be extracted, sequenced, and compared 
with that of control exosomes. The RNA signatures identified may correspond with cellular 
protein and gene expression changes detected in response to stress exosomes, and could provide 
evidence to further support the mechanism conjectured. 
 
6.5.2. Future developments 
This research could be extended by investigating the effect of exosomes extracted from cells 
treated with other types of stressor to determine whether increased cell invasiveness is limited to 
heat shock and cisplatin exosomes, or is a general effect of stress exosomes irrespective of the 
type of stress their parental cells endured. Research has been performed in our group using 
exosomes extracted from irradiated cells (donor cells received 2.0 Gy radiation) but the effect of 
these exosomes upon invasiveness of naïve cells was not investigated. This experiment could be 
performed along with testing exosomes extracted from cells that have endured other types of 







Novel research findings of this thesis were: (1) the discovery of increased invasiveness of cells 
following receipt of exosomes that were extracted from cells that had endured either heat shock 
or cisplatin treatment; (2) the identification of secretion of significantly smaller exosomes from 
stressed cells; and (3) establishment of the motility rates, proliferation rates, exosome secretion 
levels, and invasive capacities of ten cancer cell lines. Additional experimentation performed as 
part of this project included: (1) exosome characterisation using WB, TEM, NTA, and confocal 
microscopy; (2) assessment of the effect of exosomes upon cell motility using the scratch assay; 
and (3) exosome uptake analysis and inhibition. Attempts were made to elucidate the mechanism 
responsible for increased cancer cell invasiveness in response to receiving stress exosomes, with 
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E
xtracellular vesicles (EVs) are small spherical pack-
ages that are released by cells into the extracellu-
lar environment (1). EVs consist of a lipid bilayer
membrane that encases a small organelle-free cytosol.
Suspended in the aqueous core, or associated with the
lipid casing, are proteins and nucleic acids derived from
the cell of origin (2,3). EVs can be categorized further
depending upon where in the cell they originate; for
example, vesicles that are derived from multi-vesicular
bodies (MVBs) are referred to as exosomes and those
from the plasma membrane as microvesicles (1). It has
become evident that EVs are important factors involved
in a range of physiological processes including intercel-
lular exchange of proteins and RNA (4,5), induction
of angiogenesis (6), bystander effect (7) and immune
regulation (2,8,9).
EVs protect their cargo from enzymatic degrada-
tion during transit through the extracellular environment
(1012). Upon release of their functionally active mRNA
and microRNA load inside the recipient cell, EV contents
can regulate gene expression through de-novo translation
and post-translational regulation of target mRNAs (3).
Changes in miRNA levels are particularly important
during development (13) and stress response (14), and
EVs may play a role in their exchange between cells (7).
EVs can also exert effects on cells by stimulating specific
signalling pathways (15). The ability of EVs to alter the
transcriptome and signalling activity within recipient
cells allows them to induce specific phenotypic changes
(1618). Indeed, alterations in EV activity may be a
feature of certain pathologies, including cancer (19).
There is also interest in EVs as potential therapeutics.
By harnessing the capability of EVs to transfer their
contents into target cells it may be possible to convert
these vesicles into vehicles for the delivery of therapeutic
proteins, RNA molecules and drugs (20,21). Given their
emerging roles in normal physiological processes and in
disease, and their therapeutic potential, it is important to
understand the molecular mechanisms of EV release by
donor cells and the processes by which they are taken up

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by recipient cells. In this review we will outline the ways in
which EV uptake can be studied and review the current
understanding of how EVs enter target cells.
Evidence for EV uptake
Both direct and indirect evidence exists to suggest that
EVs are internalized into recipient cells. EVs have been
shown to transfer functional mRNA and miRNA from
mouse to human mast cells where mouse proteins were
identified in the recipient human cells (3). EV-mediated
siRNA delivery has been shown to knockdown target gene
expression (20), and administration of EVs laden with
luciferin substrate to luciferase expressing cells resulted in
production of bioluminescence (22). These results imply
that merging of the EV cytosol and the cytoplasmic com-
partment had occurred through membrane fusion at the
plasma membrane or by uptake through other pathways
followed by fusion with the endosomal membrane (22).
EV uptake can also be visualized directly. The most
common method for detecting EV uptake involves the
use of fluorescent lipid membrane dyes to stain EV
membranes. Examples of such dyes include PKH67
(2329), PKH26 (28,3032), rhodamine B (also known
as R18) (22,3338), DiI (30,33,39) and DiD (40) which
are lipophilic dyes. Membrane permeable chemical com-
pounds are also used to stain EVs. These include carboxy-
fluorescein succinimidyl ester (CFSE) (3946) and
5(6)-carboxyfluorescein diacetate (CFDA) (46). These
compounds become confined to the cytosolic lumen and
fluoresce as a consequence of esterification. Subsequent
entry of EVs into recipient cells can be measured using
methods such as flow cytometry and confocal microscopy.
To distinguish between internalized and surface-bound
fluorescent EVs, the surface of the cell can be stripped by
treatment with acid (27) or trypsin (32). Such experiments
suggest that many cells do indeed internalize EVs.
One potential issue with membrane-binding dyes is
that the presence of the fluorescent molecules could
affect the normal behaviour of EVs. Uptake of EVs has
been observed with many different lipid-binding dyes,
suggesting that such molecules do not affect the coarse
internalization of vesicles; nevertheless, further experi-
mentation is needed to verify whether the precise biolo-
gical behaviour of EVs is affected by dyes. Another
consideration is that the distinct types of dyes may lead
to different patterns of cellular staining following uptake.
Lipophilic dyes associate with lipids, whereas molecules
that become esterified in the lumen remain in solution;
their fate is thus bound with membrane and cytosol,
respectively. Another potential limitation of the use of
such lipophilic dyes is the leaching of the fluorescent
molecules from EVonto cellular membranes, leading to a
pattern of internalization that is due to normal membrane
recycling rather than EV uptake. However, this seems un-
likely given the numerous reports of molecular inhibitors
that appear to prevent EV uptake (Table I). Other control
experiments, such as incubation of cells with excess
unlabelled EVs and direct measurement of the rate of
transfer of fluorescence between EVs also support the idea
that the increased fluorescence in recipient cells is due
to specific uptake of EVs rather than non-specific dye
leaching (25).
It should also be appreciated, however, that almost
all studies have relied on fluorescence microscopy, which
has limited resolution because the wavelength of visible
light is approximately 390700 nm; therefore single EVs
or clusters of vesicles that are less than 390 nm in dia-
meter cannot be distinguished. This should not affect the
assessment of EV uptake in general but may affect the
visualization and dynamic localization analysis of indivi-
dual EVs. EVs can be visualized in a potentially more
specific way via the use of fluorescent proteins fused with
vesicular proteins. For example, CD9 and CD63 are
tetraspanin proteins found enriched in EVs which, when
tagged with GFP, can be used to show uptake and pro-
cessing of vesicles in cells (10,47,48). A caveat of such
experiments is the assumption the fluorescent protein tag
does not affect the normal function or trafficking of the
tetraspanin protein, and does not therefore potentially
alter the behaviour of the EV during uptake.
The evidence that EVs can enter cells and deliver their
cargo is overwhelming. The mechanism responsible for
EV internalization into cells, however, has raised great
debate in the literature. Various mechanisms for EV
uptake have been proposed (Fig. 1), including clathrin-
mediated endocytosis (CME), phagocytosis, macropino-
cytosis and plasma or endosomal membrane fusion. The
roles of lipid rafts and specific proteinprotein interac-
tions have also been studied. A range of techniques can
be used in conjunction with EV uptake assays to tease out
these molecular mechanisms. This includes the use of
antibodies to test the role of specific ligands or receptors,
and the use of chemical inhibitors to block specific up-
take pathways. The results of such studies have shed
much light on the routes by which EVs enter cells.
Protein interactions
The EV uptake mechanisms involve protein interactions
that facilitate subsequent endocytosis (9,25,26,30,49).
Proteinase K treatment of EVs was shown to significantly
reduce their uptake by ovarian cancer cells which strongly
supports the role of proteins in the EV uptake pathway
(41). Many EV proteins have been shown to interact with
membrane receptors on target cells (50,51). Hence, EV
uptake is most likely dependent upon the signalling status
of recipient cells and of the protein complement of the
vesicle. In the literature there is a growing list of specific
proteinprotein interactions that mediate EV attachment
and uptake into cells. Many of these interactions have
been elucidated by the use of specific antibodies that
Laura Ann Mulcahy et al.
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Table I. Compounds, chemicals and peptides used to inhibit EV uptake
Pathways blocked Inhibitor Target Treatment recipient
Endocytosis Heparin Heparan sulphate proteoglycans Glioblastoma multiforme primary tumour
cells (25); SW-780 bladder cancer cells (32);
Endocytosis a-difluoromethylornithine
(DFMO)
Heparan sulphate proteoglycans Glioblastoma multiforme primary tumour
cells (25);
Endocytosis Asialofetuin Galectin-5 Macrophages (24);
Endocytosis Human receptorassociated
protein (RAP)
CD91 Dendritic cells (79);
Endocytosis RGD (Arg-Gly-Asp) peptide Fibronectin Macrophages (23); Dendritic cells (30);
Endocytosis Ethylenediaminetetra acetic
acid (EDTA)
Calcium Macrophages (24); Dendritic cells (30,44);
bone marrowderived dendritic cells (22);
Endocytosis Cytochalasin D Actin Human macrophages (23); SKOV-3 ovarian
cancer cells (41); RAW-264.7 macrophages
(27); Microglia (28); Dendritic cells (30,44);
Bone marrowderived dendritic cells (22);
human A549 alveolar epithelial cells (77);
Human umbilical cord endothelial cells (26);
HeLa cells (26);
Endocytosis Cytochalasin B Actin Macrophages (24);
Endocytosis Latrunculin A Actin Human umbilical cord endothelial cells (26);
HeLa cells (26);








Dynasore Dynamin-2 Macrophages (24); Microglia (28);
Clathrin-dependent
endocytosis
Chlorpromazine Dopamine receptors, serotonin
receptors, histamine receptors,
a1- and a2-adrenergic receptors
and M1 and M2 muscarinic
acetylcholine receptors




Sodium/proton exchanger SKOV-3 ovarian cancer cells (41);
RAW-264.7 macrophages (27);








Annexin-V Phosphatidylserine Microglia (28,31); Ovarian cancer patient
ascites-derived EVs (10); Neuro-2A mouse
neuroblastoma cells (31);
Phagocytosis Wortmannin Phosphoinositide 3-kinases (PI3Ks) RAW-264.7 macrophages (27);





Cholesterol SKOV-3 ovarian cancer cells (41);
RAW-264.7 macrophages (27); BT-549
breast cancer cells (47); Human umbilical




Filipin Cholesterol Bone marrowderived dendritic cells (22);




Simvastatin Cholesterol Human umbilical cord endothelial cells (26);
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recognize ligands or receptors, leading to a steric block
that prevents their interaction. Here we review some of the
proteins shown to participate in EV uptake. It should be
noted that in some cases the phenotypic effects of EVs do
not require internalization of the vesicle (see conclusions
and future directions); therefore in our discussion we focus
on examples where the involvement of specific protein
protein interactions is evidenced by the effect on direct EV
uptake or binding, rather than by functional outputs.
Tetraspanins
Tetraspanins are membrane proteins which have numer-
ous functions including cell adhesion, motility, activation
and proliferation (reviewed in (52)). Tetraspanins are
highly abundant on the EV surface which suggests they
may have a role in EV function (53,54). CD63, CD9
and CD81 are well-established markers of EVs (2,5458).
CD9 and CD81 are tetraspanins involved in oocyte-
spermatozoa and phagocyte fusion (56,57,59,60); in addi-
tion, numerous viruses and parasites require interaction
with tetraspanins in order to enter the cell and replicate
(61). Due to the high abundance of tetraspanins and
their roles in cell adhesion it is possible that EV uptake
could occur through similar processes (37). Tetraspanin-
enriched microdomains (TEMs) are clusters of tetraspa-
nins, adhesion molecules and transmembrane receptor
proteins located in raft-like structures in the plasma
membrane (52). TEMs have been shown to be involved in
a number of processes, including vesicular and cellular
fusion (52,62,63), leading to the hypothesis that they have
a role in EV-cell binding (6467).
Treatment of recipient cells with antibodies against
the tetraspanins CD81 or CD9 can reduce uptake of EVs
by dendritic cells (30). Tspan8 is a tetraspanin known to
complex with integrins (35). Cells over-expressing Tspan8
released EVs bearing a Tspan8-CD49d complex, the pre-
sence of which contributed to EV uptake by rat aortic
endothelial cells (35). Antagonistic antibody treatment
suggests that CD106 strengthens this interaction (35).
In addition, it was discovered that EVs that presented
Tspan8-CD49d complex on their surface were readily
internalized by endothelial cells and pancreatic cells where
intercellular adhesion molecule 1 (ICAM-1, also known
as CD54) was the major ligand (37). These data point to a
role for tetraspanins in the internalization of EVs.
Integrins and immunoglobulins
The observation that EVs play a role in the immune
response has garnered much interest in the roles of in-
tegrins and immunoglobulins in the interaction between
vesicles and cells. These proteins are involved in a range
of functions, including cell-to-cell adhesion, cell signal-
ling, leukocyte transendothelial transmigration and anti-
gen presentation (68). Indeed, several reports in the
literature suggest they may also be involved in EV uptake.
Antibodies that mask the binding sites of CD11a or
its ligand ICAM-1 can reduce dendritic cell uptake of
EVs (30). Similar results were observed after blocking
the integrins av (CD51) and b3 (CD61) on the dendritic
cell surface (30). CD11a is a subunit of the lymphocyte
function-associated antigen 1 (LFA-1), which interacts
with ICAM-1 to regulate critical pathways in the immune
response (69). Inducing a high-affinity state of LFA-1 on
resting T-cells using manganese chloride treatment was
sufficient to increase EV binding in a dose-dependent
manner (70). Antagonistic antibody treatment inhibited
this process (44,45,70). Naı̈ve T-cells have been shown
to internalize EVs through a mechanism requiring the
participation of T-cell receptor (TCR), CD28 and LFA-1
(71). It was also shown that dendritic cellderived EVs
were internalized via TCR-major histocompatibility com-
plex (MHC) and LFA-1ICAM-1 interactions in CD4
cells (44). Similarly dendritic cells take up CD8T-cell
EVs in an endocytic pathway that requires pMHC I/TCR
and LFA-1-ICAM-1 interactions (43). The protein milk
fat globule-epidermal growth factor 8 (MFG-E8) is
thought to enhance the phagocytic uptake of apoptotic
cells by binding phosphatidylserine (PS) via 1 domain
and with cell surface integrin proteins CD51 and CD61
via a second domain (72). Perturbation of MFG-E8 leads
to alterations in the rate of EV uptake (30). These results
highlight the emerging roles of proteinprotein interac-
tions in vesicle uptake, particularly in cells of the immune
system.
Table I (Continued )






Glycosphingolipid Pre-treatment of EV-producing Jurkat
cells (80); HEK-293T kidney cells (80);
Lipid raftmediated
endocytosis
U0126 ERK1/2 Human umbilical cord endothelial cells (26),
HeLa cells (26); Mouse embryonic
fibroblasts (26);
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A role for proteoglycans
Proteoglycans are proteins with significant carbohydrate
components. For example, the heparin sulphate proteo-
glycans (HSPGs) are proteins with sulphated glycosami-
noglycan polysaccharides attached. Various complexes,
including viral particles and lipoproteins, use HSPGs to
help gain entry into cells (73). Fluorescently labelled EVs
co-localize with internal vesicles containing GFP-linked
syndecan or glypican (the 2 main types of HSPG) inside
recipient cells (25). Treatment of cells with a heparin
sulphate mimetic reduced EV uptake in a dose-dependent
manner (25,32). Cells whose ability to produce normal
levels and structures of HSPGs, either because of genetic
defects or chemical inhibition, showed a reduced ability
to internalize EVs (25). These results are consistent with a
role for proteoglycans in the uptake of EVs. Interestingly,
treatment of EVs with heparinase to remove surface
proteoglycans had no effect on uptake, suggesting that it
is the presence of HSPGs on the cell surface that are
important for mediating vesicular entry (25).
Lectins
DC-SIGN is a C-type lectin receptor (a receptor able to
recognize and internalize glycoprotein ligands) that can
trigger phagocytic entry for a range of molecules, includ-
ing viruses and bacteria (74). One potential ligand is the
MUC1 protein found on epithelial cells and on the sur-
face of EVs derived from breast milk. The recruitment
of these EVs by monocyte-derived dendritic cells was
blocked by antibodies specific to DC-SIGN on the reci-
pient cell surface (29). Another C-type lectin, DEC-205,
also appears to mediate entry of EVs into dendritic cells;
vesicle uptake was inhibited by treatment with DEC-205-
specific antibodies or by incubation with excess man-
nose (a sugar recognized by DEC-205) (44). Chelation of
calcium with ethylenediaminetetraacetic acid (EDTA)
Fig. 1. Pathways shown to participate in EV uptake by target cells. EVs transport signals between cells. EVs have been shown to be
internalized by cells through phagocytosis, clathrin- and caveolin-mediated endocytosis. There is also evidence to support their
interaction with lipid rafts resulting in EV uptake. Lipid rafts are involved in both clathrin- and caveolin-mediated endocytosis. EVs can
be internalized by macropinocytosis where membrane protrusions or blebs extend from the cell, fold backwards around the EVs and
enclose them into the lumen of a macropinosome; alternatively EVs are macropinocytosed after becoming caught in membrane ruffles.
EVs may also deliver their protein, mRNA and miRNA cargo by fusion with the plasma membrane. Alternatively, intraluminal EVs
may fuse with the endosomal limiting membrane following endocytosis to enable their EV contents to elicit a phenotypic response.
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significantly reduced EV uptake by dendritic cells (44),
and also in macrophages (24); supporting the hypothesis
that the EV uptake is facilitated by C-type lectin/C-
type lectin receptor interactions. Interestingly, ovarian
cancerderived EVs were found to be enriched in specific
mannose- and sialic acid containing glycoproteins (41).
Sialic acid removal caused a small but non-significant
increase in uptake (41). Galectin-5, a lectin with binding
specificity towards certain glycoproteins, can be found
associated with EVs (24). Incubating EVs with cells in the
presence of excess galectin-5 significantly reduced vesicu-
lar internalization (24). When asialofetuin (a glycoprotein
that can bind galectin-5) was included in the uptake assay
the entry of EVs was abrogated (24). These results are all
consistent with a role for glycoproteins and proteoglycans
in the uptake of EVs.
Endocytosis
Most experimental evidence suggests that EVs are usually
taken up into endosomal compartments via endocytosis
(22,30,41). Uptake can be extremely rapid, with EVs being
identified inside cells from as early as 15 minutes after
initial introduction (27,48). A number of research groups
have shown that when cells are incubated at 48C their
capacity to internalize EVs is dramatically reduced
suggesting that uptake is an energy-requiring process
(25,30,33,38,41,46). Further evidence that internalization
is not a passive process is provided by observations that
EVs are not taken up by cells fixed in paraformaldehyde
(28,36). Cytochalasin D is a metabolite known to depoly-
merize the actin filament network resulting in inhibition
of endocytic pathways (75,76). Cytochalasin D treatment
has been shown, on several occasions in various cell
types, to significantly reduce, but not completely prevent,
EV uptake in a dose dependent manner (22,23,2628,
30,41,44,77). Taken together these results suggest that
EV uptake is an energy-dependent process that requires
a functioning cytoskeleton, both of which are indicative
of endocytic pathways. However, one implication of the
frequent failure to completely abrogate internalization
following treatment with any given inhibitor is that
EV uptake occurs through more than one mechanism
(24,27,30,40,41,44,77).
Endocytosis is an umbrella term for a range of mole-
cular internalization pathways (78). By using a range of
inhibitors to block specific pathways (Table I), antibodies
to prevent receptorligand interactions (Table II) and
other experimental techniques such as RNAi to knock-
down certain genes the role of the endocytic processes
responsible for EV uptake are being elucidated. Roles for
many of these subdivisions have been shown, including
macropinocytosis (28,41), phagocytosis (22,27,41,82) and
CME (41) (Fig. 1).
Clathrin-mediated endocytosis
CME involves cellular internalization of molecules
through progressive and sequential assembly of clathrin-
coated vesicles that contain a range of transmembrane
receptors and their ligands. The clathrin-coated vesicles
strategically deform the membrane which collapses into a
vesicular bud, matures and pinches off. The subsequent
intracellular vesicle undergoes clathrin un-coating and
then fuseswith the endosomewhere it deposits its contents
(83). Various studies implicate CME in the uptake of EVs.
Chlorpromazine prevents formation of clathrin-coated
pits at the plasma membrane (84). CME inhibition by
chlorpromazine decreased uptake of EVs by ovarian
cancer recipient cells (41) and phagocytic recipient cells
(27). Dynamin2 is aGTPase required for the CMEprocess
(85,86). Dynamin2 is recruited to nascent clathrin-coated
pits where it forms a collar-like structure at the neck of
deeply invaginated clathrin-coated pits (8789). GTP-
hydrolysis mediated changes in dynamin2 conformation
lead tomembrane fission and clathrin-coated vesicle release
(86,9092). Dynamin2 also facilitates membrane binding
(9395) and membrane curvature (96) during CME. In
phagocytic cells, inhibition of dynamin2 (85,86) prevented
almost all EV internalization activity (24,27,28). A small
percentage of EVs were also shown to co-localize with
clathrin during uptake in macrophages (27). Epidermal
growth factor receptor pathway substrate clone 15
(EPS15) is a component of clathrin-coated pits that is
ubiquitously associatedwith AP-2 adaptor complex which
is an integral component of the clathrin coat (97).
Expression of a dominant-negative mutant of EPS15
inhibits CME and leads to a reduction in EV uptake
(27). These results suggest that CME plays at least some
part in EV uptake.
Caveolin-dependent endocytosis
CME has been extensively studied for many years, but
it is becoming increasingly apparent that a plethora of
clathrin-independent endocytotic pathways exist in eukar-
yotic cells (78). One suchmechanism is caveolin-dependent
endocytosis (CDE). Caveolae are small cave-like invagina-
tions in the plasma membrane which, like clathrin-coated
pits, can become internalized into the cell. Caveolae
are sub-domains of glycolipid rafts of the plasma mem-
brane that are rich in cholesterol, sphingolipids and
caveolins; hence, CDE is sensitive to cholesterol depletion
agents such as filipin, and methyl-b-cyclodextrin (MbCD)
(98100). Caveolin-1 is a protein that is required and
sufficient for the formation of caveolae (78) and can be
found clustered within such membrane invaginations.
Oligomerization of caveolins (facilitated by caveolin oli-
gomerization domains) mediates formation of caveolin-
rich rafts in the plasma membrane. The increased levels
of cholesterol accompanied by attachment of caveolin
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scaffolding domains to the plasma membrane and dyna-
min2 (also required in CME) activity enable assembly
and expansion of caveolar endocytic vesicles (78,100,101).
Dynamin2, can be blocked by the specific inhibitor
dynasore (102). Blocking dynamin2 leads to significantly
reduced internalization of exosomes (103) or larger
microvesicles (24,104), suggesting a role for caveolae-
mediated endocytosis in vesicular uptake. However, be-
cause dynamin2 is also required for CME it is not possible
to rule out a role for clathrin-coated vesicles in these
experiments (105). Specific knockdown of the CAV1 gene
leads to reduced caveolin-1 protein and significantly
impaired uptake of EVs (103). Paradoxically, knockout
of CAV1 in mouse embryonic fibroblast cells leads to
increased EV uptake (26). CAV1 null mice show pheno-
typic changes in vasculature but are viable (106), suggest-
ing that either CAV1 is not essential for full EV uptake
or that the ability to internalize vesicles via CDE is not
essential for viability. Nevertheless, taken together the
results described above imply some kind of function for
caveolae-mediated endocytosis in EV uptake, though the
precise role of this pathway may vary between cell and EV
types.
Macropinocytosis
Macropinocytosis is an endocytic uptake pathway that
involves the formation of invaginated membrane ruffles
that then pinch off into the intracellular compartment.
The vesicles carry extracellular fluid and components
sampled from the region around the membrane ruffles
(78). Ruffled extensions of the plasma membrane pro-
trude from the cell surface and encompass an area of
extracellular fluid, subsequently this area of extracellular
fluid is internalized entirely as a result of fusion of the
membrane protrusions with themselves or back with the
plasma membrane (Fig. 1) (107). The mechanism is
similar to that of phagocytosis, however, direct contact
with the internalized material is not required. This mecha-
nism is rac1-, actin- and cholesterol-dependent and
requires Na /H exchanger activity (108). Cholesterol
is required for the recruitment of activated rac1 to sites
of macropinocytosis (109). Phosphatidylinositol-3-kinase
(PI3K), ras, and src activities have also been shown
to stimulate macropinocytosis (78). Rac1 is a GTPase
which not only has a major role in macropinocytosis
(110), but also in regulation of cell growth, cytoskele-
tal reorganization, protein kinase activation (111) and
epithelial-to-mesenchymal transition (EMT) in cancer
(112). Abrogation of macropinocytosis by inhibiting
the Na /H exchanger results in significantly reduced
oligodendrocyte-derived EV uptake by microglia (28). A
small molecule inhibitor of rac1, NSC23766, also inhi-
bited EV uptake by microglia (28). The alkalinizing drugs
bafilomycin A, monensin and chloroquine all inhibited
microglial internalization of EVs, consistent with a role
for the acidification of vacuoles in macropincytosis (28).
However, other studies using inhibitors do not find a role
for macropinocytosis in the uptake of EVs (25,27,103).
These findings suggest that macropinocytosis is either
a minor pathway used by cells to internalize EVs, or a
mechanism used in specific cell types.
Phagocytosis
The process of phagocytosis involves the internalization
of opsonized particulate matter, including bacteria and
fragments of apoptotic cells. This function is often per-
formed by specialized cells such as macrophages (78).
Phagocytosis is a receptor-mediated event that involves
the progressive formation of invaginations surround-
ing the material destined for internalization, with or with-
out the participation of enveloping membrane extensions
(as required for macropinocytosis) (78,107). Generally,
phagocytosis is employed to internalize larger particles.
Table II. Antibodies used to block EV uptake
Target Treatment recipient
ICAM-1 Dendritic cells (30); lymph node cells and spleen
cells (38);
LFA-1 Dendritic cells (43,44); CD8 ConA T cells (45);
T cells (70);
TIM-4 RAW-264.7 macrophages (27); BaF3 bone marrow
pro-B cells (79);
MFG-E8 Dendritic cells (30);
DC-SIGN Monocyte-derived dendritic cells (29);
DEC205 Dendritic cells (44);
H-2Kb Dendritic cells (43);
Tspan8 Rat aortic endothelial cells (35);
CD9 Dendritic cells (30); Lung fibroblasts (35); rat
pancreatic adenocarcinoma
BSp73ASML (ASML) cell-derived EVs (38);
CD11a Dendritic cells (30);
CD11b Lymph node cells and spleen cells (38);
CD11c Lymph node cells and spleen cells (38);
CD44 Lymph node cells and spleen cells (38);
CD49c Lung fibroblasts (35);
CD49d Rat aortic endothelial cells (35); lymph node cells
and spleen cells (38);
av (CD51) Dendritic cells (30);
b3 (CD61) Dendritic cells (30);
CD62L Lymph node cells and spleen cells (38);
CD81 Dendritic cells (30); rat pancreatic
adenocarcinoma BSp73ASML (ASML) cell-derived
EVs (38);
CD91 Dendritic cells (79);
CD106 Rat aortic endothelial cells (35);
CD151 Lung fibroblasts (35);
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However, it has been shown that particles as small as
85 nm in diameter have been internalized by phagocytosis;
therefore it is possible that EVs could be internalized
via this route (113). In one study the EVs released by
leukaemia cells were shown to be taken up efficiently by
macrophages but were not internalized by other cell types
(27). PI3Ks play an important role in phagocytic pro-
cesses, particularly in enabling membrane insertion into
forming phagosomes (114). The PI3K inhibitors wort-
mannin and LY294002 were used to assess the necessity of
functional PI3Ks in EV uptake. Both drugs inhibited EV
uptake in a dose dependantmanner (27). Furthermore, the
EVs co-localized with fluorescent phagosome tracers (27).
Dendritic cellderived EVs were labelled with pHrodo, a
dye that becomes fluorescent red at the phagosome pH.
Acceptor dendritic cells treated with pHrodo-EVs emitted
red fluorescence confirming that dendritic cells can phago-
cytose EVs (22). Taken together these results implicate
phagocytosis in EV uptake.
Phosphatidylserine (PS) is essential in initiating the
removal of apoptotic bodies by phagocytosis (115) and is
used by some viruses to enter cells by macropinocytosis
(116). PS is typically located on the inner leaflet of the
plasma membrane; however, EVs are enriched for PS on
their outer-membrane (117) whichmay facilitate entry into
cells. Incubation of macrophages with an antibody that
masks TIM4, a receptor involved in PS-dependent phago-
cytosis (27,81), leads to reduced uptake of EVs (27).
Treatment of dendritic cells with a competitive soluble
PS analogue also reduced EV uptake (30). Treatment of
EVs with annexin-V (a protein that binds PS) reduces the
uptake of EVs into macrophages (31) and natural killer
cells (70). Phagocytic and macropinocytic uptake of EVs
may therefore be, at least in part, triggered by the PS found
on the outer leaflet of EV membranes.
Involvement of lipid rafts
Lipid rafts are microdomains within the plasma mem-
brane with altered phospholipid compositions. They are
rich in protein receptors and sphingolipids such as sphin-
gomyelin. They act as organizing centres for the assembly
of signalling molecules, they affect membrane fluidity
and mediate membrane protein trafficking (100). Com-
ponents of lipid rafts are highly ordered and more tightly
packed than the surrounding bilayer, consequently they
are less fluid but float freely in the plasma membrane
(118). Endocytosis that is clathrin-independent largely
requires cholesterol, which is found enriched in lipid
rafts. Lipid rafts are known to contribute to viral particle
uptake by mediating glycoprotein binding and adjusting
the physicochemical and mechanical properties of the
membrane (119). These rafts can be found in the invagi-
nations formed by caveolin-1 or in planar regions of the
plasma membrane marked by another family of proteins
called flotillins (120). Flotillins associate with lipid rafts
and mediate endocytosis independent of clathrin and
caveolin (121125). Flotillins have been found to bind
to GPI-anchored proteins during their internalization
(121,122,125). It is possible that EVs are internalized by
cells through lipid raft domains.
To test the role of lipid rafts in EV uptake, a range
of inhibitors have been employed. EV uptake was
significantly reduced in dendritic cells when EV-
producing cells were pre-treated with fumonisin B1 and
N-butyldeoxynojirimycin hydrochloride (80), compounds
which decrease glycosphingolipid composition in the plasma
membrane by preventing its biosynthesis (126,127). This
suggests that sphingolipids within the EV have an im-
portant role in binding and endocytosis, possibly through
cholesterol-rich microdomains in dendritic cells (80). EV
uptake was prevented following pre-treatment of reci-
pient cells with the cholesterol reducing agents MbCD
(26,27,41,47), filipin (22,26,34) and simvastatin (26).
These treatments disrupt lipid raftmediated endocytosis
but may also affect EV membrane integrity, causing the
reduced EV uptake effects observed. Co-localization can
be observed between fluorescently labelled EVs and
cholera toxin B (a protein known to be internalized via
lipid rafts) in recipient cells (26,47). Poor co-localization
was observed between caveolin-1 and labelled EVs, sug-
gesting that the lipid rafts used by EVs may be caveolae-
independent (26,41). The potential roles of some proteins
involved in this process are also being identified. For
example, annexin II may have a role in anchoring of EVs
to lipid raft domains of the plasma membrane whilst
annexin-VI may contribute to the trafficking of EVs to the
late endosomal compartment (47). These findings support
the hypothesis that lipid rafts are involved in the EV
uptake mechanism; the scale and precise mechanisms of
this route into cells remains to be elucidated.
Cell surface membrane fusion
Another possible entry mechanism is via direct fusion of
the EV membrane with the cell plasma membrane (34).
Fusion of lipid bilayers in an aqueous environment is a
process whereby 2 initially distinct membranes merge.
The lipid bilayers are brought into close proximity and
the outer-leaflets come into direct contact which leads to
formation of a hemi-fusion stalk with fused outer-leaflets.
Following this, stalk expansion produces the hemi-fusion
diaphragm bilayer from which a fusion pore opens (128
130). As a result, the two hydrophobic cores mix forming
one consistent structure. Several protein families partici-
pate in this process including SNAREs, Rab proteins, and
Sec1/Munc-18 related proteins (SM-proteins) (131).
Fusion of membranes can be observed in various ways,
including via fluorescent lipid dequenching. This tech-
nique was applied to study the uptake of EVs from
melanoma cells, the results suggested that at least some
of the vesicles are able to fuse with the recipient cell
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(34); this fusion was enhanced under acidic conditions.
Similarly, when the dequenching method was used to
demonstrate fusion of R18-labelled EVs with the plasma
membrane of bone marrow-derived dendritic cells (22).
The delivery of miRNAs and luciferin to the cytosol of
the recipient cells provides further evidence of fusion of
EVs with either the plasma or endosomal membrane (22).
The lipid raft-like membrane composition of EVs may
aid their fusion with recipient cell membranes (132). EV-
cell fusion may be limited to acidic pH conditions which
are present in endosomes, perhaps owing to differences
in lipid content or overall ionic charge of the EV surface
following release (34). The body of research supporting a
primarily endocytic mechanism for EV uptake makes it
unlikely that fusion is the main entry route, but a fusion-
based pathway cannot be ruled out. Future work will be
needed to ascertain the extent to which fusion-based EV
entry occurs under physiological conditions.
Cell-specific EV uptake
One question currently vexing the EV field is whether
or not EV uptake is a cell typespecific process. Results
from some studies show that fluorescently labelled EVs
can be taken up by virtually every cell type tested (26,38),
whereas others suggest that vesicular uptake is a highly
specific process which can only occur if cell and EV share
the right combination of ligand and receptor. Hetero-
geneity in the donor/recipient cells, EVs, experimental
setup and the context of experiments will all affect the
outcome, and may thus account for the observed dis-
crepancies. However, there are certainly examples of cell-
type specific uptake. Pancreatic adenocarcinomaderived
EVs were shown to be internalized most efficiently by
peritoneal exudate cells and less proficiently in granulo-
cytes and T-cells (38). Tspan8 containing lymph node
stromaderived EVs were most effectively internalized
by endothelial cells and pancreatic cells but to a lower
degree by parental lymph node stroma cells (37). In some
cases, the basis for a specific interaction may have been
elucidated. For example, milk EVs can be taken up via
monocyte-derived dendritic cells thanks to the interaction
between DC-SIGN and MUC1, whereas EVs derived
from other sources and lacking MUC1 were unable to
enter these cells (29). Treatment with an RGD peptide
(which can block integrin-mediated receptor internali-
zation) reduced EV uptake in dendritic cells (30) and
macrophages (23), but did not inhibit EV uptake by
microglia (28). This indicates that multiple mechanisms
are responsible for EV-cell communication and different
combinations of EV communication strategies are used
by different cell types.
Conclusions and future directions
A growing body of evidence suggests that EVs are in-
volved in normal homeostasis (133) and are deregulated in
disease (51). EVs, which are released in greater numbers
by cancer cells (134), can promote tumour development
and are involved in mediating intercellular communica-
tion within the tumour microenvironment (135). Further
advancing our understanding of both the EV uptake
mechanism and characterization of disease-promoting
EVs will enable development of therapeutic strategies to
inhibit interactions between such EVs and healthy reci-
pient cells (136). EVs are also being explored as natural
vectors for therapeutic delivery, with some early studies
showing great potential (20,137,138). Improved under-
standing of the EV uptake mechanism will therefore
benefit design of novel and sophisticated drug delivery
systems.
To this end, we have reviewed here the mechanisms
by which EVs are internalized by cells. Endocytosis, in
its various guises, appears to be the primary method of
entry by EVs. There appears to be little agreement in
the literature as to which type of endocytic mechanisms
are most important, with clathrin-dependent, caveolae-
dependent, macropinocytosis, phagocytosis and lipid raft
mediated uptake variously described as being prevalent.
These differences reflect the heterogeneity both in EV
populations and in the cell types being used. It is possible
that a population of EVs can simultaneously trigger a
number of different gateways into a cell, with the primary
entry points depending on the cell type and EV consti-
tuents (29,37,38). This would also explain why inhibition
of any given pathway rarely leads to a complete abroga-
tion of EV entry (2325,27,34,38,4042,44,45,81). There
are also potential problems with the use of some
inhibitors that have known (or potentially unknown)
cross-reactivity with multiple pathways. For example,
cytochalasin D inhibits actin polymerization and so the
finding that it reduces EV uptake has been used to
support an endocytic uptake pathway for vesicles (139).
However, the global cellular effects of disrupting the
actin cytoskeleton are profound. The reduced EV uptake
caused by cytochalasin D could therefore be caused
indirectly via perturbation of other cellular processes,
such as cellular polarization (140), migration or cell cycle
(141). Similarly, PI3K has a multitude of roles within
various cell-signalling networks (142). PI3K signalling has
been implicated in phagocytic uptake (143). The reduced
EV uptake observed following treatment of recipient cells
with the PI3K inhibitors wortmannin and LY294002
could be independent of any effects on phagocytosis,
and instead caused indirectly by the deregulation of
other processes such as migration, cell growth, or motility
(144,145). There is also overlap in the pathways that such
inhibitors can affect. For example, inhibiting PI3K can
perturb both phagocytosis and macropinocytosis (146).
Dynamin2 is involved in both CME and CDE, so its inhi-
bition cannot easily distinguish between these 2 processes
(147,148). MbCD causes depletion of cholesterol and can
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cause a decrease in both lipid raftmediated uptake as
well as caveolin-dependent internalization. Furthermore,
MbCD has substantial effects across a range of cellular
functions, including effects that are independent of cho-
lesterol chelation (149). The results of studies using small
molecular inhibitors are important contributions towards
understanding the EV uptake puzzle, but the pleiotropic
nature of these compounds means that interpretation of
such data must be tempered with extreme caution.
Large areas of plasma membrane are naturally re-
cycled as part of normal cellular maintenance (150).
Indeed, an area equivalent to the entire surface of the cell
can be internalized and replenished every few hours
(151). It could be expected that EVs bound at the cell
surface would eventually be internalized as part of this
normal membrane recycling. In such a scenario, it would
stand to reason that inhibiting any of the processes that
regulate membrane recycling would also reduce EV
uptake. The results of the small molecule inhibitor experi-
ments described above (28) could therefore be explained
by their effects on membrane recycling rather than by their
proposed ability to affect a direct EV uptake pathway.
However, the rapidity of EV uptake would argue against
this model of ‘‘passive endocytosis.’’ The ability to inhibit
uptake with antibodies that block specific protein
protein interactions also suggest that internalization is
an active process. Nevertheless, these arguments all
highlight the complexities in studying vesicular uptake.
It is also worth mentioning that there are several other
clathrin-independent endocytic pathways, such as the
recently described CLIC/GLEEC pathway (78,152). The
extent to which these other pathways may be involved
remains to be determined.
Whilst EV uptake leads to the delivery of nucleic acids
and protein, internalization is not always necessary to
elicit a phenotypic response. Receptorligand interactions
which take place on the cell surface may be sufficient;
for example, interaction of soluble ligands (produced by
proteolytic cleavage of EV membrane proteins) with cell
receptors may successfully permit signal transduction and
subsequent downstream signalling effects in the reci-
pient cell (153155). In another study, uptake of EVs by
phagocytosis was not actually essential for the induction
of cytokine IL-1b secretion suggesting that EV-associated
fibronectin surface receptor interaction is sufficient to
direct this activity (23). Interestingly, EVs may stimulate
MAPK signalling leading to altered activity within the
recipient cell (25,104). Indeed, pharmacological inhibition
of ERK1/2 actually inhibited EV uptake, suggesting that
these signalling pathways may also be involved in EV
uptake (25).
In this review, we have focused on the mechanisms of
exosomal uptake. However, there exists a range of types
and sizes of EV. Many preparations of vesicles used in
studies contain heterogeneous collections of such vesicles.
This heterogeneity probably contributes to the differences
in apparent internalization mechanisms observed in
various studies, as well as the lack of a single clear up-
take route in any given study. Our ability to pinpoint the
uptake route for different vesicles of similar sizes is still
limited by a lack of biochemical markers to characterize
and isolate them. As this knowledge increases the means
by which they enter cells will be unravelled.
Understanding of EV internalization is a key goal of
the fledgling EV field. Despite the EV research field still
being in its infancy and the limited number of relevant
studies performed to date, the discoveries concerning
EV uptake made so far are promising for future research.
The potential that EVs have shown as therapeutic agents
means that it is imperative that the EV uptake mechanism
is understood to aid prospective therapeutic design. Exci-
tingly, EV research is continually expanding and devel-
oping, therefore greater understanding of the EV uptake
pathway is certainly achievable in the foreseeable future.
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Abstract
Organisms are often exposed to environmental pressures that affect homeostasis, so it is important to understand
the biological basis of stress-response. Various biological mechanisms have evolved to help cells cope with
potentially cytotoxic changes in their environment. miRNAs are small non-coding RNAs which are able to regulate
mRNA stability. It has been suggested that miRNAs may tip the balance between continued cytorepair and induction
of apoptosis in response to stress. There is a wealth of data in the literature showing the effect of environmental
stress on miRNAs, but it is scattered in a large number of disparate publications. Meta-analyses of this data would
produce added insight into the molecular mechanisms of stress-response. To facilitate this we created and manually
curated the miRStress database, which describes the changes in miRNA levels following an array of stress types in
eukaryotic cells. Here we describe this database and validate the miRStress tool for analysing miRNAs that are
regulated by stress. To validate the database we performed a cross-species analysis to identify miRNAs that respond
to radiation. The analysis tool confirms miR-21 and miR-34a as frequently deregulated in response to radiation, but
also identifies novel candidates as potentially important players in this stress response, including miR-15b, miR-19b,
and miR-106a. Similarly, we used the miRStress tool to analyse hypoxia-responsive miRNAs. The most frequently
deregulated miRNAs were miR-210 and miR-21, as expected. Several other miRNAs were also found to be
associated with hypoxia, including miR-181b, miR-26a/b, miR-106a, miR-213 and miR-192. Therefore the miRStress
tool has identified miRNAs with hitherto unknown or under-appreciated roles in the response to specific stress types.
The miRStress tool, which can be used to uncover new insight into the biological roles of miRNAs, and also has the
potential to unearth potential biomarkers for therapeutic response, is freely available at http://
mudshark.brookes.ac.uk/MirStress.
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Introduction
When faced with an environmental stressor an organism can
either extricate itself from the situation or adapt by other
means. When individual cells encounter such stresses they are
often unable to escape, and so a number of biological
mechanisms have evolved to help cells cope with potentially
cytotoxic changes in their environment. Stressful stimuli or
‘stresses’ may include extremes of temperature, chemical
exposure, hypoxia, radiation or nutrient stress [1]. Cells within a
multi-cellular organism employ mechanisms to adapt to the
change, repair the damage caused by the stressor, or undergo
apoptosis to protect the organism [2]. Organisms are often
exposed to environmental pressures, such as radiation
exposure, which affect homeostasis, and so it is important to
understand the biological basis of stress-response.
Key survival mechanisms of cells include the heat shock
response [3] or the unfolded protein response (UPR) [4]. In
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reaction to most stresses there is a swift intervention to normal
protein production within the cell. Though global translation is
often reduced following stress-induction [5], translation of
specific transcripts is up-regulated [6]. Cellular material that is
deemed unnecessary, including various transcripts, are
degraded [7]. Stress granules (SG) form inside cells, which
appear to sequester specific transcripts along with ribosomal
proteins; SGs are dispersed soon after the stimulus is removed
[8]. Steady-state levels of different mRNAs can be affected by
post-transcriptional mechanisms [9]. Post-transcriptional
regulation, for example by interaction between mRNAs and
binding proteins [7], affords a potentially more rapid response
to stress [1].
Recent findings from genome analysis consortia have
indicated that most organisms produce a myriad of non-coding
RNAs. Whilst the role of the majority of this transcriptional
output remains controversial, there are an increasing number
of long [10,11] and short [12] non-coding RNAs with a
demonstrated functional role in health or disease. miRNAs are
short (approximately 22 nt) RNAs that can interact with the
3’UTRs of target mRNAs, resulting in translational repression
and mRNA degradation [13]. Because the interaction between
a miRNA and its target is based on a small region of ~7
nucleotides, which does not need to match perfectly, a single
miRNA can affect the expression of many genes
simultaneously [14]. Given the importance of regulating mRNA
stability in response to stress it is unsurprising that miRNAs
also show a dynamic response when cells encounter a
perturbagen [15]. Indeed, it has been suggested that miRNAs
may ultimately tip the balance between continued cytorepair
and induction of apoptosis [1,16].
The importance of miRNAs in a cellular and organismal
context remains controversial. Although miRNAs were first
discovered through their phenotypic effect on C. elegans [17],
deletion of various miRNAs has no apparent consequence
[18,19]. This contradicts the functional importance of these
miRNAs implied by their often high sequence conservation.
This paradox has, at least in part, been resolved by studies
looking at the effects of miRNAs in response to stress. Indeed,
in some cases the phenotypic effects of the miRNA deletion
only became apparent after the organism is exposed to
environmental stress. For example, miR-214 was shown to be
a marker of cardiac stress [20], yet knocking out miR-214 in
mice had no effect on physiology under normal conditions [21].
However, when these mice were stressed by ischemia/
reperfusion injury they exhibited increased apoptosis of cardiac
cells and decreased overall survival [21]. Similarly, miR-7
mutant flies have a wild-type phenotype under normal
conditions, but when exposed to fluctuating temperature at the
larval stage they exhibit aberrations in retinal development [22].
The role of some miRNAs may be to add biological robustness
during development or homeostasis by modulating gene
regulatory networks [23]. For these reasons it is particularly
important to understand the roles of miRNAs in stress
response.
Stress can originate biologically from within the organism
(such as that caused by disease or abnormal cellular
behaviour) or externally from non-biological sources (such as
toxic agents or changes in the environment). In this study we
have analysed the changes in miRNA levels that occur in
response to the latter. Over the past decade a number of
studies have been performed to profile changes in miRNA
expression following insult with various environmental
challenges. The results of such studies are often conflicting,
and may be due to differences in the experimental setup. In
order to make sense of this increasing pool of data a central
resource is required which can be used to meta-analyse the
results of these studies, confirm the identity of key miRNAs and
infer novel biological roles for non-coding RNAs in stress. A
database exists for miRNA responses following stress
induction in plants [24]. However, a comprehensive database
of such data with the functionality to perform useful meta-
analyses has not been reported for other eukaryotes. Here we
address this issue with a novel database and web tool which
we call miRStress. This manually curated database contains
more than 7,500 entries from over 300 publications. To validate
the usefulness for biological discovery of this resource we used
the database to meta-analyse the effects of various stress
types, including hypoxia and radiation. The results confirm the
identification of several miRNAs already known from functional
studies to be directly involved in response to these stimuli. In
addition, several other miRNAs are identified that have not
previously been associated with these stresses. These results
suggest the miRStress database is a useful new tool for
understanding the biology of miRNAs.
Results and Discussion
The miRStress database
There is a wealth of data in the literature showing the effect
of environmental stresses on miRNAs, but it is scattered in a
large number of disparate publications. Meta-analyses of this
data would produce added insight into the molecular
mechanisms of stress-response. To facilitate this process we
manually curated the miRStress database, which describes the
changes in miRNA levels following a varied array of stress
types in eukaryotic cells. As of June 2013 the database
contained more than 7,500 entries, annotated from 315
publications spanning seven years. An initial analysis of all the
entries in the database reveals the miRNAs that are most
frequently deregulated in response to all stress types (table 1).
The miRNAs that are affected most often are miR-21, miR-210
and miR-34a. This is consistent with previous reports of clear
roles for these miRNAs in DNA damage-response and hypoxia
[16].
Identification of miRNAs involved in radiation response
To demonstrate the potential of miRStress in identifying
miRNAs with biological importance in stress response we
analysed entries related to radiation. Several studies have
attempted to measure the effects of radiation on miRNA levels.
The degree of overlap between these studies is variable, due
to the differences in radiation type, dose, cell type, miRNA
measurement technique and other differences in experimental
approach. Observing miRNAs that consistently change in
response to radiation across many studies could imply they
Meta-Analysing Stress-Related miRNAs
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have greater functional importance. Some attempts have been
made to collate and analyse these disparate publications
[25,26], but a recent comprehensive meta-analysis of these
studies has not been described.
To identify radiation-related miRNAs we selected the
radiation treatment group on the miRStress database. The
database returned a list of miRNAs along with the number of
reports of a miRNA being significantly deregulated. Table 2
shows the list of miRNAs whose level changes in at least ten
instances in the database. The most frequently deregulated
miRNAs were miR-21 and miR-34a. This is consistent with
previous work showing a role for these miRNAs in the
response to genotoxic stress, including radiation [1,27,28].
Indeed, many of the miRNAs in table 2, which we term
‘radiation-miRNAs’ have been previously shown to play a role
in either the response to radiation or in conferring differential
sensitivity to radiation. There are other miRNAs in table 2,
including miR-15b and miR-19b, which have not been overtly
identified as being related to radiation, suggesting that these
miRNAs represent novel candidates for further study by the
radiobiology field. With some of these miRNAs there are clues
to their potential involvement in radiation response from other
studies. For instance, the let-7 family are known to regulate a
number of oncogenes, so specific members of the family may
tip the balance between cell cycle arrest and apoptosis
following irradiation [29]. Evidence suggests that miR-15b can
regulate cell cycle progression [30] and apoptosis [31].
Interestingly, miR-19a/b are able to increase resistance of
gastric cancer cells to chemotherapy by affecting drug efflux
pathways and inhibiting apoptosis [32]. The finding that
exosomes associated with RNA mediate the radiation-induced
bystander-effect also hints at a role for miRNAs in the
intercellular response to ionizing radiation [33]. Whilst there is
much left to elucidate in the miRNA-mediated responses to
radiation, the results from this study provide some strong
candidates worthy of further characterisation.
In order to gain further insight into the potential roles of
miRNAs returned by miRStress we used bioinformatics tools to
Table 1. miRStress-generated list of the most frequently
deregulated miRNAs across all stress types.
miRNA Up Down NR Sum % up % down
21 68 25 1 94 72.3 26.6
210 72 10 1 83 86.7 12.0
34a 49 14 0 63 77.8 22.2
17 24 37 1 62 38.7 59.7
16 35 23 1 59 59.3 39.0
125b 30 25 1 56 53.6 44.6
26a 25 27 1 53 47.2 50.9
20a 19 27 1 47 40.4 57.4
155 33 14 0 47 70.2 29.8
29a 25 20 1 46 54.3 43.5
Columns indicate the miRNA name, the number of incidences where the miRNA is
stimulated (up) or repressed (down) by the stress. NR indicated that the direction
of change was not reported in the publication.
doi: 10.1371/journal.pone.0080844.t001
analyse the functions of their predicted targets. The online
miRNA binding-site prediction tool miRWalk [34] was used to
produce a list of predicted gene targets for each of the
radiation-miRNAs in table 2. miRWalk reports the result of
various miRNA target-prediction algorithms, thereby allowing
the user to estimate whether predicted targets are low- or high-
confidence interactions. For each radiation-miRNA we obtained
a list of high-confidence predicted gene targets (at least six
different algorithms within miRWalk predict an interaction). To
analyse the potential role of these predicted genes we used the
DAVID functional annotation [35,36]. For each radiation-miRNA
we generated a list of high-confidence ‘predicted’ KEGG
pathways that are enriched in the target mRNAs. The
predicted-pathways most commonly targeted are shown in in
text S1. Interestingly, the most commonly predicted pathway
was MAPK signalling, which has been previously observed as
playing a role in radiation response [37]. To assess whether the
predicted-pathways targeted by radiation-miRNAs underpin a
genuine biological phenomenon, rather than a non-specific
quirk obtained when any set of miRNAs is analysed, we
repeated the analysis with an equivalent number of control
miRNAs. The control miRNAs were chosen on the basis that
they appear only once on the list of radiation-affected miRNAs
and are therefore unlikely to represent genuine radiation-
miRNAs. The pattern of predicted-pathways for the control-
miRNAs is different to those obtained with radiation-miRNAs
(text S1). Indeed, many of the predicted pathways (such as the
MAPK signalling pathway) appear much more often for the
Table 2. miRStress-generated list of the most frequently
deregulated miRNAs following radiation treatment.
miRNA Up Down NR Sum % up % down
21 11 6 1 18 61.1 33.3
34a 11 6 0 17 64.7 35.3
16 10 5 1 16 62.5 31.3
17 8 6 1 15 53.3 40.0
let-7b 5 9 1 15 33.3 60.0
let-7g 9 5 0 14 64.3 35.7
let-7a 5 8 1 14 35.7 57.1
let-7f 6 7 0 13 46.2 53.8
19b 6 5 1 12 50.0 41.7
let-7d 4 6 2 12 33.3 50.0
let-7c 7 5 0 12 58.3 41.7
125b 5 6 1 12 41.7 50.0
143 4 5 2 11 36.4 45.5
24 8 3 0 11 72.7 27.3
20a 4 6 1 11 36.4 54.5
15b 4 5 2 11 36.4 45.5
106a 3 6 1 10 30.0 60.0
106b 4 5 1 10 40.0 50.0
let-7e 4 6 0 10 40.0 60.0
221 8 2 0 10 80.0 20.0
Columns indicate the miRNA name, the number of incidences where the miRNA is
stimulated (up) or repressed (down) by the stress. NR indicated that the direction
of change was not reported in the publication.
doi: 10.1371/journal.pone.0080844.t002
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radiation miRNAs than the control miRNAs, suggesting that
they do represent a biological effect.
In addition to the studies measuring the levels of miRNAs
there have also been a number of publications describing
changes in mRNA levels in response to radiation. We
downloaded 18 sets of microarray data from such studies and
identified genes deregulated by at least two-fold from each
dataset. These genes were then analysed using DAVID and
the pathways enriched in the datasets were counted and
compared to the predicted pathways (text S1). Interestingly,
MAPK signalling was enriched in half of the 18 datasets,
consistent with the identification of MAPK signalling in the
radiation miRNA predicted-pathways. Radiation predicted-
pathways appeared on average 4.2 times in the actual
radiation pathways. This was significantly more (t test, p =
0.002) than the control predicted-pathways, which appeared on
average 1.5 times in the list of pathways that are actually
deregulated in radiation response (Figure 1A). In other words,
the miRNAs which are most frequently affected by radiation are
‘predicted’ to target the pathways which are ‘actually’ affected
following irradiation. This is consistent with a role for the
radiation-miRNAs in influencing gene expression following
irradiation of cells.
To further validate the biological relevance of the radiation
miRNAs identified by miRStress we utilised previously
published datasets featuring radiosensitivity and miRNA
expression data across the NCI-60 panel. The NCI-60 panel is
a collection of human cell lines derived from various cancer
types. This panel has been well characterised at the molecular
level [38], with data available on expression of miRNAs and
mRNAs, as well as sensitivity to radiation and thousands of
compounds. Specifically we used the SF5 (surviving fraction of
cells after a 5 Gray dose of radiation) value for each cell line
[39] and the levels of miRNA expression in the E-MTAB-327
dataset [40]. To test for relationships between miRNAs and
radiation resistance we performed Pearson correlation
analyses between miRNA levels and radiosensitivity across the
panel. For each miRNA this yielded a Pearson correlation
which is indicative of the strength of association between the
level of that miRNA and the level of radioresistance. We then
assessed whether the magnitude of the Pearson correlations
for radiation miRNAs was, on average, significantly higher than
those for the control miRNAs. Our results show that the
magnitude of the average Pearson correlation for radiation
miRNAs is indeed significantly higher (t test, p = 0.017) for the
radiation miRNAs compared to control miRNAs (Figure 1B). A
similar analysis using the coefficient of determination (R2) for
these correlations showed that the average R2 value for
radiation miRNAs was more than three times higher than that
for control miRNAs (t test, p = 0.03). This suggests that the
miRNAs identified by miRStress as being associated with
radiation response are more likely to correlate with
radiosensitivity than the control miRNAs.
In order to be more confident in the accuracy of miRStress in
calling genuine radiation-related miRNAs we performed a
receiver operating characteristic (ROC) curve analysis. This
method can be used to determine how good a tool is at taking
a variable input (in this case the number of times a miRNA is
de-regulated by a specific stress, as determined by miRStress)
and a binary output (whether the miRNA really is involved in
radiation). To determine whether a miRNA represents a true
functional miRNA we analysed the literature. A true positive
was categorised as a miRNA that had previously been shown
to be functionally involved in radiation response, either by
being involved in a defined radiation response pathway or by
affecting radiation resistance when manipulated. To perform
Figure 1.  Radiation-responsive miRNAs predicted by
miRStress are biologically relevant.  A: The miRNAs which
are most frequently deregulated following radiation stress, as
reported by miRStress, were used to ‘predict’ radiation-
responsive pathways, as described in the methods. Control
pathways were selected by using a list of control miRNAs.
These were then compared to a list of KEGG pathways which
are observed (as opposed to predicted) to actually change
following radiation (in a total of 18 datasets). The average
frequency with which the predicted control or radiation
pathways appears in the observed pathways is shown. On
average the radiation predicted-pathways are more frequently
present in the observed pathways (t test, p 0.002). In other
words, the radiation miRNAs are predicted to target pathways
which actually change following radiation. Error bars show
standard error of the mean for 20 (for radiation) and 21 (for
control) pathways. B: Radiation and control miRNAs used in
part A were used to test for correlations between SF5
(surviving fraction of cells following a 5 Gray radiation dose)
and miRNA level across the NCI-60 panel. A Pearson
correlation was obtained for each radiation and control miRNA
(not all were available on the microarray platform). The
average Pearson correlation value (see methods) for the
control and radiation miRNAs is shown. The radiation miRNAs
have a significantly higher correlation with radiosensitivity
compared to the control miRNAs (t test, p = 0.02).
doi: 10.1371/journal.pone.0080844.g001
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the ROC curve analysis we used the list of radiation miRNAs
(in table 2) and the same control miRNAs used in the previous
analyses (that appear only once in the miRStress list of
radiation-de-regulated miRNAs). The analysis resulted in an
area under the curve (AUC) of 0.857, which is indicative of a
good test. One note of caution is that in this analysis the
assignment of ‘true positives’ is based on appearance in the
literature (which for the purposes of this test we take at face
value). However, just because a miRNA does not appear in the
literature as a functional radiation miRNA does not mean that
this miRNA definitely does not play a role, which makes it more
difficult to accurately determine the binary input for the ROC
test. Nevertheless, the high AUC of 0.857 is consistent with a
good sensitivity and specificity of the miRStress tool in
determining miRNAs involved in stress. Taken together these
results confirm that the data produced by miRStress are of
biological relevance, and that the program can identify new
candidate miRNAs that may be involved in response to specific
stressors.
Novel miRNAs in hypoxia
Hypoxia, which occurs in cells exposed to lower levels of
oxygen, is extensively studied as it is a key feature of tumour
progression and chemotherapy response [41].. Hypoxia is also
associated with the pathology of ischemic disorders, including
myocardial infarction and stroke [42]. As with many other
biological processes, miRNAs have been shown to play a role
in mediating the response to hypoxia [23]. Having validated the
miRStress database we next wished to identify novel roles for
miRNAs in response to hypoxia. The most frequently
deregulated miRNAs in hypoxia response, which we term
‘hypoxia miRNAs’, are shown in table 3. In contrast to radiation
miRNAs, which are more variably up- or down-regulated by
radiation, the hypoxia miRNAs appear much more likely to be
induced by hypoxic stress.
A key regulator of the hypoxic response is miR-210, which is
capable of regulating various pathways including cell cycle,
apoptosis and oxidative metabolism [43]. The prominence of
Table 3. miRStress-generated list of the most frequently
deregulated miRNAs following hypoxia treatment.
miRNA Up Down NR Sum % up % down
210 56 0 0 56 100 0
21 12 2 0 14 85.7 14.3
155 8 3 0 11 72.7 27.3
181b 8 3 0 11 72.7 27.3
26b 9 1 0 10 90.0 10.0
106a 9 0 0 9 100 0
26a 8 0 0 8 100 0
213 8 0 0 8 100 0
192 8 0 0 8 100 0
Columns indicate the miRNA name, the number of incidences where the miRNA is
stimulated (up) or repressed (down) by the stress. NR indicated that the direction
of change was not reported in the publication.
doi: 10.1371/journal.pone.0080844.t003
this miRNA was confirmed by our miRStress analysis which
identified miR-210 as by far the most frequently deregulated
miRNA in response to hypoxia. Hypoxia-inducible factors (HIF)
are transcription factors that regulate various genes involved in
response to hypoxia, including miR-210 [41,43]. Regulating the
levels of HIFs, and in particular HIF-1α, is critical to an
appropriate response during low oxygen tension. Various
miRNAs have been shown to negatively regulate HIF-1α,
including miR-155 [44], another miRNA that was identified by
the miRStress analysis of hypoxia-responsive miRNAs. As
described above, miR-21 has been implicated in numerous
stress responses and is able to confer resistance to hypoxia by
regulating the tumour suppressor PTEN [45]. Several miRNAs,
including miR-20a/b and miR-424, which have been reported to
affect hypoxia response [23,43,46], did not appear in the top
ten hypoxia miRNAs identified in the miRStress analysis.
Instead a number of other miRNAs (miR-181b/c, miR-213,
miR-26a/b, miR-106a and miR-192), which have no obvious
connection to hypoxia in the literature, are more frequently
deregulated. This does not rule out a role for previously
identified hypoxia-related miRNAs, but suggests that other
miRNAs may have an equally important role in hypoxia
response. Interestingly, according to the miRStress analysis,
miR-181b is deregulated almost as frequently as miR-21 in
hypoxia. NF-κB has been shown to be involved hypoxia
response [47], and miR-181b is able to regulate vascular
inflammation by directly targeting NF-κB [48]. Glycerol-3-
phosphate dehydrogenase 1-like (GPD1L) is repressed by
miR-210 under hypoxic conditions, which leads to stabilisation
of HIF-1α [49]. Analysis using the miRNA-mRNA target
prediction algorithm miRWalk suggests that miR-181b may
also target GPD1L and thus stabilise HIF-1α. miR-26a/b have
been shown to be involved in cancer progression by targeting
the cell cycle or apoptosis [49,50]; whether miR-26a/b act on
oncogenes or tumour suppressors is unclear, and the
conflicting reports in the literature suggest that the effects of
miR-26a/b are context-dependent. Indeed, the finding that
miR-26a plays a role in oxidative stress response via apoptotic
signalling suggests a potential role in hypoxic response
[51].The ROC curve analysis performed on the hypoxia miRNA
list shows an AUC of 0.859, suggesting that the tool is
consistent in producing accurate lists of biologically relevant
miRNAs in hypoxia. It also suggests that the accuracy of the
tool is consistent for different stresses. Whilst further
experimental evidence is needed to confirm the role (if any)
and pathways of these miRNAs, our results nevertheless have
uncovered several novel candidates for potential involvement
in the hypoxic response.
The ability of miRStress to identify useful candidates will in
part depend on how many reports have been published using a
particular stress. At the time of submission the miRStress
database included 491 incidences of stress treatment. Most of
the >170 specific treatments were performed once, twice or
three times. However, 23 specific treatments were reported in
at least five different instances, of which there are ten stress
types that were performed on nine different occasions.
Therefore there are a number of stress types that are
amenable to a useful meta-analysis using miRStress. For
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stress-types with fewer publications the accuracy of the tool in
predicting genuinely functional miRNAs and stress biomarkers
will most likely be lower. However, given that we have shown
that miRStress works accurately for well-studied stress types,
such as radiation and hypoxia, it follows that as the database is
updated and the number of included publications grows, so will
the ability of this tool to identify biologically relevant miRNAs
and stress biomarkers for more stress types.
There are a number of potential biases which must be
considered when analysing the miRStress output. There will be
an element of publication bias as only English-language
articles were included, and research with seemingly negative
results may have been withheld from publication. There is also
a degree of bias within the database caused by the
methodology used in the different publications. Some use more
‘open’ platforms such as RNA-seq, microarrays or high-
throughput PCR-panels, whereas others only include a small
number of primers to test specific miRNAs by PCR. Even within
the more open platforms there is bias; for example, different
microarray platforms contain different selections of miRNAs.
Early discoveries in the field can also lead to subsequent bias.
A good example of this is miR-210, which was shown in 2008
to be an important player in hypoxia [52]. Since then a number
of articles have used PCR to confirm the induction of miR-210
without testing the effect on many other miRNAs. This is
reflected in the miRStress analysis which shows a very high
number of instances of miR-210 deregulation following
hypoxia. This high number relative to other miRNAs is in part
due to the bias described above. The database is therefore
more likely to produce false negatives than false positives.
Nevertheless, as we have shown for miRNAs involved in
hypoxia and radiation, it is possible to identify miRNAs with
previously undiscovered roles in stress response. 
The miRStress analysis has therefore uncovered the
importance of hitherto under-appreciated miRNAs in the
processes of hypoxia and radiation response, and will be a
useful tool for researchers studying the effects of stress
response. Future work should unravel the precise roles and




The search term ‘microRNA’ was entered into PubMed to
obtain a list of all microRNA publications to date. The entire
history of microRNA publication abstracts (>20,000
publications) were manually searched for any abstracts
mentioning differential regulation of microRNAs following any
stress treatment of cells. If the abstract did not specifically
mention the use of a stressor followed by miRNA measurement
then it was not included. Should users encounter a paper which
should be included in the database but has been omitted then
they are encouraged to contact the corresponding author
(DRFC). We did not include reports of treatments related to
biological stresses, such as disease, infection with viruses or
bacteria, or treatment with biological macromolecules such as
hormones and peptides. For ease of interpretation we also
excluded combination treatments. For inclusion in the database
the miRNA changes needed to be indicated as statistically
significant. At the time of manuscript preparation a total of
7,663 miRNA entries from 315 papers were included in the
database. For each paper we manually annotated various
details, including the cell type, stressor conditions,
quantification methods and miRNAs that were deregulated.
Database construction
The miRStress database is stored in a plain ascii flat file
format, and a module to interrogate it was constructed using
the Python programming language (http://www.python.org).
Additional Python modules were written utilising “pyro” (https://
pypi.python.org/pypi/Pyro4) and the moinmoin wiki framework
(http://moinmo.in) to build the web interface. Interested readers
should contact DRFC or MGP concerning the availability of the
software. The database is hosted on the Cell Systems
Modelling Group website and is freely accessible at http://
mudshark.brookes.ac.uk/MirStress.
Data is accessed by browsing the different stress types.
Clicking on a given treatment group or a specific treatment
loads the miRNA information into the results output page.
These results can then be accessed as a list of miRNA
frequencies (by clicking on the browse RNAs option) or a list of
publications (by clicking on browse PMIDs [Pubmed IDs]). The
number of ‘reports’ describes the number of publications in
which the selected stress appears. The output also includes
the number of incidences within those reports in which the
given miRNA is increased or decreased. If a paper describes
multiple readings for a given miRNA in a cell line (for example
at different time points, or different stress doses) then these not
considered to be multiple incidences (so would only add one to
the incidence count).
In addition to the web interface a more flexible downloadable
version of miRStress is available at https://sourceforge.net/
projects/mirstress/. The miRStress download module is also
written in python and allows users to search the database
whilst offline. The download module is powered using the same
python script as the online miRStress website with a separate
tkinter script used to form the graphical user interface.
Radiation miRNA validation
For each of the radiation and control miRNAs a list of high
confidence targets were identified using the online miRNA
binding-site prediction tool miRWalk [25]. This tool performs a
form of meta-analysis, comparing the results of various other
miRNA-target prediction algorithms. We selected genes that
were predicted to be targets by at least 6 of these algorithms.
The DAVID functional annotation tool was then used to identify
KEGG pathways that are enriched in the list of predicted gene
targets [35,36]. We labelled these as ‘predicted pathways’. If a
given KEGG pathway was ‘predicted’ to be targeted by at least
three radiation miRNAs and at least 50% fewer control miRNAs
then we considered this to be a ‘radiation pathway’. Otherwise
it was labelled as a ‘control pathway’. These criteria were
selected arbitrarily to reflect the heterogeneity in radiation
response pathways (as well as heterogeneity of miRNA
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targeting) and the requirement for radiation pathways to be
more abundant than random pathways.
Eighteen expression microarray datasets documenting
mRNA changes following ionizing radiation treatment were
obtained from Gene Expression Omnibus. Datasets were
individually imported into Genespring 12.5 and normalised
using Robust Multi-array Average. Each dataset was then
normalised to the median value for that dataset. Genes whose
expression was altered by at least 2-fold in irradiated compared
to control samples were imported into DAVID Bioinformatics
Resource 6.7 [35,36]. This allowed identification of KEGG
pathways that were significantly enriched in each of the 18
radiation datasets.
SF5 (surviving fraction of cells following a 5 Gray dose of
gamma rays) data were obtained for each cell line in the
NCI-60 panel from previously published results [39]. Levels of
miRNA expression for each cell line were obtained from the E-
MTAB-327 dataset [40]. Pearson correlations were obtained
between each miRNA and the SF5 data across the panel of
cell lines. For comparison of different miRNAs the magnitude of
Pearson correlation values was obtained by converting any
negative values into positives.
Receiver operating characteristic (ROC) analysis
The ROC analysis was performed using SPSS (v19). In each
test the list of high-confidence miRNAs for a given stress
(either radiation or hypoxia, see tables 2 and 3, respectively)
was compared to an equivalent number of control miRNAs
(which only appear once in miRStress for that given stress).
For the test variable we used the number of appearances in the
miRStress database. For the state variable we used a
dichotomous output of whether the miRNA was a ‘true positive’
or not. We defined a miRNA as a true positive if that miRNA
had previously been shown to be functionally involved in the
stress response, either by being involved in a defined stress
response pathway or by affecting resistance (to the given
stress) when manipulated.
Supporting Information
Text S1.  Analysis of the actual and predicted (based on




We thank all members of the lab for reading the manuscript
and for useful suggestions throughout the project.
Author Contributions
Conceived and designed the experiments: LAJ MK DRFC.
Performed the experiments: LAJ DRFC. Analyzed the data:
LAJ RCP LAM IB EMB TB DPC WC JMSC JH LK EK DL DM
AMR PS HW FBC MGP MK DRFC. Contributed reagents/
materials/analysis tools: FBC MGP. Wrote the manuscript: LAJ
DRFC. Designed the software used in analysis: FBC MGP.
Analyzed the publications and curated the database: LAJ RCP
LAM IB EMB TB DPC WC JMSC JH LK EK DL DM AMR PS
HW DRFC.
References
1. Thomas MP, Lieberman J (2013) Live or let die: posttranscriptional
gene regulation in cell stress and cell death. Immunol Rev 253:
237-252. doi:10.1111/imr.12052. PubMed: 23550650.
2. Fulda S, Gorman AM, Hori O, Samali A (2010) Cellular stress
responses: cell survival and cell death. Int J Cell Biol 2010: 214074.
3. Lindquist S (1986) The heat-shock response. Annu Rev Biochem 55:
1151-1191. doi:10.1146/annurev.bi.55.070186.005443. PubMed:
2427013.
4. Schröder M, Kaufman RJ (2005) The mammalian unfolded protein
response. Annu Rev Biochem 74: 739-789. doi:10.1146/
annurev.biochem.73.011303.074134. PubMed: 15952902.
5. Holcik M, Sonenberg N (2005) Translational control in stress and
apoptosis. Nat Rev Mol Cell Biol 6: 318-327. doi:10.1038/nrm1618.
PubMed: 15803138.
6. Wouters BG, van den Beucken T, Magagnin MG, Koritzinsky M, Fels D
et al. (2005) Control of the hypoxic response through regulation of
mRNA translation. Semin Cell Dev Biol 16: 487-501. doi:10.1016/
j.semcdb.2005.03.009. PubMed: 15896987.
7. von Roretz C, Di Marco S, Mazroui R, Gallouzi IE (2011) Turnover of
AU-rich-containing mRNAs during stress: a matter of survival. Wiley
Interdiscip Rev RNA 2: 336-347. doi:10.1002/wcs.129. PubMed:
21957021.
8. Buchan JR, Parker R (2009) Eukaryotic stress granules: the ins and
outs of translation. Mol Cell 36: 932-941. doi:10.1016/j.molcel.
2009.11.020. PubMed: 20064460.
9. Molin C, Jauhiainen A, Warringer J, Nerman O, Sunnerhagen P (2009)
mRNA stability changes precede changes in steady-state mRNA
amounts during hyperosmotic stress. Rna-a Publication of the Rna
Society 15: 600-614.
10. Caley DP, Pink RC, Trujillano D, Carter DR (2010) Long noncoding
RNAs, chromatin, and development. ScientificWorldJournal 10: 90-102.
doi:10.1100/tsw.2010.7. PubMed: 20062956.
11. Pink RC, Wicks K, Caley DP, Punch EK, Jacobs L et al. (2011)
Pseudogenes: pseudo-functional or key regulators in health and
disease? RNA 17: 792-798. doi:10.1261/rna.2658311. PubMed:
21398401.
12. Fabbri M, Calin GA (2010) Epigenetics and miRNAs in Human Cancer.
In: Z HercegT Ushijima. Epigenetics and Cancer, Pt A. San Diego:
Elsevier Academic Press Inc.. pp. 87-99.
13. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian
microRNAs predominantly act to decrease target mRNA levels. Nature
466: 835-840. doi:10.1038/nature09267. PubMed: 20703300.
14. Bartel DP (2009) MicroRNAs: target recognition and regulatory
functions. Cell 136: 215-233. doi:10.1016/j.cell.2009.01.002. PubMed:
19167326.
15. Leung AKL, Sharp PA (2007) microRNAs: A safeguard against turmoil?
Cell 130: 581-585. doi:10.1016/j.cell.2007.08.010. PubMed: 17719533.
16. Mendell JT, Olson EN (2012) MicroRNAs in Stress Signaling and
Human Disease. Cell 148: 1172-1187. doi:10.1016/j.cell.2012.02.005.
PubMed: 22424228.
17. Lee RC, Feinbaum RL, Ambros V (1993) THE C-ELEGANS
HETEROCHRONIC GENE LIN-4 ENCODES SMALL RNAS WITH
ANTISENSE COMPLEMENTARITY TO LIN-14. Cell 75: 843-854. doi:
10.1016/0092-8674(93)90529-Y. PubMed: 8252621.
18. Alvarez-Saavedra E, Horvitz HR (2010) Many families of C. elegans
microRNAs are not essential for development or viability. Curr Biol 20:
367-373. doi:10.1016/j.sbi.2010.03.007. PubMed: 20096582.
19. Miska EA, Alvarez-Saavedra E, Abbott AL, Lau NC, Hellman AB et al.
(2007) Most Caenorhabditis elegans microRNAs are individually not
essential for development or viability. PLOS Genet 3: e215. doi:
10.1371/journal.pgen.0030215. PubMed: 18085825.
20. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J et al.
(2006) A signature pattern of stress-responsive microRNAs that can
evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A
Meta-Analysing Stress-Related miRNAs
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e80844
103: 18255-18260. doi:10.1073/pnas.0608791103. PubMed:
17108080.
21. Aurora AB, Mahmoud AI, Luo X, Johnson BA, van Rooij E et al. (2012)
MicroRNA-214 protects the mouse heart from ischemic injury by
controlling Ca² overload and cell death. J Clin Invest 122: 1222-1232..
22. Li X, Cassidy JJ, Reinke CA, Fischboeck S, Carthew RW (2009) A
microRNA imparts robustness against environmental fluctuation during
development. Cell 137: 273-282. doi:10.1016/j.cell.2009.01.058.
PubMed: 19379693.
23. Ezcurra ALD, Bertolin AP, Melani M, Wappner P (2012) Robustness of
the hypoxic response: Another job for miRNAs? Dev Dynam 241:
1842-1848. doi:10.1002/dvdy.23865.
24. Zhang S, Yue Y, Sheng L, Wu Y, Fan G et al. (2013) PASmiR: a
literature-curated database for miRNA molecular regulation in plant
response to abiotic stress. BMC Plant Biol 13: 33. doi:
10.1186/1471-2229-13-33. PubMed: 23448274.
25. Dickey JS, Zemp FJ, Martin OA, Kovalchuk O (2011) The role of
miRNA in the direct and indirect effects of ionizing radiation. Radiat
Environ Biophys 50: 491-499. doi:10.1007/s00411-011-0386-5.
PubMed: 21928045.
26. Lhakhang TW, Chaudhry MA (2012) Interactome of Radiation-Induced
microRNA-Predicted Target Genes. Comp Funct Genomics 2012:
569731. PubMed: 22924026
27. He L, He X, Lim LP, de Stanchina E, Xuan Z et al. (2007) A microRNA
component of the p53 tumour suppressor network. Nature 447:
1130-1134. doi:10.1038/nature05939. PubMed: 17554337.
28. Kumarswamy R, Volkmann I, Thum T (2011) Regulation and function of
miRNA-21 in health and disease. RNA Biol 8: 706-713. doi:10.4161/
rna.8.5.16154. PubMed: 21712654.
29. Wang X, Cao L, Wang Y, Liu N, You Y (2012) Regulation of let-7 and
its target oncogenes (Review). Oncol Lett 3: 955-960 PubMed:
22783372.
30. Xia H, Qi Y, Ng SS, Chen X, Chen S et al. (2009) MicroRNA-15b
regulates cell cycle progression by targeting cyclins in glioma cells.
Biochem Biophys Res Commun 380: 205-210. doi:10.1016/j.bbrc.
2008.12.169. PubMed: 19135980.
31. Shen J, Wan R, Hu G, Yang L, Xiong J et al. (2012) miR-15b and
miR-16 induce the apoptosis of rat activated pancreatic stellate cells by
targeting Bcl-2 in vitro. Pancreatology 12: 91-99. doi:10.1016/j.pan.
2012.02.008. PubMed: 22487517.
32. Wang F, Li T, Zhang B, Li H, Wu Q et al. (2013) MicroRNA-19a/b
regulates multidrug resistance in human gastric cancer cells by
targeting PTEN. Biochem Biophys Res Commun 434: 688-694. doi:
10.1016/j.bbrc.2013.04.010. PubMed: 23603256.
33. Al-Mayah AH, Irons SL, Pink RC, Carter DR, Kadhim MA (2012)
Possible Role of Exosomes Containing RNA in Mediating Nontargeted
Effect of Ionizing Radiation. Radiat Res, 177: 539–45. PubMed:
22612287.
34. Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk--database:
prediction of possible miRNA binding sites by "walking" the genes of
three genomes. J Biomed Inform 44: 839-847. doi:10.1016/j.jbi.
2011.05.002. PubMed: 21605702.
35. Huang dW, Sherman BT, Lempicki RA (2009) Bioinformatics
enrichment tools: paths toward the comprehensive functional analysis
of large gene lists. Nucleic Acids Res 37: 1-13. doi:10.1093/nar/
gkp505. PubMed: 19033363.
36. Huang dW, Sherman BT, Lempicki RA (2009) Systematic and
integrative analysis of large gene lists using DAVID bioinformatics
resources. Nat Protoc 4: 44-57. PubMed: 19131956.
37. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S (2003) MAPK
pathways in radiation responses. Oncogene 22: 5885-5896. doi:
10.1038/sj.onc.1206701. PubMed: 12947395.
38. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW et al. (2012)
CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to
Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set.
Cancer Res 72: 3499-3511. doi:10.1158/1538-7445.AM2012-3499.
PubMed: 22802077.
39. Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA et al.
(2008) Integrating global gene expression and radiation survival
parameters across the 60 cell lines of the National Cancer Institute
Anticancer Drug Screen. Cancer Res 68: 415-424. doi:
10.1158/0008-5472.CAN-07-2120. PubMed: 18199535.
40. Patnaik SK, Dahlgaard J, Mazin W, Kannisto E, Jensen T et al. (2012)
Expression of microRNAs in the NCI-60 cancer cell-lines. PLOS ONE
7: e49918. doi:10.1371/journal.pone.0049918. PubMed: 23209617.
41. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer
progression and targets for cancer therapy. Trends Pharmacol Sci 33:
207-214. doi:10.1016/j.tips.2012.01.005. PubMed: 22398146.
42. Semenza GL (2010) Vascular responses to hypoxia and ischemia.
Arterioscler Thromb Vasc Biol 30: 648-652. doi:10.1161/ATVBAHA.
108.181644. PubMed: 19729615.
43. Devlin C, Greco S, Martelli F, Ivan M (2011) miR-210: More than a
silent player in hypoxia. IUBMB Life 63: 94-100. PubMed: 21360638.
44. Bruning U, Cerone L, Neufeld Z, Fitzpatrick SF, Cheong A et al. (2011)
MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha
activity during prolonged hypoxia. Mol Cell Biol 31: 4087-4096. doi:
10.1128/MCB.01276-10. PubMed: 21807897.
45. Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I
et al. (2011) Akt2 regulates all Akt isoforms and promotes resistance to
hypoxia through induction of miR-21 upon oxygen deprivation. Cancer
Res 71: 4720-4731. doi:10.1158/1538-7445.AM2011-4720. PubMed:
21555366.
46. Shen G, Li X, Jia YF, Piazza GA, Xi Y (2013) Hypoxia-regulated
microRNAs in human cancer. Acta Pharmacol Sin 34: 336-341. doi:
10.1038/aps.2012.195. PubMed: 23377548.
47. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE (1998) Response of
tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 51: 55-61.
doi:10.1136/mp.51.2.55. PubMed: 9713587.
48. Sun X, Icli B, Wara AK, Belkin N, He S et al. (2012) MicroRNA-181b
regulates NF-κB-mediated vascular inflammation. J Clin Invest 122:
1973-1990. PubMed: 22622040.
49. Kelly TJ, Souza AL, Clish CB, Puigserver P (2011) A hypoxia-induced
positive feedback loop promotes hypoxia-inducible factor 1alpha
stability through miR-210 suppression of glycerol-3-phosphate
dehydrogenase 1-like. Mol Cell Biol 31: 2696-2706. doi:10.1128/MCB.
01242-10. PubMed: 21555452.
50. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ et al. (2010)
Integrative genome analysis reveals an oncomir/oncogene cluster
regulating glioblastoma survivorship. Proc Natl Acad Sci U S A 107:
2183-2188. doi:10.1073/pnas.0909896107. PubMed: 20080666.
51. Suh JH, Choi E, Cha MJ, Song BW, Ham O et al. (2012) Up-regulation
of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes
by repressing GSK-3β protein expression. Biochem Biophys Res
Commun 423: 404-410. doi:10.1016/j.bbrc.2012.05.138. PubMed:
22664106.
52. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J et al.
(2008) miR-210 links hypoxia with cell cycle regulation and is deleted in
human epithelial ovarian cancer. Cancer Biol Ther 7: 255-264. doi:
10.4161/cbt.7.2.5297. PubMed: 18059191.
Meta-Analysing Stress-Related miRNAs




8.1.3. Mulcahy, L.A. and Carter, D. R. (2013). RNAi2013: RNAi at Oxford. J RNAi Gene Silencing, 
9:486-489. 
  
©The Authors | Journal of RNAi and Gene Silencing | 2013 | Vol 9 | 486-489 | OPEN ACCESS 486
MEETING REVIEW
ISSN: 1747-0854 J RNAi Gene Silencing, 2013, Vol 9, 486-489
RNAi2013: RNAi at Oxford
Laura A Mulcahy and David RF Carter*
Oxford Brookes University, Faculty of Health and Life Sciences, Department of Biological and Medical Sciences. Gypsy 
Lane, Oxford, OX3 0BP, UK
*Correspondence to: David Carter, Email: dcarter@brookes.ac.uk, Tel: +44 1865 484216, Fax: +44 1865 483242
Received: 01 May 2013; Accepted: 02 May 2013; Published: 20 May 2013
© Copyright The Author(s): First Published by Library Publishing Media. This is an open access article, published 
under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5). This license permits non-commercial use, distribution and reproduction of the article, provided the original 
work is appropriately acknowledged with correct citation details.
The eighth annual RNAi international conference and exhi-
bition, RNAi2013 was hosted at St Hilda’s College, Oxford, 
UK (19-21 March 2013), and provided a platform for con-
gregation of researchers with both academic and industrial 
backgrounds to share and discuss their most recent work in 
the fast advancing field of RNAi. RNAi has been recognised 
as a fundamental method for functional genomic investiga-
tions and has great potential as a therapeutic intervention 
for several human diseases. RNA-induced gene expression 
inhibition mechanisms were discussed for both the ben-
efit of research and clinical therapeutics. The conference 
conveyed an impressive series of presentations given by 
national and international RNAi research leaders. Addition-
ally, research posters were exhibited for the entirety of the 
conference. Furthermore, technology workshops were pro-
vided by Sigma-Aldrich, Eupheria Biotech GmbH and Carl 
Zeiss enabling conference attendees to learn about their 
most advanced RNAi expertise. These companies also par-
ticipated in a trade exhibition along with Exiqon to promote 
the latest commercial RNAi products.
RNAi DEVELOPMENTS
Professor Kaz Taira (University of Tokyo, Japan) was invited 
as a special guest speaker and opened the conference with 
a presentation describing the recent discovery that siRNA 
strand antagonism is the major cause of reduced siRNA 
potency when compared with the potency of shRNA. RNAi 
activity of siRNA is reduced compared to shRNA due to the 
sense RNA strand negatively regulating RNAi. By modify-
ing the relative sense and antisense components of duplex 
siRNA during expression, improved potency of siRNA in 
target gene RNAi was achieved (Jin et al, 2012). Further-
more, Taira identified DEAD-box helicase 3 (DDX3) using 
a short hairpin RNA-expression library, as a fundamental 
component of the RNAi pathway. DDX3 was found to co-
localise with Argonaut2 (Kasim et al, 2013).
Dr Laure-Alix Clerbaux (Université catholique de  Louvain) 
elucidated the mechanism used by cells to maintain  cholesterol 
metabolism. Clerbaux explained that the primary transcript 
of sterol regulatory element binding protein (SREBP) 2 con-
tains not only the genetic code for a sterol sensing transcrip-
tion factor which promotes transcription of numerous genes 
involved in cholesterol and fatty acid synthesis, but also holds 
the highly conserved intronic miR-33. miR-33 was shown to 
target and successfully down-regulate activity of the cho-
lesterol export pump, ABCA1, which considerably reduced 
cellular cholesterol export and hence increased cellular cho-
lesterol concentration. The SREBP is triggered during low 
cellular cholesterol levels; it was revealed therefore, that 
miR-33 interacts with the gene in which it is located to main-
tain normal cellular cholesterol levels (Gerin et al, 2010).
NANOPARTICLE DELIVERY OF RNAi 
 THERAPEUTICS
Due to their sensitivity to enzymatic degradation, large 
negative charge, high molecular weight, and rapid plasma/
renal clearance, ncRNA therapeutics are notoriously dif-
ficult to deliver into mammalian cells. Hence, successful 
delivery of ncRNA is a great challenge within the RNAi 
therapeutic field. In an attempt to overcome these issues, 
numerous non-viral nanoparticles administered by sys-
temic intravenous injection have been developed recently to 
enable therapeutic use of synthetic ncRNA for a number of 
RNAi applications.
Dr Klaus Giese (Silence Therapeutics, Germany) described 
Atu027 which employs a novel method for small interfer-
ing RNA (siRNA) delivery involving siRNA cationically 
complexed with liposomal nanoparticles which specifically 
down regulate protein kinase N3 gene expression in the vas-
cular endothelium. This protein target has promising effects 
in terms of inhibition of tumour progression through lymph 
node metastasis and angiogenesis. Phase I clinical trial 
results are promising, Atu027 is well tolerated in patients 
with advanced solid tumours; plasma samples showed dose 
related increase in circulating siRNA antisense strand levels 
(Strumberg et al, 2012).
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Dr Raymond Schiffelers (University Medical Centre Utrecht, 
the Netherlands) discussed biodegradeable ncRNA carriers 
which are formulated by electrostatic interaction between 
ncRNA and nanoparticles. To avoid opsonisation and clear-
ance by macrophages the particle’s surface is covered by a 
flexible, ligand-displaying, hydrophilic polymer layer of 
poly(ethylene)glycol. Using this technology intergrin tar-
geted anti-angiogenic miRNAs were administered to cancer-
ous mouse cells resulting in hindered tumour growth through 
inhibition of tumour vascularisation (Coimbra et al, 2012).
Professor Gilles Divita (Centre National de la Recherche 
Scientifique, France) described NANOVEPEP technol-
ogy which involves nanoparticle self-assembly around the 
siRNA, aided by electrostatic and hydrophobic interactions 
between short amphipathic CADY peptides. NANOVEPEP 
technology is particularly advantageous since delivery of 
siRNAs into specific cell targets is possible without initiat-
ing an inflammatory response (Konate et al, 2012).
ANTI-CANCER RNAi THERAPEUTICS
Since cancer is caused by accumulation of genetic abnor-
malities, nucleic acid medicines are an obvious therapeu-
tic choice and are predicted to have the most potential for 
success. Many nucleic acid therapies are currently being 
developed; a selection of the latest RNAi associated cancer 
therapies were presented at RNAi2013.
Chemoresistance is a major limitation of drugs currently 
used to treat cancer and results in significantly reduced sur-
vival rates. Dr David Carter (Oxford Brookes University, 
UK) described characterisation of miRNA levels in ovarian 
cancer cell lines that are resistant or sensitive to cisplatin 
treatment. Through loss or gain of function experimentation 
a miRNA and coding gene pair were identified that can con-
tribute to cisplatin resistance during carcinogenesis.
Professor Achim Aigner (University of Leipzig, Germany) 
demonstrated that Pim-1 activity, previously linked with 
poor prognosis, is fundamental to signal transduction in 
colon carcinoma and glioblastoma cells and is regulated by 
miR-15b and miR-33a. Knockdown resulted in anti-tumour 
effects; treated cells also became more sensitised to 5-FU 
(Thomas et al, 2012). 
Dr Nigar Babae (University Medical Centre Utrecht, the 
Netherlands) presented results that identified a novel anti-
angiogenic miRNA using a lentiviral miRNA expression 
library. Following local delivery by electroporation in a 
Neuro2A mouse tumour model, tumour growth rate dimin-
ished by 50% and tumour vascularisation was prevented. 
The identified miRNA was discovered to regulate expres-
sion of approximately 2500 genes; two of these genes were 
further investigated due to their role in vascularisation.
Hai-Feng Zhang (Shantou University, China and University 
of Alberta, Canada) showed that loss of miR-200b is pos-
sible marker of reduced survival, lymph node metastasis 
and advanced clinical stage in esophageal squamous cell 
carcinoma (ESCC). Kindlin-2 was found to participate in 
epigenetic repression of the tumour suppressor miR-200b 
by inducing CpG island hypermethylation resulting in 
increased ESCC invasion and tumour formation (Yu et al, 
in press).
ANTI-VIRAL RNAi THERAPEUTICS
The most difficult challenge for anti-viral drug design is the 
prevention of drug-resistant strains. In order to prevent such 
occurrences, many strategies are currently being developed; 
with the most sophisticated methods involving RNAi.
Dr Susanna Obad (Santaris Pharma, Denmark) described the 
development of miravirsen, a drug to treat chronic hepatitis 
C virus (HCV) infection. Miravirsen is a locked nucleic acid 
(LNA) and DNA mixmer oligonucleotide that targets miR-
122. miR-122 acts as a liver specific host factor during HCV 
infection. After success in chronically HCV infected chim-
panzees (Elmén et al, 2008), the first clinical trial involving 
miRNA inhibition was launched. Phase IIa clinical trials 
have recently been completed which concluded that when 
used to treat patients suffering with chronic HCV genotype 
1 infection, miravirsen exhibited extended dose-dependent 
decrease in HCV RNA levels with no evidence of resistant 
viral strains (Janssen et al, in press). These results are prom-
ising for the development of LNA-antimiR oligonucleotides 
for targeting of additional miRNAs that contribute to patho-
genesis in humans.
Dr Patrick Lu (Siranomics, USA) described the siRNA 
antidote for influenza A viruses H5N1 (avian) and H1N1 
(swine) which target conserved regions of the viral genome 
in an effort to prevent arise of drug resistant viral mutants. 
Delivery of “potency enhancing motif ” (PEM)-modified 
siRNA inhibitors increased therapeutic and prophylactic 
siRNA potencies. Antiviral activity was detected in mouse 
lungs after infection with a 10x lethal dose of H5N1. 
Professor Jens Kurreck (University of Technology Ber-
lin, Germany) described siRNA and coxsackie-adenovirus 
receptor (CAR) combination therapy developed to treat cox-
sackievirus B3 which improved heart function in the mouse 
myocarditis model (Werk et al, 2009; Fechner et al, 2011). 
RNAi TREATMENT FOR DISEASE
DMD-associated miRNAs (dystromiRs) are potential bio-
markers for Duchenne Muscular Dystrophy (DMD). Dr 
Tom Roberts (University of Oxford, UK and the Scripps 
Research Institute, USA) showed that differing levels of 
dystromiRs were detected between different types of skel-
etal muscle (Roberts et al, 2012). Additional results suggest 
that dystromiRs are transported in the circulation bound to 
protein/lipoprotein complexes to protect them from nucle-
ase activity.
Dr Kathia Zaleta-Rivera (Stanford University, USA) dis-
cussed allele specific oligonucleotide treatment for hyper-
trophic cardiomyopathy (HCM) anticipated to salvage 
expression of the wild-type allele enabling recovery of car-
diomyocyte functionality. siRNA and short hairpin (shRNA) 
treatments were identified for 2 mutations associated with 
HCM. Models for each mutation have been developed to 
measure changes in cell contractility and force generation 
after treatment with shRNAs. 
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Professor Paul Holvoet (University of Leuven, Belgium) 
described the relationship between obesity and athero-
sclerosis identified by shared expression of a collection of 
miRNAs. The identified miRNAs were found to regulate 
adipocyte differentiation, oxidative stress, inflammation, 
and angiogenesis in adipose tissues of obese patients and 
vascular tissues of atherosclerosis patients. Repression of 
specific miRNAs was discovered to induce oxidative stress 
and inflammation. To complete the vicious circle, reduced 
levels of these miRNAs were recognised to contribute to 
development of obesity a condition that in itself increases 
the risk of development of atherosclerosis. The discovery 
of miRNA containing monocyte-derived micro-particles 
that participate in intercellular communication within and 
between adipose and atherosclerotic vascular tissues, were 
also discussed (Hulsmans et al, 2011). 
OLIGONUCLEOTIDES IN RNAi
The conference keynote speaker Dr Mike Gait (MRC Lab-
oratory of Molecular Biology, Cambridge, UK) presented 
recent work involving development of peptide nucleic acids 
(PNA) anti-miRs which rapidly inhibit miR-122 in liver cells 
without the participation of transfection agents (Torres et al, 
2012). Following uptake anti-miRs target miRNAs within or 
in relation to the endosomal compartment and strong dose 
dependent miR-122 inhibition has been observed for phos-
phorothioated oligonucleotide counterparts (Torres et al, 
2011). These results are promising for the development of 
both diagnostic markers and anti-miR therapeutics for a 
wide range of genetic disorders.
Dr Dmitry Samarsky (RiboBio, China) reported the design 
of a sophisticated type of RNAi molecule composed of sin-
gle chain oligonucleotide which has both 5′ and 3′ targeting 
regions which mediate self-dimerisation with partial com-
plementarity. The loop containing-RNA duplex molecule 
has been shown to enter and activate RISC and is promis-
ing for the future design of single-stranded oligonucleotide 
therapies (Lapierre et al, 2011).
Dr Jonathan Watts (University of Southampton, UK) 
showed that combining a DNA analogue (2′F-ANA) with 
rigid RNA analogues (2′F-RNA and/or LNA) in siRNA 
duplexes increases therapeutic potency and effectively 
induces gene silencing through interaction with mRNA. 
Modified duplexes with potency equivalent to native siRNA 
were identified and were far less immunogenic (Deleavey 
et al, 2010). In addition, Watts elucidated and discussed the 
cause of increased binding affinity following ribonucleic 
sugar fluorination at the 2′ position.
MINIMALISATION OF OFF-TARGET EFFECTS
One of the greatest limitations of siRNA-based gene silenc-
ing is the incidence of sequence-specific off-target effects. 
These adverse interactions are often not foreseen because 
siRNAs can induce gene silencing through association 
with regions of the genome with only partial complemen-
tarity. During these incidences the siRNA functions as a 
miRNA inhibiting gene expression by destabilising mRNA 
or blocking transcription. Therefore off-target interactions 
are a major consideration during siRNA design. Dr Michael 
 Hannus (Intana Bioscience GmbH, Germany) described a 
possible resolution which employs siPools which contain up 
to 60 specifically selected siRNA molecules. Within a siPool 
each siRNA is retained at a low concentration so off-target 
interactions are reduced to such a degree that they lie below 
the lower limit of detection. 
TECHNICAL FOCUS
In order for the ever-evolving field of RNAi to grow, the 
most advanced and innovative technology needs to be devel-
oped and utilised by researchers worldwide. Presentations 
and exhibitions by Sigma-Aldrich, Eupheria Biotech GmbH 
and Carl Zeiss described their latest products and/or tech-
niques that may assist scientists in cutting-edge research. 
Dr Steven Thompson (Sigma-Aldrich, UK) described 
CompoZr® Zinc Finger Nucleases (ZFNs) which facilitate 
genome manipulation through site-specific mutagenesis 
by generating double-strand breaks in DNA. As a result 
the cell’s DNA repair mechanisms are exploited to include 
gene knockouts, integrations or modifications (Hansen et al, 
2012). Dr Christina Smith (Sigma-Aldrich, USA) described 
a range of products for the analysis and manipulation of 
miRNAs.
Dr Mirko Theis (Eupheria Biotech GmbH, Germany) pro-
moted Eupheria Biotech’s latest endoribonuclease-prepared 
siRNA (esiRNA) products which target long non-coding 
transcripts for RNAi loss of function screens. These multi-
ple silencing triggers result in efficient gene silencing which 
is highly target specific and has lower off-target interactions 
than similar methods which employ single or pooled siR-
NAs (Chakraborty et al, 2012). 
Dr Tom Quick (Carl Zeiss, UK) presented information about 
their PALM MicroBeam Laser micro-dissection for isolat-
ing high-purity tissue. The specimen of interest, typically 
a single cell, is isolated without contact, hence contamina-
tion of the sample is prevented and neighbouring tissues/
cells remain unchanged. The genetic and proteomic mate-
rial of both the specimen of interest and adjoining areas are 
sustained enabling further DNA, RNA and protein analysis 
(Micke et al, 2005). This technique can also be used to iso-
late live cells which can be successfully re-cultured. 
POOLED shRNA SCREENS 
Highly efficient, adaptable and cost effective phenotypic 
loss-of-function RNAi screens that employ pooled com-
plex lentiviral-based shRNA expression libraries allow syn-
chronized screening of multiple transcripts to accurately 
determine sequences that participate in specific cellular 
mechanisms. Continual development and optimisation of 
these methods of RNAi screening is essential and supports 
progression of the RNAi research field.
Dr Annaleen Vermeulen (Thermo Fisher Scientific, USA) 
explained that technical reproducibility between PCR repli-
cates in a pooled shRNA screen are significantly improved 
by ensuring amplification remains within the exponen-
tial phase and that the correct quantity of genomic DNA 
is used to sustain the average template copies per shRNA 
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used during library transduction. This enabled identification 
of higher reproducibility of biological replicates in screens 
with at least 500-fold shRNA representation (Strezoska 
et al, 2012).
Dr Paul Diehl (Cellecta, USA) described the in-house ser-
vice offered by Cellecta where pooled shRNA screens are 
coupled with quantitative sequencing which enables accu-
rate depiction of hairpin levels inside cells transduced with 
shRNA libraries. In vitro “drop-out” screens which identify 
critical functional genes and novel drug targets fundamen-
tal to cell growth and proliferation and positive selection 
screens which recognise genes that participate in specific 
cell signalling pathways were described (Tsujii et al, 2010). 
CONCLUDING REMARKS
Results discussed at RNAi2013 are very promising and 
strongly suggest that many common limitations of RNAi-
based therapies including successful delivery of ncRNA 
and reduction of off-target effects could be overcome in 
the foreseeable future. Additionally, RNAi-based therapies 
have been developed to specifically target chemoresistant 
cancers, DMD, HCV and influenza, amongst many others, 
which shows great reassurance for development of personal-
ised medicines; attendees were encouraged to continue their 
work in this field in order to achieve this objective. Data pre-
sented continue to provide hope that RNAi-based therapies 
will revolutionise future treatment of disease. Indeed, in the 
words of one speaker at the conference, RNAi looks set to 
become the next treatment modality. 
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8.2. Appendix B – Cancer cell line motility rate, proliferation rate, exosome secretion 
level, migration rate and invasion capacity data 
 
8.2.1. Summary of cell line characteristics 
Table 8.1: Summary of cell line characteristics: proliferation, exosome size, exosome secretion rate, 






















A-2780 19.44 147.53 704.66 1.48 528.19 449.53 
CP-70 21.69 139.14 572.29 1.95 2827.52 80.91 
IGROV-1 48.18 136.93 3489.83 0.97 2724.88 894.56 
MCF-7         303.04 527.28 
MCP-1 17.51 134.37 385.57 1.33 2730.87 112.13 
OVCAR-3 33.69 132.83 721.92 2.18 99.07 49.64 
OVCAR-4 37.62     1.64 10615.56 67.17 
OVCAR-5 27.10 131.70 924.52 3.65 32914.30 8525.26 
OVCAR-8 27.69 127.67 740.32 5.26 6176.49 307.00 




Table 8.2: Normalised scratch percentage area for ovarian cancer cell lines. 
Time 
(hours) A-2780 CP-70 IGROV-1 MCP-1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 SKOV-3 
0 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 
6 - - - - - - - - 67.01 
12 85.18 61.03 92.29 92.77 68.65 74.37 54.21 36.88 14.76 
24 63.83 33.29 80.35 68.90 44.24 53.76 15.12 0.00 0.00 
36 42.69 16.54 67.45 51.13 20.97 38.14 0.16 0.00 0.00 






Table 8.3: Standard error of the mean for normalised scratch percentage area in Table 8.1. 
Time 
(hours) A-2780 CP-70 IGROV-1 MCP-1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 SKOV-3 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
6 - - - - - - - - 4.89 
12 1.97 4.04 2.05 4.44 4.89 2.88 3.11 4.65 4.94 
24 2.78 3.72 2.74 6.20 4.06 4.37 3.02 0.00 0.00 
36 3.17 3.04 3.55 7.67 5.08 4.86 0.16 0.00 0.00 
48 3.04 1.42 4.60 8.91 3.32 4.58 0.00 0.00 0.00 
 
Table 8.4: Average scratch closure speed for ovarian cancer cell lines. 
Cell line 
Average scratch closure 
speed (% area 
reduction/hour) 
Standard error of the 
mean 
A-2780 1.48 0.06 
CP-70 1.95 0.03 
IGROV-1 0.97 0.10 
MCP-1 1.33 0.19 
OVCAR-3 2.18 0.20 
OVCAR-4 1.64 0.13 
OVCAR-5 3.65 0.27 
OVCAR-8 5.26 0.39 







Table 8.5: Ovarian cancer cell concentration over 120 hours. 
Cell Line 
Time (hours) 
0 24 48 72 96 120 
A-2780 500000 840000 2677777.8 8422222.2 15337500 22088888.9 
CP-70 500000 1213333.3 3500000 8088888.9 14466666.7 15622222.2 
IGROV-1 500000 373333.33 1223333.3 1328889 4773333.33 1873333.33 
MCP-1 500000 484444.44 1305555.6 3477777.8 11316666.7 16244444.4 
OVCAR-3 500000 440000 646666.67 1233333.3 2622222.22 3383333.33 
OVCAR-4 500000 982222.22 1120000 2500000 3057777.78 4033333.33 
OVCAR-5 500000 500000 1280000 4662222.3 6723333.33 3086666.67 
OVCAR-8 500000 741666.67 2253333.3 5022222.3 8743333.33 5400000 
SKOV-3 500000 440000 555000 1988888.7 3136666.67 4573333.33 
 
Table 8.6: Standard error of the mean for ovarian cancer cell concentration over 120 hours. 
Cell Line 
Time (hours) 
0 24 48 72 96 120 
A-2780 0 46825.13 137549.09 419140.80 673416.35 623411.56 
CP-70 0 30061.67 212785.76 146986.18 771542.47 145720.86 
IGROV-1 0 57324.61 231666.67 106272.37 2136510.65 373511.86 
MCP-1 0 77872.96 29397.24 117588.95 116666.67 160246.72 
OVCAR-3 0 53333.33 32829.53 91792.84 67586.25 116666.67 
OVCAR-4 0 39643.47 106926.77 608522.80 669165.69 357589.67 
OVCAR-5 0 108282.04 117721.42 452308.22 3404038.45 522632.23 
OVCAR-8 0 418622.08 365995.60 278017.71 3868928.94 581062.25 
SKOV-3 0 76865.68 68251.98 189827.52 231396.73 1371742.61 
 





IGROV-1 48.18 27.18 
MCP-1 17.51 0.06 
A-2780 19.44 0.61 
OVCAR-4 37.62 4.25 
CP-70 21.69 0.75 
OVCAR-3 33.69 0.75 
OVCAR-5 27.10 5.17 
OVCAR-8 27.69 6.20 






8.2.4. Exosome secretion 









Error of the 
Mean 
A-2780 704.66 359.18 
CP-70 572.29 386.78 
IGROV-1 3489.83 2692.26 
MCP-1 385.57 165.92 
OVCAR-3 721.92 426.55 
OVCAR-5 924.52 500.85 
OVCAR-8 740.32 440.56 
SKOV-3 736.39 333.99 




8.2.5. Exosome size 





error of the 
mean 
A-2780 147.53 8.71 
CP-70 139.14 2.19 
IGROV-1 136.93 6.98 
MCP-1 134.37 2.27 
OVCAR-3 132.83 5.29 
OVCAR-5 131.70 14.56 
OVCAR-8 127.67 6.30 
SKOV-3 127.10 2.13 












A-2780 528.19 448.37 
CP-70 2827.52 231.88 
IGROV-1 2724.88 1021.64 
MCF-7 303.04 169.12 
MCP-1 2730.87 863.50 
OVCAR-3 99.07 48.34 
OVCAR-4 10615.56 2708.00 
OVCAR-5 32914.30 7045.72 
OVCAR-8 6176.49 429.18 
SKOV-3 70031.67 3131.81 
* 100,000 cells were assigned to each trans-well
insert at commencement of the assay
8.2.7. Invasion 







A-2780 449.53 132.67 
CP-70 80.91 23.62 
IGROV-1 894.56 331.60 
MCF-7 527.28 303.61 
MCP-1 112.13 53.30 
OVCAR-3 49.64 12.55 
OVCAR-4 67.17 41.98 
OVCAR-5 8525.26 4143.56 
OVCAR-8 307.00 146.76 
SKOV-3 21271.57 4569.89 
* 100,000 cells were assigned to each trans-well
insert at commencement of the assay
